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This thesis describes the development of a bioinspired approach for the efficient synthesis of 
bicyclic heterocycles assembled on a 2,8-dioxabicyclo[4.4.0]decane core decorated with 4 side 
chains. The key step involves an acid mediated dimerisation of a linear dihydroxy-
diarylheptanoid to produce two oxane rings and 4 stereocenters in one pot. This route was used 
for the total synthesis of (+)-blepharocalyxin D in 4 steps and 13% overall yield from simple 
starting materials. Further analogues were also synthesised. 
 
The conditions for the key dimerisation step were optimised in terms of temperature, Lewis acid 
and solvent, concluding in the use of TMSOTf in CH2Cl2 at 0 °C. A mechanism for the reaction was 
proposed via a cascade involving carbocationic intermediates and verified by an oxygen-18 label 
study. 
The second chapter describes the synthesis of 3-deoxo-11-dehydroxy-mutilin 183 the first cyclic 
intermediate on the biosynthetic pathway to pleuromutilin. It was used as a standard to verify 
the structure of the metabolite isolated from extracts of cultures of Aspergillus oryzae, which 
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25  – specific optical rotation at 25 °C 
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FT-IR   – Fourier Transform Infrared 
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mp   – melting point 
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pKa   – acid dissociation constant 
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s   – singlet 
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TBAF   – tert-butylammonium fluoride 
TBS  – tert-butyldimethylsilyl 
TES   – triethylsilyl 
Tf   – triflate 
TFA   – trifluoroacetic acid 
THF   – tetrahydrofuran 
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1.1.1 Natural products in drug discovery and their bioinspired synthesis 
Natural products have been the single most productive source of leads for the development of 
drugs. In 2008, over 100 new natural products were in clinical development, particularly as anti-
cancer and anti-infectives.1 Natural products are generally compliant in terms of log P and H-
bond donors, even if they violate the Lipinski’s rule of five2, making them often more readily 
absorbed than synthetic drugs. In addition, natural products are more likely to resemble 
biosynthetic intermediates or endogenous metabolites, and hence take advantage of active 
transport mechanisms.3 Despite these advantages and the past successes, many large 
pharmaceutical companies have decreased the use of natural products in drug discovery 
screening. This has been because of the potential disadvantages of natural products such as 
difficulties in access and supply due to the complexities of natural products chemistry.1 Although 
several strategies are used in the commercial production of natural products including 
fermentation, biotransformation, total synthesis and semi-synthesis, it is important to develop 
efficient new synthetic methodology. 
The use of bioinspired or biomimetic synthesis has grown in recent years,4 this attempts to 
mimic nature’s processes for the synthesis of natural occurring metabolites, drawing on the 
knowledge of known or proposed biosynthetic steps. In this type of synthesis key 
transformations are used to convert simple precursor into complex molecules often through 
highly orchestrated cascades.4 
In this chapter a bioinspired strategy for the direct conversion of monomeric 3,5-dihydroxy-
diarylheptanoids to dimeric products assembled on a trans-2,8-dioxabicyclo[4.4.0]decane 
frameworks is described alongside oxygen-18 and deuterium labelling studies to verify a 
proposed cascade mechanism involving carbocationic intermediates and the concise total 
synthesis of blepharocalyxin D analogues. 
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1.1.2 Isolation, structure elucidation and bioactivities of diarylheptanoids from 
Alpinia blepharocalyx 
Alpinia blepharocalyx K. Schum belongs to the large genus of the Zingiberaceae family which 
consists of over 250 species of which about 50 species are distributed in East and South-West 
China. Extracts of A. blepharocalyx K. Schum have been used as Traditional Chinese Medicine for 
the treatment of stomach disorders. Phytochemical studies of this plant have resulted in the 
isolation of diarylheptanoids, terpenes and many other compounds.5  
Diarylheptanoids are classified into 5 characteristic subtypes: linear (e.g. 1), cyclic (e.g. 2), 
dimeric (e.g. 3), those containing a chalcone/flavanone moiety (e.g. 4) and further miscellaneous 
diarylheptanoids (Figure 1). All these compounds have the same characteristic skeleton of two 
aromatic rings joined by a 7-carbon atom chain.6  
 
Figure 1. Examples of diarylheptanoids isolated from A. blepharocalyx 
In 1998, in order to find the biologically active compounds, seeds of A. blepharocalyx were 
extracted with 95% EtOH, and the EtOH extract was suspended in water containing 10% MeOH 
and partitioned with hexane and Et2O.7 Linear diarylheptanoid 5 (32 mg) was one of the first 
isolated compounds. Its formula C19H18O4 (M+ 310.1183) was determined by HRMS and was 
positive to FeCl3 reagent, so it was suggested to be the enol form of a 1,3-diketone. Using IR and 
extensive 1D and 2D NMR spectroscopy the structure of compound 5 was determined. Its 
antiplatelet activity was assessed and showed strong inhibition in platelet aggregation induced 
by collagen, arachidonic acid and adenosine diphosphate (Figure 2).7  




Figure 2. Linear diarylheptanoids isolated for A. blepharocalyx7 
A few years later in 2001 it was reported that the diethyl ether and residual aqueous fractions 
from the EtOH extract of seed of A. blepharocalyx showed significant antiproliferative activity 
against liver metastatic murine colon 26-L5 carcinoma cells8 and human HT-1080 fibrosarcoma 
cells;9 hence, these fractions were further examined. The residual aqueous fraction was 
separated by a series of chromatographic methods and the linear diarylheptanoids (6-10), 
diarylheptanoids bearing a chalcone or a flavanone moiety (11-14), cyclic (15 & 16) and dimeric 
(17-19) diarylheptanoids were isolated. Their structures were determined by HRMS, IR and 
extensive 1H and 13C NMR spectroscopy. 
Linear diarylheptanoids 6 (3.2 mg) and 7 (3.9 mg) contain a methoxy group at C-5. Their absolute 
stereochemistry was assigned by analyses of their MTPA derivatives using Mosher’s method.10 
Compounds 8 (2 mg) and 9 (2 mg) have an ethoxy group at C-5 instead of the methoxy group. 
Their absolute configurations were assumed based on comparison with 6 and 7 and that all have 
positive optical rotation. β-Methoxy ketone 10 (2.5 mg) was also isolated and its configuration 
at C-3 was assumed to be the same as 6-9 (Figure 2).11 
Among the diarylheptanoids bearing a chalcone or a flavanone moiety, calyxin I (11) (18.6 mg), 
epicalyxin I (12) (4.0 mg) , calyxin J (13) (18.3 mg) and an epimeric mixture (18.2 mg) of calyxin J 
(13) and epicalyxin J (14) were also isolated (Figure 3). 
 
Figure 3. Diarylheptanoids containing a chalcone or flavanone moiety isolated from A. blepharocalyx12 
A Bioinspired Strategy for the Synthesis of Fused Oxygen Heterocycles 
4 
 
Calyxin I (11) and epicalyxin I (12) contain a chalcone moiety and were assumed to be epimers 
at C-7’’’’ based on the similarity on their 1H and 13C spectra and because the coupling constant 
between H-6 and H-7’’’’ in 12 (J 4 Hz) differed from that of 11 (J 10 Hz).12 Calyxin J (13) and 
epicalyxin J (14) contain a flavanone moiety13 and they were assigned as epimers at C-9’’ 
although this stereochemistry could not be determined due to the paucity of 13 and 14 
available.12 The structures of several related calyxin natural products originally assigned by 
Kadota, were reassigned by Rychnovsky following total synthesis.14 
 
Figure 4. Cyclic and dimeric diarylheptanoids isolated from A. blepharocalyx15 
Cyclic diarylheptanoids such as 15 and its epimer 16 and dimeric diarylheptanoids including 
blepharocalyxins C (17), D (18) and E (19) were also isolated (Figure 4). The structure of 
dihydropyran 16 (1.4 mg) was verified via hydrogenation with Pd/C catalyst to give the known 
diarylheptanoid (−)-de-O-methylcentrolobin (20)16–18 (Scheme 1) which has been synthesised 
several times.19–21 
 
Scheme 1. Hydrogenation of dihydropyran 16 to (−)-de-O-methylcentrolobin 2018 
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Dihydropyran 15 (7.1 mg) was assumed to be an epimer of 16 at C-7 based on the similarity of 
its 1H and 13C NMR spectra. As the configuration at C-3 was assumed to be S from the biogenetic 
point of view,22 the absolute configuration of 15 was determined as 3S, 7R.15 
Dimeric diarylheptanoids blepharocalyxin C (17) (5.8 mg) and blepharocalyxin D (5.5 mg) (18) 
were also isolated. Blepharocalyxin D has a similar structure to blepharocalyxin C except that 
ring closure had occurred to form a second oxane ring. Blepharocalyxin E (19) (7.0 mg) has the 
two diarylheptanoids coupled via the 6-7’ bond as shown in Figure 4.22 
The antiproliferative activity of these compounds 6-19 against liver metastatic murine colon 26-
L5 carcinoma cells and human HT-1080 fibrosarcoma cells was tested and compared with 5-
fluorouracil, a current medication used to treat cancer.23 Their ED50 values (median effective 
dose, the concentration of drug at which 50% of the population will have the desired response24) 
are shown in Table 1.  
Compound Colon 26-L5 HT-1080 
6 86.4 >100 
8 94.6 >100 
10 5.2 10.1 
Calyxin I (11) 8.39 9.08 
Epycalyxin I (12) 12.1 5.88 
Calyxin J (13) 23.2 8.19 
calyxin J (13) and epicalyxin J (14) 13.7 0.32 
15 71.2 45.3 
16 >100 79.4 
Blepharocalyxin C (17) 29.6 54.3 
Blepharocalyxin D (18) 3.61 25.7 
Blepharocalyxin E (19) 32.2 9.02 
5-fluorouracil 0.5 8.0 
Table 1. Antiproliferative activity for compounds 6-19 and 5-fluorouracil (ED50 values in μM) 11,12 
Linear diarylheptanoids 7 and 9 were inactive (ED50 > 100 μΜ) in both cells, whereas 6 and 8 
showed antiproliferative activity only towards human fibrosarcoma cells and compound 10 
showed cytotoxicity against both cell lines.11 Calyxins 11-14 showed moderate to potent 
cytotoxicity against human fibrosarcoma cells with ED50 values less than 10 μΜ.12 
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Blepharocalyxin D (18) showed the most potent antiproliferative activity against murine colon 
carcinoma cells with an ED50 value of 3.61 μM, which falls within the range of significantly active 
cytotoxic agent (ED50 < 4.0 μM) introduced by Geran et al.25 Blepharocalyxin E (19) exhibited the 
most potent activity against human fibrosarcoma cells with a ED50 value of 9.02 μM, which is 
comparable with that of 5-fluorouracil (ED50 8.0 μM).22,26 
1.1.3 Previous synthetic studies and total syntheses of blepharocalyxin D 
A characteristic feature of blepharocalyxin D is the unusual trans-2,8-dioxabicyclo[4.4.0]decane 
central core which is adorned by four side chains each in an equatorial position (Figure 5). Its 
structure was assigned by Kadota and co-workers in 2000 based on 1H and 13C NMR 
spectroscopic data and its stereochemistry determined as 1R, 3S, 5S, 6S, 7S, 9S by comparison 
with blepharocalyxin C which was reported at the same time.22,26 
 
Figure 5. 3D representation of blepharocalyxin D (18) 
The interesting structure of blepharocalyxin D combined with its high cytotoxicity against murine 
colon carcinoma cells and the need for further material for biological assessment (only 5.5 mg 
was isolated from 10 Kg of seeds) led several research groups to investigate the total synthesis 
of this natural product. In 2003, Mead and co-workers27 reported a ring cleavage strategy of 
model bicyclic lactones promoted by a Lewis acid. Cleavage of 21 using TiCl4 generates an 
intermediate oxycarbenium ion 22 which can be captured by a variety of carbon-based 
nucleophiles. Mead found that anisole reacts only at the para-position to give the desired trans 
diequatorial C-aryl pyranoside product 23 (Scheme 2). 
 
Scheme 2. Preparation of tetrahydropyran 2327 
A Bioinspired Strategy for the Synthesis of Fused Oxygen Heterocycles 
7 
 
Initial studies towards the synthesis of blepharocalyxin D within our group were begun by former 
PhD student, Jon Elsworth. The retrosynthetic plan via a Prins cyclisation is shown in Scheme 3. 
The key step involved the reaction of homoallylic alcohol 25, containing a tethered ester, with 
aldehyde 24 to form 26, the bicyclic scaffold of blepharocalyxin D in one step.28 
 
Scheme 3. Retrosynthetic analysis of blepharocalyxin D 28 
Elsworth conducted model studies to investigate this novel cyclisation. Hydroxy ester 28 was 
synthesised and reacted with various aldehydes and a ketone in the presence of TMSOTf giving 
the required bicyclic framework 29 in good yields. In each case the reaction proceeded with 
excellent stereocontrol forming 3 new stereogenic centres in a single pot and a variety of groups 
could be introduced at C-7 including electron-rich and electron-deficient aromatic rings, alkyl 
side chains and a cyclopentane group (Table 2).29  
 
Electrophile 
   
  
 
Yield (%) 81 71 73 72 84 63 
Table 2. Reaction of alcohol 28 with a range of electrophiles29 
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Having developed this novel intramolecular Prins cyclisation, Elsworth then explored the 
installation of the side chains which adorn blepharocalyxin D. He successfully introduced an alkyl 
chain at C-3 using a Grignard addition and subsequent stereoselective reduction using SnCl4 and 
Et3SiH to give 31 (Scheme 4).  
The installation of the side chain at C-5 proved to be more challenging. Lactone 30 was treated 
with lithium tetramethylpiperidide (LiTMP) and trimethylsilyl bromide, subsequent Saegusa 
oxidation produced unsaturated lactone 32. Treatment of 32 with boronic acid 33 in the 
presence of [Rh(cod)Cl]2 and lithium hydroxide in a 10:1 mixture of dioxane/water gave alkylated 
lactone 34 as a single diastereomer in 91% yield (Scheme 4). However, product 34 had the 
opposite stereochemistry at C-5 to that required for the total synthesis of blepharocalyxin D.28  
 
Scheme 4. Installation of side chains at C-3 and C-528 
With the model studies showing promise, a further PhD student within our group Tshepo Pheko 
synthesised unsaturated ester 41 with a phenylethyl side chain (Scheme 5). First, reaction of 
crotyl transfer reagent30 36 with dihydrocinnamaldehyde 35 in the presence of pTSA·H2O in 
CH2Cl2 gave alcohol 37 in 66% yield and >98% ee. Protection of alcohol 37 and subsequent 
oxidative cleavage of the alkene gave aldehyde 39. Reaction of vinylmagnesium bromide in THF 
with aldehyde 39 gave an epimeric mixture of alcohols 40. Subsequent Johnson-Claisen 
rearrangement with trimethylorthoacetate and TBAF deprotection gave homoallylic alcohol 
41.31 




Scheme 5. Synthesis of homoallylic alcohol 4131 
Pheko treated homoallylic alcohol 41 and various aldehydes (differing in the p-substitution of 
the aromatic ring), with TMSOTf to give bicyclic lactones 42-45 in good yields and excellent 
stereoselectivities (Scheme 6). 
 
Scheme 6. Synthesis lactones 42-4531 
The side chain at C-7 was installed using a two-step Grignard addition/reduction protocol in the 
presence of either an electron-donating (OMe) 46 or electron-withdrawing (OSO2Ph) 47 
substituent in the para-position of the aromatic ring (Scheme 7).  
 
Scheme 7. Installation of side chain at C-731 
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This had been good progress towards the synthesis of blepharocalyxin D, although the issue of 
obtaining the correct stereochemistry at C-5 remained. 
The first total synthesis of blepharocalyxin D was reported in 2007 by Lee and co-workers.32,33 
The synthesis was completed in 17 steps and 0.9% overall yield. The two keys steps included a 
Prins cyclisation and, an unusual Prins-pinacol rearrangement to form the two oxane rings.  
The key Prins cyclisation of homoallylic alcohol 50 with p-anisaldehyde to produce 
tetrahydropyran 52 was performed under TMSOTf, TMSOAc and AcOH conditions, a 
modification of the Prins cyclisation conditions developed within our group34 with creation of 3 
new stereocenters. The mechanism of this Prins cyclisation is shown in Scheme 8. Homoallylic 
alcohol 50 reacts with aldehyde 51 to form intermediate oxycarbenium ion 53, which cyclises to 
form stabilised secondary carbocation 54 which is trapped by a nucleophile to form the 
tetrahydropyran 52.35  
 
Scheme 8. Mechanism of the Prins cyclisation 
The second key step is a Prins-pinacol rearrangement. Treatment of seven-membered cyclic 
acetal 55 with boron trifluoride diethyl etherate gave a mixture of the axial aldehyde 56 (83%) 
and the equatorial aldehyde 57 (2%) (Scheme 9). The authors propose that the unexpected 
preference for the axial aldehyde was due to conformational constraints originating from 
the steric crowding. 
 
Scheme 9. Prins-pinacol rearrangement of 55 to give unexpected axial aldehyde 5632,33 
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The proposed mechanism for this unusual Prins-pinacol reaction starts by activation of the most 
available oxygen of the seven-membered cyclic acetal 55 by the Lewis acid to form intermediate 
oxycarbenium ion 58. The alkene attacks the activated carbonyl and forms the six-membered 
ring 59 in the Prins reaction, then pinacol rearrangement gives aldehyde 56 (Scheme 10).36,37  
 
Scheme 10. Proposed mechanism of Prins-pinacol reaction 
Epimerisation at C-5 of aldehyde 56 under basic conditions gave 52% of equatorial aldehyde 57 
and 25% recovered starting material 56 which could be recycled to produce the desired 
aldehyde 57 (Scheme 11). The synthesis of blepharocalyxin D was completed via a Julia 
reaction38 of lithiated sulfone 60 with aldehyde 57 and LiHMDS, giving tetramethyl ether 61 in 
77% yield with a 50:1 E:Z ratio. The structure of 61 was confirmed by X-ray crystallography. 
Finally, 61 was demethylated using lithium propanethiolate in hot HMPA giving (−)-
blepharocalyxin D (18) in 56% yield.  
Lee reported several optical rotation values for blepharocalyxin D 18: [𝛼]𝐷
22 −88.1 (c. 0.43, 
MeOH); [𝛼]𝐷
22 −77.1 (c. 0.11, MeOH); [𝛼]𝐷
22 −89.9 (c. 0.027, MeOH); [𝛼]𝐷
23 −72.9 (c. 0.32, 
acetone); [𝛼]𝐷
24 −85.0 (c. 0.31 MeOH-CH2Cl2 (1:1)).33 These values were inconsistent with the 
values reported by Kadota and co-workers for the natural product:22,26 [𝛼]𝐷
22  +18.5 (c. 0.025, 
MeOH). To confirm the structure beyond any doubt a synthetic sample of blepharocalyxin D 18 
was converted back to the tetramethyl ether 61 using iodomethane and potassium carbonate 
in hot acetone. The optical rotation of this sample ([𝛼]𝐷
23 −87.8 (c. 0.065, CHCl3)) was in close 
correspondence with the value of the original synthetic sample ([𝛼]𝐷
14 −90.4 (c. 0.32, CHCl3)) of 
Blepharocalyxin D (18).  




Scheme 11. Final steps in the synthesis of blepharocalyxin D32,33  
It is interesting to note that both Lee and Elsworth obtained the axial substituent at C-5 in their 
approaches towards the synthesis of blepharocalyxin D, although in Lee’s approach the aldehyde 
could be epimerised to the required equatorial position.  
In 2012, Willis and co-workers reported a modification to the standard Prins cyclisation in which 
instead of using an homoallylic alcohol, a γ,δ-unsaturated alcohol  was used. In this alcohol the 
alkene is placed one position further away generating a secondary carbocation which could be 
stabilised by an adjacent aromatic ring. Reaction of alkenols 62 with various functionalised 
aromatic groups (Cl, Br, CF3 and OSO2Ph) and 3-benzyloxypropanal 63 under Lewis acidic 
conditions afforded the trans-fused products 64 in good yields (Scheme 12).39  
 
Scheme 12. Intramolecular Prins cyclisation to generate bicyclic compound 6439 
This was an efficient approach for the rapid stereocontrolled assembly of 
2,8-dioxabicyclo[4.4.0]decanes, creating up to 3 new stereogenic centers in a single pot. 
Inconveniently, this method does not allow the introduction of a C-9 substituent requiring the 
synthesis of several functionalised alkenols and aldehydes prior to acid-mediated cyclisation. 
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Hence Adam Bunt, another former PhD student within the group, proposed that γ,δ-unsaturated 
alcohols could be used to generate bicyclic lactones with the carbonyl at C-9 to functionalise 
further.40 Bunt achieved the synthesis of various bicyclic lactones 70-73 by reacting alcohols 65-
68 and methyl 3,3-dimethoxypropionate 69 with TMSOTf to form the trans-fused bicyclic core 
(Scheme 13). 
 
Scheme 13. Synthesis of bicyclic lactones 70-7340 
This new methodology paved the way for the development of a new approach for the total 
synthesis of blepharocalyxin D which was reported by Cons, Willis and co-workers41 in 2013. The 
retrosynthetic analysis is showed in Scheme 14. The key step was proposed to be the reaction 
of dienol 74 with methyl 3,3-dimethylpropionate 69 to generate lactone 75 followed by 
installation of the required side chain at C-9.  
 
Scheme 14. New retrosynthetic analysis for the synthesis of blepharocalyxin D.  
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The required dienol 74 was synthesised from enone 75 which was converted to ketone 76 as a 
1:1 mixture of diastereomers via a rhodium-mediated 1,4-addition reported by Hiyashi42 
(Scheme 15). Subsequent reduction with NaBH4 gave corresponding benzylic alcohol which was 
converted to a xanthate using NaH/CS2/MeI. The xanthate was refluxed with NaHCO3 in xylene 
to effect a Chugaev elimination43 giving the required alkene 77 in 61% yield. Silyl ether 77 was 
deprotected using 2% HCl in ethanol to give the required γ,δ-unsaturated alcohol 74.41 
 
Scheme 15. Synthesis of dienol 7441 
With the required dienol 74 in hand, the key cyclisation was performed. Reaction of dienol 74 
and ester 69 with TMSOTf gave bicyclic lactone 76 as a single diastereomer with the creation of 
two oxane rings and four stereocenters in 75% yield (Scheme 16). When dienol 74 reacts with 
ester 69, in the presence of a Lewis acid, it generates an intermediate oxycarbenium ion 78. 
Cyclisation gives stabilised carbocation 79 containing the first of the oxane rings with an 
equatorial substituent at C-5. Intramolecular trapping of the carbocation with the ester 
generates the second heterocycle giving lactone 76 with an equatorial substituent at C-7 
(Scheme 16).  
 
Scheme 16. Mechanism of the key cyclisation. 
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To complete the total synthesis, treatment of lactone 76 with 2-(p-methoxyphenyl)ethyl-
magnesium bromide followed by reduction of the resultant lactol with TMSOTf and Et3SiH gave 
80 with the fully assembled carbon framework. Finally, deprotection of the phenolic groups with 
LiSPr/HMPA gave (−)-blepharocalyxin D in 8% overall yield after 15 steps (Scheme 17). The 
optical rotation of the synthetic sample [𝛼]𝐷
25 −79.2 (c. 0.23, MeOH) was in accord with Kadota’s 
data.33 
 
Scheme 17. Completing the synthesis of blepharocalyxin D 41 
 
1.2 Aim of the Project 
This total synthesis is not easily adaptable for the preparation of analogues of blepharocalyxin 
D, as three of the side chains must be installed on the dienol used in the cyclisation step. With 
this in mind, a bioinspired strategy towards the synthesis of blepharocalyxin D was investigated.  
Whilst no biosynthetic studies have been reported for these diarylheptanoids, Kadota and 
co-workers speculated on their possible biogenesis based on co-metabolites isolated from A. 
blepharocalyx.22 They proposed that loss of water from dihydroxy-diarylheptanoid 81 would give 
allylic carbocation 82. Intramolecular attack of the C-3 hydroxyl group to the benzylic (C-7) 
carbocation could cyclise to dihydropyran 16 (Scheme 18). Reaction of 16 with another molecule 
of carbocation 82 may give the dimeric structure 83. The secondary carbocation on 83 could 
then be subject to a final intramolecular attack by the secondary alcohol to form the second 
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oxane ring of blepharocalyxin D. Thus, this was the starting point for our investigations on the 
development of a concise new approach to the synthesis of dimeric diarylheptanoids. 
 
Scheme 18. Proposed biosynthetic pathway for the formation of blepharocalyxin D.22 
 
1.3 Results and Discussion 
1.3.1 Initial studies towards the synthesis of dimeric diarylheptanoids 
Based on this proposed biosynthetic pathway we decided to investigate the feasibility of an acid-
mediated coupling between dihydropyran 16 and linear diarylheptanoid 81 to give dimeric 
diarylheptanoids. 
Dihydropyran 87 bearing methoxy and chloro-substituted aromatic rings was selected for the 
initial studies. First, Z-homoallylic alcohol 86 was readily synthesised via an indium-mediated 
propargylation44 and subsequent DIBALH reduction of alkyne 85 in 35% overall yield (Scheme 
19). Then, a silyl-Prins cyclisation was performed by reacting homoallylic alcohol 86 with 
p-chlorobenzaldehyde in the presence of InCl3 achieving a 40% yield of the desired dihydropyran 
87 as a single diastereomer. The syn configuration was determined by 1H-NMR spectroscopy and 
comparison with reported analogues.15,22 Other reaction conditions were investigated for the 
cyclisation including the use of BF3·OEt2 and BiBr345 giving 34% and 58% yield of the required 
product, respectively. 




Scheme 19. Synthesis of dihydropyran 87 
Diol 88 was prepared following the approach of Cossy et al.46 Allylation of 
dihydrocinnamaldehyde 35 with allyl magnesium bromide gave vinyl alcohol 89 (Scheme 20). A 
cross-metathesis with 1-phenylallyl acetate in the presence of Grubbs II catalyst (GII) and CuI47 
produced E-alkene 90, which was transformed into carbonate 91 upon treatment with Boc 
anhydride, DMAP and Et3N. 91 was then treated with FeCl3 to give carbonate 92 in 58% yield. 
InCl3 was tested as an alternative Lewis acid but a poor yield of 25% was isolated. Finally, ring 
opening using K2CO3 in MeOH gave the desired diol 88 as a mixture of diastereomers, 88:12 in 
favour of the syn-diastereomer. 
 
Scheme 20. Synthesis of diol 88 
The proposed coupling of dihydropyran 87 and diol 88 was then investigated in the presence of 
5% TMSOTf in dry dichloromethane at 0 °C. The crude mixture was purified by column 
chromatography. Interestingly, the starting dihydropyran 87 was returned unchanged and new 
products were found to originate solely from diol 88. Syn- and anti-dihydropyrans 93 and 94 
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were isolated in 4% and 9% yield, dimeric diarylheptanoid 95 in 13% yield and a mixture of 
dimeric diarylheptanoids 96 in 8% yield.  
 
Scheme 21. Acid-mediated reaction of dihydropyran 87 and diol 88 
The structures of the dihydropyrans were determined by NMR studies. Dihydropyran 93 had a 
similar 1H NMR spectrum to 87 except for the aromatic region, thus its relative stereochemistry 
was determined as syn. The relative stereochemistry of anti-dihydropyran 94 was established 
by 2D NOESY where 6-H showed correlation to 5-Heq, and 2-H correlated to the alkene proton 3-
H (Figure 6). 
 
Figure 6. Diagnostic NOESY correlations of 94 
The structure and relative stereochemistry of dimeric diarylheptanoid 95 was determined by 
comparison of its 1H and 13C NMR spectra with the data of blepharocalyxin D analogue 97 which 
had been previously synthesised within our group and for which crystallographic data confirmed 
its stereochemistry.41 Analogue 97 only differs from the isolated compound 95 by the presence 
of a 9-p-methoxyphenethyl side chain rather than the 9-phenylethyl group. The comparison of 
the 1H and 13C NMR spectra of analogues 95 and 97 (Figure 7 & Figure 8) illustrates the close 
correspondence present between them, confirming the structure and relative stereochemistry 
of the isolated bicyclic compound 95. 




Figure 7. 1H NMR spectra of analogue 97 and isolated compound 95 
 
Figure 8. 13C NMR spectra of analogue 97 and isolated compound 95 
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This result indicated that pre-formed dihydropyran 87 was not required for the synthesis of the 
dimeric diarylheptanoids. To confirm this, diol 88 was treated with 5% TMSOTf in anhydrous 
dichloromethane at 0 °C (Scheme 22). As anticipated, after column chromatography, syn- 93 and 
anti-dihydropyrans 94 were isolated in 2% and 15% yield respectively, along with 11% of the 
corresponding blepharocalyxin D analogue 95 and 27% of a mixture of dimeric diarylheptanoid 
isomers 96.  
 
Scheme 22. Acid-mediated reaction of diol 88 
As both anti-7 and syn-diarylheptanoids 6 have been isolated from the seeds of A. blepharocalyx 
(Figure 2),48 our next goal was to investigate if the outcome of an acid-mediated dimerisation of 
each diastereomer would lead to a different outcome. 
1.3.2 Enantioselective synthesis of diols 104 and 106 and their acid-mediated 
cyclisation 
The enantioselective synthesis of the required diols 104 and 106 was undertaken using a similar 
approach to that previously described by Cons.41 Aldehyde 100 was synthesised from 
commercially available 3-(4-hydroxyphenyl)propionic acid 97 in 5 steps and 47% overall yield. 
This sequence included two keys steps, a Nokami crotyl transfer reaction30 with 98 giving alcohol 
99 with 99% ee, as determined by chiral HPLC, and a “one pot” OsO4/NaIO4 oxidative cleavage 
of alkene 99 (Scheme 23).41  





Scheme 23. Synthesis of aldehyde 100 
 
Reaction of aldehyde 100 with vinylmagnesium chloride and subsequent TBAF deprotection 
produced diol 101 as a mixture of diastereomers (Scheme 24). Cross-metathesis of 101 with 
styrene and Grubbs II catalyst (GII) gave alkene 102 with exclusive E-geometry of the double 
bond. As the mixture of diastereomers could not be separated by column chromatography, a 
selective allylic oxidation with manganese dioxide49 was performed giving β-hydroxyketone 103. 
 
 
Scheme 24. Synthesis of β-hydroxyketone 103 
 
To complete the synthesis of the required syn- and anti-dihydroxy-diarylheptanoids directed 
reductions were required. Syn-diol 104 was obtained via a Narasaka-Prasad reduction50,51 by 
treatment of β-hydroxyketone 103 with Et2BOMe and NaBH4 with a 99:1 dr, as determined by 
1H NMR spectroscopy (Scheme 25). The selectivity of the reaction is achieved by the 
intermolecular delivery of the hydride to 105 formed by chelation with boron. Unfavourable 
steric interactions of the ethyl group with R1 destabilise TS favouring transition state TA resulting 
in the hydride attacking from the top face.50  





Scheme 25. Narasaka-Prada asymmetric reduction of β-hydroxyketone 103 to syn-diol 104 
 
For the preparation of the anti-diol 106 an Evans-Saksena directed reduction52,53 was performed. 
β-Hydroxyketone 103 was treated with Me4NHB(OAc)3 in a 1:1 mixture of MeCN:AcOH giving 
anti-diol 106 with a 9:1 dr, as determined by 1H NMR spectroscopy. Evans and co-workers52 state 
that the stereoselectivity of the reaction reflects a competition between chair-like transitions 
states TA and TS, each of which involves intramolecular hydride delivery. Unfavourable steric 
interactions between R2 and OAc destabilise TS favouring transition state TA with R2 in an 
equatorial position (Scheme 26). 
 
 
Scheme 26. Evans-Saksena asymmetric reduction of β-hydroxyketone 103 to anti-diol 106 
 
The 1H NMR spectra below show the olefinic and methine regions of syn-diol 104 and anti-diol 
106 (Figure 9). It is possible to observe the presence of very small quantities of syn-diol present 
in the sample of anti-diol. 




Figure 9. Diagnostic region of the 1H NMR spectra of syn-104 and anti-diol 106 (CDCl3, 400 MHz) 
Having synthesised diols 104 and 106, these were treated separately with 5% TMSOTf in CH2Cl2 
at 0 °C with stirring for 5 h. Syn-diol 104 gave syn- and anti-dihydropyrans 107 and 108 in 12% 
and 5% yield respectively along with 17% of dimeric diarylheptanoid 109, whereas the anti-diol 
106 produced 3% and 15% yield of 107 and 108 and 31% yield of dimeric analogue 109 (Figure 
10). Hence, in further investigations only anti-diols were used. 
 
Figure 10. Isolated products from the acid-mediated cyclisations of syn-104 and anti-diols 106 
1.3.3 Two steps synthesis of racemic diols and optimisation of the acid-mediated 
coupling reaction 
At this point of the research our attention turned to the optimisation of conditions for the 
dimerisation reaction, aiming to increase the yield of the blepharocalyxin D analogue with all 
the side chains in equatorial positions. Ideally, a shorter synthetic approach to anti-diols than 
that shown in Scheme 20 was required. Wei and co-workers54 reported a regioselective aldol 
addition of unsymmetrical ketones with aldehydes using MgI2 as promoter. They synthesised 
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the required β-hydroxyketone 112 as an inseparable 9:1 mixture of isomers. We hoped that this 
mixture could be separated after reduction to the required diol. Thus, following this literature 
procedure, 4-phenyl-2-butanone 110, cinnamaldehyde 111, MgI2 and N,N-
diisopropylethylamine were stirred at room temperature for 2 h and after an acid work-up a 
56% yield of a 6:1 mixture of regioisomers 112 and 113 was obtained (Scheme 27). 
 
Scheme 27. Aldol reaction of aldehyde 111 and ketone 110 
In the case of unsymmetrical ketones such as 110, deprotonation of both carbonyl α-carbons 
can occur, and the use of a bulky amine is intended to favour deprotonation of the more 
available methyl group. Unfortunately, in this case, deprotonation at the internal α-carbon of 
the carbonyl is not completely avoided leading to formation of 113. 
Thus, the use of enone 114 instead of ketone 110 should avoid the undesired deprotonation and 
only the required β-hydroxyketone 115 should be isolated. Hence, 4-phenyl-3-buten-2-one 114 
and dihydrocinnamaldehyde 35 were treated with Hünig's base and MgI2, and only 
β-hydroxyketone 115 was isolated in 45% yield (Scheme 28). In an attempt to improve this yield, 
a 50% increment on the equivalents of the base and Lewis acid were used but a lower yield (19%) 
of 115 was isolated. Although the inseparable mixture of regioisomers was avoided the yield 
was very low compared to the 81% yield reported by Wei.54 
 
Scheme 28. Aldol addition of aldehyde 35 and enone 114 
After these disappointing results, it was decided to continue using 4-phenyl-2-butanone 110 and 
cinnamaldehyde 111 as starting materials and to optimise the reaction conditions (Scheme 27). 
Firstly, increasing the equivalents of MgI2 (1.5 eq.) and i-Pr₂NEt (1.6 eq.) and a slower addition 
of the base resulted in a lower 36% yield but improved regioselectivity with a 10:1 ratio of 
isomers, suggesting that the slow addition of base improved the selectivity. In this reaction, TLC 
analysis of the crude reaction mixture after the acidic work-up (2N HCl) showed the presence of 
news spots, suggesting that the use of acid was leading to the formation of further products and 
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so causing a decrease in the yield of 112. Changing to a basic work-up (NaHCO3) increased the 
yield of 112 to 67%. 
As magnesium iodide is light sensitive, the reaction was protected from light and a syringe pump 
was used to add the base very slowly resulting in 86% isolated yield of a 10:1 inseparable mixture 
of regioisomers 112 and 113 (Scheme 29). With this improved yield, β-hydroxyketone 112 was 
reduced using Evans-Saksena directed reduction to obtain anti-diol 116 in 67% yield and 5:1 dr. 
As expected, diol 117 was evident in the crude mixture by both TLC and 1H NMR spectrum but 
was readily removed by column chromatography. 
 
Scheme 29. Two step synthesis of anti-diol 116 
Although this reaction sequence was not enantioselective, it was short and simple to perform 
on a multigram scale producing the required substrate 116 to continue further investigations on 
the dimerisation reaction. 
Different reaction conditions were investigated with the aim of improving the yield of 
blepharocalyxin D analogue 95. First, diol 116 was treated with TMSOTf for 2 h at four different 
temperatures: room temperature, 0, −10 and −30 °C (Scheme 30). After standard work-up, the 
four crude mixtures were analysed by 1H NMR spectra (Figure 11). 
 
Scheme 30. Acid-mediated reaction of anti-diol 116 at different temperatures 
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1H NMR analysis showed that the reactions at room temperature and 0 °C gave no starting 
material and anti-dihydropyran 94 and dimeric diarylheptanoid 95 were produced. The reaction 
at −10 °C showed a significant amount of starting diol 116 and a very small amount of anti-
dihydropyran 94 was detected. When the reaction was performed at −30 °C mainly starting 
anti-diol 116 was observed.  
 
 
Figure 11. 1H NMR spectra comparison among standard compounds 94, 95 & 116 and crude reaction 
mixtures 
 
Having set the optimal temperature at 0 °C, several non-nucleophilic Lewis acids which are 
commonly used for Prins cyclisations35,55,56 were tested. Thus, anti-diol 116 was treated 
separately with 5% of seven different Lewis acids: Yb(OTf)3, Ag(OTf)3, Sc(OTf)2, Sn(OTf)3, In(OTf)3, 
Bi(OTf)3 and BF3·Et2O, with stirring for 7 h at 0 °C. Following a standard work-up the crude 
mixture of each reaction was analysed by 1H NMR spectroscopy. It was apparent that reactions 
with Yb(OTf)2 and Ag(OTf)3 returned starting material after 7 hours. In the case of Sc(OTf)3 no 
starting material was apparent, but a complex mixture had been formed and no further 
investigation was undertaken. The reactions with Sn(OTf)2, In(OTf)3, Bi(OTf)3 and BF3·Et2O gave 
no starting material and anti-dihydropyran 94 and dimeric diarylheptanoid 95 were produced. 
Sn(OTf)3 and BF3·Et2O showed the most promising results, hence, larger scale reactions with 
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these Lewis acids were performed and after 24 h dimeric diarylheptanoid 95 was isolated in 7% 
and 27% yield respectively, not showing an improvement over the use of TMSOTf.  
Rychnovsky and co-workers57 have shown that non-polar solvents play an important role in 
reactions as Prins cyclisation favour ion-pairing, and the use of hexane has proved effective in 
the synthesis of bicyclic tetrahydropyrans in intramolecular Prins cyclisations.29 Hence, hexane 
was tested as an alternative solvent in our dimerisation reaction, but diol 116 was not very 
soluble and only small quantities of products were obtained and most of the starting material 
was recovered. 
In conclusion, none of the reaction conditions showed an improvement on the original 5% of 
TMSOTf in CH2Cl2 at 0 °C and so future studies used these conditions. 
1.3.4 Synthesis and dimerisation of allylic ether 119 and acetate 121 
Diarylheptanoids 6-9 (Figure 2) incorporating methyl and ethyl ethers were also isolated from 
the seeds of A. blepharocalyx,11 thus we investigated if these compounds would react to give 
the same mixture of products under acidic conditions as the analogous diols. Hence, methyl 
ether 119 was synthesised in two steps and 49% overall yield from β-hydroxyketone 112. First, 
112 was methylated using iodomethane and silver(I) oxide in diethyl ether to give β-methoxy 
ketone 118 after three days of stirring, then subsequent reduction using NaBH4 gave methyl 
ether 119 as a mixture of diastereomers in 81% yield. 
 
Scheme 31. Synthesis of methyl ether 119 and its acid-mediated cyclisation 
Methyl ether 119 was treated with 5% TMSOTf in dichloromethane at 0 °C, however after 1 h of 
stirring TLC showed that no reaction had occurred. Hence the temperature was increased to 
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room temperature and the mixture stirred for 1 h. After purification by column chromatography 
anti-94 and syn-dihydropyrans 93 were isolated in 23% and 20% yield along with blepharocalyxin 
analogue 95 in 7% yield and a mixture of bicyclic isomers 96 in 15% yield (Scheme 31).  
Next, the effect of a better leaving group at the allylic position was investigated. Acetate 121 
was synthesised in two steps from anti-diol 116 (Scheme 32). Standard acetylation of 116 with 
acetyl chloride gave an inseparable mixture of both mono-acetylated diarylheptanoids 120 and 
121 in a 2.5:1 ratio favouring the required allylic acetate 121. The mixture was treated with 
manganese dioxide to selectively oxidise allylic alcohol 120 to enone 122 and after purification 
by column chromatography, the desired ester 121 was isolated in 45% yield over the two steps. 
 
Scheme 32. Synthesis of acetate 121 
Acetate 121 was treated with 5% TMSOTf at 0 °C for 30 minutes. After standard work-up and 
column chromatography syn- and anti-dihydropyrans 93 and 94 were isolated, along with 18% 
of dimeric diarylheptanoid 95 and 35% of a mixture of dimeric isomers 96 (Scheme 33). 
 
Scheme 33. Acid-mediated cyclisation of ester diarylheptanoid 121 
Hence, the presence of a good leaving group increases the rate of the reaction and favours the 
intermolecular reaction producing about 50% of dimeric diarylheptanoids 95 and 96 and only 
14% of dihydropyrans 93 and 94. 
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1.3.5 Effect of the electron-density on the allylic aromatic ring on the 
dimerisation process 
Taking into consideration the results obtained so far, it was proposed that the 
2,8-dioxabicyclo[4.4.0]decanes are likely to be generated via allylic carbocationic intermediates 
which could be stabilised by an electron-rich aromatic ring. To test this hypothesis two new 
unsaturated diols 126 and 131 with electron-rich and electron-deficient aromatic rings were 
synthesised via an aldol reaction. Treatment of commercially available 
p-methoxycinnamaldehyde 123 and 4-phenylbutan-2-one 110 with Hünig’s base and MgI2 gave 
an inseparable mixture of regioisomers of β-hydroxyketone 124 and 125 in 5.5:1 ratio (Scheme 
34). Reduction of the mixture with Me4NHB(OAc)3 gave diol 126 containing an electron rich 
aromatic ring in 37% over two steps.  
 
Scheme 34. Synthesis of dihydroxy-diarylheptanoid 126 with an electron rich aromatic ring.  
For the synthesis of dihydroxy-diarylheptanoid 131 bearing an electron deficient aromatic ring, 
the required aldehyde 128 was not commercially available. Hence 4-(trifluoromethyl)cinnamic 
acid 127 was reduced with NaBH4 via reaction of the acid with ethyl chloroformate and 
triethylamine giving the primary alcohol. Subsequent manganese dioxide oxidation produced 
the corresponding aldehyde 128 in 75% over two steps (Scheme 35). Aldehyde 128 was reacted 
with 4-phenylbutan-2-one 110, MgI2 and DIPEA giving β-hydroxyketones 129 and 130 as an 
inseparable mixture of regioisomers in 20:1 ratio, which after Evans-Saksena reduction, diol 131 
was isolated. 




Scheme 35. Synthesis of dihydroxy-diarylheptanoid 131 with an electron deficient aromatic ring.  
Diols 116, 126 and 131 were treated separately with 5% of TMSOTf at 0 °C for 1 h. Diol 131 with 
the electron-withdrawing p-trifluoromethylphenyl group simply returned starting material 
(Figure 12). In contrast, diol 126 containing the electron-donating methoxy group gave 
blepharocalyxin D analogue in 23% yield along with a further 32% of mixed dimeric products and 
2% of anti-dihydropyran. Diol 116 containing an allylic phenyl group returned 50% of the starting 
material and a poor yield of cyclic products were obtained. 
 
Figure 12. Acid-mediated cyclisations of dihydroxy-diols 116, 126, 131. 
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These results are in accord with the reaction proceeding via carbocationic intermediates 
stabilised by the presence of the electron-rich p-methoxyphenyl ring.  
1.3.6 Two step enantioselective synthesis of dihydroxy-diarylheptanoids 
At this point of the research, we focused our attention on the development of a short 
enantioselective synthesis of precursor diarylheptanoids with different aryl groups aiming to 
produce enantiopure dimeric diarylheptanoids. 
Firstly, a proline catalysed direct asymmetric aldol reaction was investigated.58 Thus 4-
phenylbutan-2-one and cinnamaldehyde were treated with L-proline in DMSO for 12 days, but 
unchanged starting materials were recovered. Next, a Mukaiyama aldol using (R)-BINOL as 
asymmetric catalyst and titanium tetraisopropoxide (Ti(OiPr)4)59 was tested which also returned 
unreacted starting materials.  
Paterson and co-workers have used Ipc2BCl to perform several asymmetric aldol reactions with 
good diastereoselectivity.60–65 For example, in the synthesis of the macrocyclic core of 
laulimalide, 65 reaction of 132 and 133 with (+)-Ipc2BCl and Et3N in Et2O at −100 °C gave 134 in 
91% and 3:1 dr (Scheme 36).  
 
Scheme 36. Synthesis of 134  via boron aldol coupling61 
Paterson and co-workers66 proposed a mechanism for the reaction as illustrated in Scheme 37. 
The methyl ketone is converted to an enolate 135, then reaction with aldehyde favours the 
twist-boat conformation 137 over the chair conformation 136 as it avoids steric interaction 
between R1 and a bulky Ipc group which is apparent in the chair structure 136 (Scheme 37). This 
then leads to an attack of the aldehyde on the top face of the enolate 137, which prefers to have 
the Ipc group tilted up out of the plane. 




Scheme 37. Mechanism of (Ipc)2BCl aldol reaction66 
Thus, following Paterson’s conditions enone 114 and aldehyde 35 were reacted with (+)-Ipc2BCl 
and Et3N producing β-hydroxyketone 138 in 81% yield with 83:17 er along with a 9% of anti-diol 
139 in 88:12 er as determined by chiral HPLC (Scheme 38). 
 
Scheme 38. Synthesis of β-hydroxyketone 138 and diol  116 
In an attempt to improve the enantioselectivity of the reaction different solvents were tested. 
Thus, five reactions were performed under the same reaction conditions of stirring at −20 °C for 
4 h using either THF, hexane, dichloromethane or toluene as the solvent. The yields and 




% yield er 
Total yield 
138 116 138 116 
THF 73 6 73:27 92:8 79 
Hexane 81 18 79:21 84:16 99 
DCM 85 13 68:32 93:7 98 
Toluene 75 14 74:26 87:13 89 
Et2O 81 9 83:17 88:12 89 
Table 3. Optimisation of the (Ipc)2BCl aldol reaction 
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The five reactions produced good yields (>70%) of β-hydroxyketone 138, with dichloromethane 
being the most efficient with 85% yield, unfortunately the use of this solvent reduce the 
selectivity of the reaction (68:32 er). THF, hexane and toluene showed better enantioselectivity 
(>70:30 er) but none of the solvent tested improved the 83:17 er obtained when using diethyl 
ether. Along with β-hydroxyketone 138, low yields of diol 116 with different enantiomeric ratios 
and >98 dr in favour of the anti-diol, as determined by 1H NMR spectroscopy, were also isolated. 
It is apparent that after the aldol reaction, reduction of hydroxyketone 138 occurred.  
The mechanism of this reduction is shown in Scheme 39. Firstly, an aldol reaction between 
enone 114 and aldehyde 35 occurred in the twist conformation 139, which leaves the Ipc group 
close enough to deliver a hydride from the bottom face of the carbonyl on 140 producing diol 
116 and the loss of pinene. 
 
 
Scheme 39. Mechanism of reduction with (+)-Ipc2BCl 
 
Hence, in order to improve the overall er of hydroxyketone 138, enone 114 and aldehyde 35 
were treated with (+)-Ipc2BCl and Et3N at −20 °C for 4 h to allow the aldol reaction to reach 
completion, then the reaction was warmed to room temperature and stirred overnight (Scheme 
40). After work-up and column chromatography 20% of β-hydroxyketone 138 with 98:2 er was 
isolated along with 60% of diol 116 with 57:42 er as determined by chiral HPLC. In this case, the 
er of the isolated β-hydroxyketone 138 was excellent although the isolated yield (20%) was 
disappointing. Thus, for future reactions a continuous monitoring using chiral HPLC was 
performed to obtain a good selectivity without sacrificing too much yield of β-hydroxyketone 
138. 




Scheme 40. Synthesis of β-hydroxyketone 138 and diol 116 
1.3.7 Synthesis of anti-diols (+)-126 and 126 and their acid-mediated cyclisation 
Having an enantioselective route for the synthesis of hydroxyketones in hand, we pursued the 
synthesis of (+)-anti-diol 126, with the electron-rich aromatic ring. Enone coupling partner 142 
was synthesised in 90% yield from reaction of p-anisaldehyde 141 with acetone in the presence 
of a 10% solution of NaOH (Scheme 41).67 Aldol reaction of enone 142 with aldehyde 35 using 
(+)-Ipc2BCl and Et3N produced β-hydroxyketone 125 in 31% yield and 95:5 er, as determined by 
HPLC (Figure 13). Directed reduction using Me4NHB(OAc)3 gave diol (+)-126 in 82% yield with a 
dr of 12:1.  
 
Scheme 41. Synthesis of (+)-anti-diol 126 
 
Figure 13. Chiral HPLC trace of enantioenriched hydroxyketone 125 
(+)-Anti-diol 126 was treated with 5% TMSOTf at 0 °C for 10 minutes. After standard work-up 
normal phase HPLC purification of the crude extract was performed and five dimeric compounds 
128, 143-146 were isolated (Scheme 42). 




Scheme 42. Acid mediated cyclisation of (+)-anti-diol 126 (yield determined by HPLC)  
The structure and relative stereochemistry of the most abundant dimeric diarylheptanoid 128 
isolated was determined by comparison of its 1H and 13C NMR spectra with the data of analogue 
95, which had been synthesised earlier in this research project (Scheme 21). Analogue 95 differs 
from the isolated compound 128 by the presence two p-methoxyphenyl groups in the side 
chains at C-5 and C-7. Comparison of the 1H and 13C NMR spectra of analogues 95 and 128 (Figure 
14 & Figure 15) illustrates the close correspondence present between them, confirming that 
bicyclic compound 128 has a trans-2,8-dioxabicyclo[4.4.0]decane framework with the four side 
chains in equatorial positions.  
 
Figure 14. 1H NMR spectra of analogue 95 and isolated compound 128  




Figure 15. 13C NMR spectra of analogue 95 and isolated compound 128  
The other four isolated compounds 143-146 have the same molecular formula (C40H44O4) as 
determined by HRMS. The similarity of their 1H and 13C NMR spectra compared with those of 
blepharocalyxin D analogue 128 indicated that they are diastereomers. Extensive spectroscopic 
studies were used to fully assign all of the NMR spectra and the relative configuration of the side 
chains were determined by analysis of the coupling constants and nOe correlations. The 
couplings of 1-H to 6-H (J 10-11 Hz) and nOe correlations showed that all four products were 
assembled on a trans-2,8-dioxabicylodecane framework with the 7-methoxyphenyl ring 
equatorial (coupling 6-H to 7-H J 10-11 Hz). The structures 143-146 varied by having one or more 
axial side chains. 
 
Figure 16. nOe correlations (blue) of analogue 143 
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In compound 143, 5-H shows trans-diaxial couplings (J 10 Hz) to 4-Hax and 6-H indicating that the 
C-5 side chain is equatorial. This assignment was supported by nOe correlations among 1-H, 5-
H and 7-H revealing their co-axial relationship (Figure 16). The side chains at C-9 and C-3 are 
axial with coupling (J 5-6 Hz) of the equatorial 9-H with 10-Hax and equatorial 3-H with 4-Hax. The 
small coupling (J 1 Hz) of 3-H with 4-Heq suggest that the chair conformation is slightly flattened, 
due to repulsion of the side chains, bringing 3-H to almost a 90° angle with 4-Heq. There were 
further nOe correlations of the axial 7-H to 9-CH2 and from 1-H to both 3-CH2 and 9-CH2 in accord 
with both the C-3 and C-9 chains being axial. It is interesting to note the downfield shift of the 
signal assigned to 9-H from the blepharocalyxin D analogue 128 (9-Hax  3.5) to  4.2 for this 
isomer in which 9-H is now equatorial. This proved characteristic in analysis of the data for the 
other isomers (Figure 18).  
 
Figure 17. nOe correlations (blue) of analogue 144 
For compound 144 only the side chain at C-7 is equatorial and those at C-3, C-5 and C-9 are all 
axial. This was determined from the magnitude of the vicinal coupling constants (J 3-6 Hz) of 3-
H, 5-H and 6-H and was supported by nOe correlations shown in Figure 17. There were 
correlations between 1-H and 3-CH2, 5-CH, 7-H and 9-CH2 as well as from 7-H to 5-CH and 9-CH2. 
It is particularly interesting to note the downfield shift of the olefinic signals in 144 ( 6.33 &  
6.02) compared with the other isomers ( 5.74 &  5.01) as the double bond is no longer on the 
same face as the aromatic ring at C-7 and hence not within its shielding region (Figure 18). In 
addition, there was the characteristic downfield shift of the signal assigned to 9-H to  4.2 for 
this isomer compared with blepharocalyxin D analogue 128 (9-Hax  3.5). 




Figure 18. 1H-NMR spectra of compounds 128, 143-146 showing the signals of the double bond 
protons (1’H-2’H) and those bonded to oxygen (1-H, 3-H, 7-H & 9-H) 
These left structures of the diastereomers 145 and 146 remaining to be assigned. These were 
isolated in small quantities (1-2 mg) but sufficient material was available for full NMR analysis. 
 
Figure 19. nOe correlations (blue) of analogue 145 
A Bioinspired Strategy for the Synthesis of Fused Oxygen Heterocycles 
39 
 
In the case of isomer 145, only the side chain at C-9 was axial and 3-H, 5-H and 7-H all showed 
characteristic vicinal trans-diaxial couplings (J 10-12 Hz) in accord with the substituents at C-3, 
C-5 and C-7 being equatorial. This was confirmed by nOe correlations among 1-H, 3-H, 5-H and 
7-H which revealed their co-axial relationship. Additionally, nOe correlations of 6-H with 4-Hax 
and 10-Hax affirmed their co-axial relationship. The assignment of the axial configuration of the 
side chain at C-9 was in accord with vicinal coupling (ca. 5 Hz) of 9-Heq with 10-Heq and 10-Hax 
and nOe correlations of 9-H with both protons on C-10. 
 
Figure 20. nOe correlations (blue) of analogue 146 
The final diastereomer was compound 146 with equatorial side chains at C-5, C-7 and C-9 with 
the expected vicinal trans-diaxial couplings (J 10 Hz) apparent for 5-H, 7-H and 9-H and the 
characteristic upfield shift of the signal assigned to 9-Hax ( 3.5). This conclusion was supported 
by nOe correlations among 9-H, 1-H, 5-H and 7-H revealing their co-axial relationship. The side 
chain at C-3 was axial and assigned from the characteristic vicinal coupling constants (J 2-4 Hz) 
and 3-H showed nOe correlations only with 4-H2. 
The major products 128, 143 and 144 each arise from coupling two molecules of the major 
enantiomer (3S, 5R) of starting diol 126. In contrast, the remaining two products 145 and 146 
were isolated in very low yields, 3% and 1% respectively, and originate from coupling the 
enantiomers of the starting material. Since these two isomers have been characterised, we next 
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investigated if the acid-mediated cyclisation of racemic anti-diol 126 would produce further 
dimeric compounds. Thus, anti-diol 126 was treated with 5% TMSOTf at 0 °C and HPLC 
purification of the crude extract was performed (Scheme 43). 
 
 
Scheme 43. Diastereomers isolated from the acid-mediated cyclisation of racemic diol 126 
 
Eight compounds were isolated, compounds 128, 143-146 have been previously characterised 
from the acid-mediated reaction of (+)-anti-diol 126. The three new dimeric compounds 147-
149 have the same molecular formula C40H44O4 as compounds 143-146, as determined by HRMS. 
The similarity of their 1H and 13C NMR spectra compared with 143-146 indicated that they are 
also diastereomers. Extensive spectroscopic studies were used to fully assign the structures and 
the relative configuration of the side chains was determined by analysis of the coupling 
constants and nOe correlations. 




Figure 21. nOe correlations (blue) of analogue 147 
Similarly to diastereomers 143-146, from nOe and the coupling of 1-H to 6-H (J 11 Hz) it was 
evident that compound 147 was assembled on a trans-2,8-dioxabicyclodecane framework with 
equatorial substituents at C-7 and C-9 (vicinal axial-axial couplings J 10-11 Hz) and axial side 
chains at C-3 and C-5 (vicinal couplings J 2-6 Hz). This assignment was verified by nOe studies 
(Figure 21) with diagnostic correlations between the axial 1-H, 5-H and 7-H whilst 3-H showed 
correlations only to 4-H2. 
 
Figure 22. nOe correlations (blue) of analogue 148 
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Unlike the other dimeric diarylheptanoids isolated from the acid-mediated reaction of diol 
(+)-126, compound 148 is assembled on a cis-2,8-dioxabicyclodecane framework as determined 
from the coupling constant (J 3Hz) of 1-H and 6-H along with their nOe correlations. The rings 
adopt a chair-chair conformation with equatorial side chains at C-7 and C-9 (Figure 22). The axial 
7-H and 9-H show nOe correlations to each other as well as to 4-Hax. The axial side chains at C-3 
and C-5 were assigned by the vicinal couplings (J 3-5 Hz) of 3-Heq and 5-Heq and nOe correlations 
among 3-H, 10-Heq, 7-H and 9-H reveal their proximity in the cis configuration of the rings. 
Additionally, there were nOe correlations between the aromatic protons of the 7-phenyl group 
and 5-H, 6-H and 7-H as well as between 1-H and 5-CH. 
 
Figure 23. nOe correlations (blue) of analogue 149 
A further product 149 was also assembled on a cis-fused bicyclic framework deduced from the 
coupling (J 5 Hz) of the protons 1-H and 6-H and their nOe correlation. Interestingly, while the 
side chains at C-3, C-5 and C-9 are equatorial with 3-H, 5-H and 9-H showing vicinal axial-axial 
couplings (J 11-12 Hz), the 7-phenyl group is axial with 7-H appearing as a broad singlet at  5.15. 
The presence of nOe correlations of 7-H, 1-H, 10-Heq and 6-H with the aromatic ring are in accord 
with the C-7 phenyl group being axial. Furthermore, this proposed structure was supported by 
nOe correlations among 3-H, 5-H and 10-Hax revealing their co-axial relationship.  
In conclusion, it is evident that more diastereomers are formed when using racemic diol 126, 
eight compounds (Scheme 43) were isolated compared to five when diol (+)-126 was used 
(Scheme 42). Additionally, the yield of those compounds that originate from coupling the two 
A Bioinspired Strategy for the Synthesis of Fused Oxygen Heterocycles 
43 
 
enantiomers of the starting material increased when using racemic diol 126 and those coming 
from the same enantiomer significantly decreased. 
1.3.8 Proposed reaction mechanism 
Results from the studies described herein using substrates with electron-rich and electron-
deficient aromatic rings (pg. 29), combined with the array of products formed (pg. 34) are in 
accord with the proposed mechanism for the formation of the dimeric diarylheptanoids 
illustrated in Scheme 44 for the generation of the major diastereomer 128. Loss of the allylic 
hydroxyl group from diol 126 gives carbocation I stabilised by the aromatic ring. Reaction of diol 
126 with I couples the two molecules together generating a further intermediate II, then 
intramolecular attack leads to formation of the carbon-carbon bond and secondary carbocation 
III again stabilised by the aromatic ring. Finally, cyclisation generates the bicyclic product 128. 
Whilst the trans-fused rings with all equatorial side chains 128 is preferred, other diastereomers 
may arise by non-stereoselective attack on the carbocationic intermediates (Scheme 44). 
 
Scheme 44. Proposed mechanism for formation of dimeric diarylheptanoids  
An interesting feature of the proposed mechanism is that the allylic alcohol at C-3 must be lost 
selectively from the diols in the coupling process, thus both oxygens in the bicyclic heterocycles 
will originate from 5-hydroxyl group of starting diol 126. To verify this proposal, we used an 
oxygen-18 labelling approach where the site of isotopic label could be tracked by 13C NMR 
spectroscopy. Risley and Van Etten68 have reported that an 18O-isotopic label in organic 
compounds results in an upfield shift in the 13C NMR signal attach to the 18O, the magnitude of 
which is dependent on the type of compound, in the case of alcohols a shift of ca. 0.02 ppm is 
expected. As such a small shift is to be detected and so ideally the substrate will have <90% 
incorporation of oxygen-18 so that two signals can be detected in the 13C-NMR spectrum. 
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Thus, 3-phenylpropanal 35 was labelled to about 50% incorporation by exchange with oxygen-
18 labelled water (Scheme 45). Then, [18O]-phenylpropanal 150 and (E)-4-phenyl-3-buten-2-one 
114 were treated with Et3N and (+)-Ipc2BCl to produce [18O]-hydroxyketone 151 in 27% yield and 
96:4 er, as determined by chiral HPLC. Directed reduction of 151 using Me4NHB(OAc)3 produced 
[18O]-anti-diol 152 with 88:12 dr and in 90% yield. The signal assigned to C-5 in the 13C-NMR 
spectrum is shown in Figure 24, in which two signals are apparent, one due to 13C-16O (δ 69.07) 
and an upfield signal from 13C-18O (δ 69.04).  
 
Scheme 45. Synthesis of [18O]-anti-diol 152 
[18O]-Diol 152 was treated with TMSOTf at 0 °C for 1.5 h and after standard work-up, column 
chromatography and further HPLC purification, dimeric product [18O]-153 was isolated in 8% 
yield. The 13C NMR spectrum of 153 clearly showed that the signals assigned to all four 
oxygenated carbons in the rings C-1 (δ 79.13), C-3 (δ 75.77), C-7 (δ 83.39), C-9 (δ 75.02), retained 
the oxygen-18 label, consistent with the proposed mechanism of dimerisation (Figure 24). 
 
Figure 24. 13C NMR showing the C-1, C-3, C-7 and C-9 of 153 recorded in CDCl3 




1.3.9 Synthesis and acid-mediated cyclisation of (+)-anti-diol 116  
To investigate if the acid-mediated cyclisation of the enantiopure material with phenyl groups, 
rather than the electron-rich p-methoxyphenyl group, would form the same group of 
compounds, (+)-anti-diol 116 was synthesised. Enone 114 and aldehyde 35 were reacted with 
(+)-Ipc2BCl and Et3N producing β-hydroxyketone 139 in 50% yield with 96:4 er as determined by 
chiral HPLC (Figure 25). Me4NHB(OAc)3 reduction of 138 gave (+)-anti-diol 116 in 84:16 dr as 
determined by 1H NMR spectroscopy (Scheme 46). 
 
 
Scheme 46. Synthesis of (+)-anti-diol 116 
 
 
Figure 25. Chiral HPLC trace of enantioenriched hydroxyketone 138 
 
(+)-Anti-diol 116 was treated with 1% TMSOTf at 0 °C with stirring for 3.5 hours (Scheme 47). 
After standard work-up, the reaction mixture was purified by column chromatography giving 
four mixed fractions which were further purified using normal phase HPLC. Seven compounds 
95 and 154-159 were isolated. 
 





Scheme 47. Acid-mediated cyclisation of (+)-anti-diol 116 
 
Compound 95 is an analogue of blepharocalyxin D with a trans-2,8-dioxa[4.4.0]bicyclodecane 
core and the four side chains in equatorial position. Racemic 95 was synthesised earlier in this 
project (Scheme 21), therefore its structure and relative configuration is known. Analogues of 
compound 154-156 have been already synthesised differing only in the aromatic ring on the C-
5 and C-7 side chains. Compounds 154-156 contain a phenyl group while analogues 143-145 
bear a p-methoxyphenyl group. Thus, these compounds were readily characterised by 
comparison of their 1H and 13C NMR spectra (Figure 26, Figure 27 & Figure 28). 




Figure 26. 1H and 13C NMR spectra of analogue 145 and isolated compound 154 




Figure 27. 1H and 13C NMR spectra of analogue 143 and isolated compound 155 




Figure 28. 1H and 13C NMR spectra of analogue 144 and isolated compound 156 
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The three new compounds 157-159 were isolated and characterised using HRMS and extensive 
1H and 13C NMR spectroscopy including nOe. All of them have the same molecular formula of 
C38H40O2, but in this case only compound 157 had similar 1H and 13C NMR spectra to previous 
analogues of blepharocalyxin D. 
 
Figure 29. 3D structure of dimeric diarylheptanoid 157 with diagnostic nOe correlations (blue).  
Compound 157 was assembled on a cis-fused ring bicyclic framework deduced from the cis 
coupling (J 3 Hz) of 6-H with 1-H. The side chains at C-3, C-5 and C-7 are equatorial with 3-H, 5-
H and 7-H showing vicinal axial-axial couplings (J 11 Hz). This proposed structure was supported 
by nOe correlations among 1-H, 3-H, 5-H and 6-H revealing their co-axial relationship. There 
were correlations between 7-H, 4-Hax and 9-CH2 confirming the co-axial relationship of 7-H, 4-
Hax and the side chain at C-9. 
 
Figure 30. 1H and 13C NMR spectra of tetrahydropyran 158 
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Interestingly, one of the new compounds isolated was tetrahydropyran 158. Its 1H NMR 
spectrum showed only two signals ( 3.74 &  3.31) assigned to CHO, and its 13C NMR spectrum 
showed the two signals ( 78.5 & 75.3) characteristic for carbon next to oxygen. Additionally, a 
characteristic signal at  209 for a carbonyl group (CO) was observed (Figure 30).  
Tetrahydropyran 158 has a chair conformation with the four side chains at C-2, C-3, C-4 and C-6 
all equatorial as determined from the vicinal trans coupling (J 10-12 Hz) of 2-H, 3-H, 4-H, 5-Hax 
and 6-H. This conclusion was supported by nOe correlations among 2-H, 4-H and 6-H revealing 
their co-axial relationship. Whilst, 3-H and 5-Hax showed nOe correlation in accord with the side 
chain at C-3 being equatorial. 
 
Figure 31. 3D structure of tetrahydropyran 158 with diagnostic nOe correlations (blue).  
The proposed mechanism for the formation of tetrahydropyran 158 is shown in Scheme 48. Loss 
of the allylic hydroxyl group from diol 116 gives carbocation I. Reaction of diol 116 with I couples 
the two molecules together generating a further intermediate II, then intramolecular attack 
leads to formation of the carbon-carbon bond and secondary carbocation III. Finally, a 1,5-
hydride shift occurs generating tetrahydropyran 158 (Scheme 48). 
 
Scheme 48. Proposed mechanism for the formation of tetrahydropyran 158 
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The final isolated product 159 has a 1H NMR spectra which resembled a 1:1 mixture of 
diastereomers of starting diol 116, but its molecular formula was that of a dimer. Analysis of the 
1D and 2D NMR spectrum revealed a 1,5-dioxocane structure (Figure 32).  
 
Figure 32. Diagnostic signals of the 1H spectrum of dimer 159 
Dimer 159 adopts the conformation shown in Figure 33 with the side chains at C-2, C-4 and C-6 
in equatorial positions and C-8 axial. This was determined from the magnitude of the vicinal 
coupling constants (J 10-11 Hz) of 2-H with 3-Hax and of 6-H with 7-Hax and supported by nOe 
correlations shown in Figure 33. There were correlations between 7-Hax and 2-H which also 
correlates with the 1’’’’-H (the side chain at C-8) as well as among 3-Hax, 6-H and 4-H revealing 
their co-axial relationship. 
 
Figure 33. 3D structure of 1,5-dioxocane 159 with diagnostic nOe correlations (blue).  
The formation of 1,5-dioxocane 159 could be explained from coupling of two molecules of the 
carbocationic intermediate I which is formed from the loss of the allylic hydroxyl group from diol 
116. Whilst shown as a concerted process it is likely to be stepwise. Eight-membered ring 159 
was treated with 5% TMSOTf at 0 °C for 1.5 h producing a mixture of dimeric diarylheptanoids 
where the major component was diastereomer 156 (Scheme 49).  




Scheme 49.Proposed mechanism for formation of 159 and its acid-mediated reaction 
To investigate the proposed mechanisms of formation of the minor components found in the 
crude reaction mixture, [3,5-2H2]-diol 162 was synthesised as a substrate in the standard 
cyclisation reaction. [2H]-Aldehyde 160 and enone 135 were reacted with (+)-Ipc2BCl and Et3N 
to produce [5-2H]-hydroxyketone 161 which was reduced to [3,5-2H2]-diol 162 using NaB2H4 in 
THF:MeOH (Scheme 50). [3,5-2H2]-Diol 162 was treated with TMSOTf in dichloromethane for 1 
h at 0 °C. The crude mixture was separated using HPLC giving [3,5-2H2]-anti- and [3,5-2H2]-syn-
dihydropyrans 93 and 94 and four dimeric [1,3,5,9-2H4]-diarylheptanoids 95, 156, 157 & 163.  
 
Scheme 50. Synthesis of [3,5-2H2]-diol 162 and its acid-mediated cyclisation 
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In the case of the dimeric diarylheptanoids the 1H NMR signals assigned to 1-H, 3-H, 5-H and 9-
H in the non-labelled product 95 were absent in [1,3,5,9-2H4]-95. (Figure 34) Similarly in 
dihydropyran 93 the signals assigned to 3-H and 5-H were absent in the [3,5-2H2]-dihydropyran 
93. (Figure 35) 
 
Figure 34. 1H NMR spectra of [1,3,5,9-2H4]-diarylheptanoid 95 and diarylheptanoid 95 
 
Figure 35. 1H NMR spectra of [3,5-2H2]-dihydropyran 93 and dihydropyran 93 
Interestingly, neither of the minor components 158 and 159 was observed in the reaction 
mixture. In the case of tetrahydropyran 158, we proposed that intermediated III required a 1,5-
hydride shift to generate the ketone. Hence a possible explanation is that, as the carbon-
deuterium bond is stronger than the C-H bond this pathway is no longer favoured, so 
tetrahydropyran 158 was not formed. 





Scheme 51. Proposed mechanism of cyclisations 
 
 
1.3.10 Total synthesis of (+)-blepharocalyxin D 
Having developed a concise approach for the synthesis of dimeric diarylheptanoids, it was then 
applied to the synthesis of (+)-blepharocalyxin D. This was of interest to compare its bioactivity 
with the natural product (−)-blepharocalyxin D (Scheme 52). The required substrate 166 for the 
key cyclisation was prepared in 2 steps via an aldol reaction of p-methoxyphenylpropanal 164 
and p-methoxyphenyl butanone 142 using (+)-Ipc2BCl and Et3N producing β-hydroxyketone 165 
in 42% yield with 90:10 er. Subsequent directed reduction using Me4NHB(OAc)3 gave anti-diol 
166 in 93% yield. Treatment of 166 with TMSOTf produced bicyclic compound 167 in 33% yield 
which was deprotected using LiSPr/HMPA to give (+)-blepharocalyxin D in 98% yield. Thus, the 
target compound was synthesised in 4 steps from simple starting materials 142 and 164 in 13% 
overall yield. The synthetic sample of (+)-blepharocalyxin D gave an optical rotation value of [α]D 
+80.3 (c. 0.7 MeOH) in accord for it being the enantiomer of the natural product with [α]D −90.4 
(c. 0.32 CHCl3). 




Scheme 52. Total synthesis of (+)-blepharocalyxin D 
At the beginning of this project a proposed biosynthesis of blepharocalyxin D (Scheme 18) was 
described with diol 81 as the natural precursor to blepharocalyxin D. Thus, to investigate if this 
compound would react to form blepharocalyxin D, we embarked in the synthesis of diol 81. 
Hence, following the concise approach that had been developed, the two components required 
for the aldol reaction were synthesised (Scheme 53). p-Hydroxybenzaldehyde and acetone were 
treated with a 10% solution of NaOH producing the required enone 168 in 55% yield, which was 
reacted with TBSCl, imidazole and DMAP to produce the corresponding silyl ether 170 in 90% 
yield. To synthesise the required aldehyde 171, benzyl ester 169 was protected with TBSCl and 
imidazole to give the corresponding silyl ether and subsequent DIBALH reduction at −78 °C gave 
the required aldehyde 171 in 86% yield. Then, silyl ethers 170 and 171 were coupled with (+)-
Ipc2BCl and Et3N giving β-hydroxyketone 172 in 30% yield with 95:5 er, as determined by chiral 
HPLC. Subsequent Evans-Saksena directed reduction produced diol 173 in 72% yield with 9:1 dr, 
as determined by 1H NMR spectroscopy. Finally, deprotection of the TBS groups using TBAF gave 
the required precursor 81 in quantitative yield.  




Scheme 53. Synthesis of diol 81 
Diol 81 was treated with 5% TMSOTf in THF for 1 h and after chromatography purification 
(+)-blepharocalyxin D was isolated in 11% yield (Scheme 54). Contrary to our standard 
dimerisation conditions, THF had to be used as the solvent as starting diol 81 was insoluble in 
dichloromethane. Inconveniently, this solvent favoured the production of dihydropyrans which 
were isolated in 50% yield. A 1:1 mixture of THF:CH2Cl2 was tested, but unfortunately no 
improvement was observed. 
 
Scheme 54. Acid-mediated cyclisation of diol 81 
This reaction demonstrated that blepharocalyxin D and dihydropyrans can be formed from diol 
81 as in the proposed biosynthesis described by Kadota and co-workers (Scheme 18, pg. 16).22  
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(+)-Blepharocalyxin D was tested for antiproliferative activity (by Summit Pharmaceuticals) and 
it proved to have moderate cytotoxic activity against HepG2 cell line with an IC50 of 48.5 μM. It 
is slightly less effective than (−)-blepharocalyxin D which gives an ED50 of 3.61 μM against 26-L5 
carcinoma cells and 25.7 μM against human HT-1080 fibrosarcoma cells. 
1.4 Conclusions 
In conclusion, we have developed a bioinspired approach for the efficient synthesis of bicyclic 
heterocycles assembled on a 2,8-dioxabicyclo[4.4.0]decane core decorated with 4 side chains. 
The key atom economic step involves an acid mediated dimerisation of a linear dihydroxy-
diarylheptanoid to produce two oxane rings and 4 new stereocentres in one pot. This route was 
used for the synthesis of (+)-blepharocalyxin D in 4 steps and 13% overall yield from simple 
starting material which is more efficient that previous published routes to blepharocalyxin D 
(Lee 17 steps, 0.9% yield and Cons & Willis 15 steps, 8% yield). 
Four routes were developed for the synthesis of linear dihydroxy-diarylheptanoids, two of them 
being short and efficient. The first one, using MgI2 as catalyst for an aldol reaction to produce β-
hydroxyketone 112 then a directed reduction gave anti-diol 116 in 57% yield over the 2 steps 
(Scheme 55). Although this synthesis is not enantioselective, it is simple to perform on a 
multigram scale. The second synthesis, using (+)-Ipc2BCl as catalyst for the aldol reaction gives 
β-hydroxyketone 138 with 96:4 er which after stereoselective reduction gives diol (+)-116 in 42% 
overall yield over the two steps.  
 
Scheme 55. Two-step approaches for the synthesis of linear diarylheptanoids 116 and (+)-116 
These routes were used in the synthesis of several dihydroxy-diarylheptanoids with electron-
deficient and electron-rich aromatic rings (Figure 36). 




Figure 36. Synthesised dihydroxy-diarylheptanoids 
The conditions for the key dimerisation step were optimised in terms of temperature, Lewis acid 
and solvent, concluding in the use of TMSOTf in CH2Cl2 at 0 °C. This dimerisation reaction 
produced mainly trans-2,8-dioxabicyclo[4.4.0]decanes, but dihydropyrans were also isolated in 
low yield (Scheme 56).  
 
Scheme 56. Acid-mediated cyclisation of diol 116 
The key acid-mediated cyclisation of dihydroxy-diarylheptanoids was used for the synthesis of 
several analogues of blepharocalyxin D (Figure 37). 




Figure 37. Synthesised analogues of blepharocalyxin D  
A mechanism for the reaction was proposed via a cascade involving carbocationic intermediates 
and verified by oxygen-18 labelling studies (Scheme 57), as well as deuterium labelling (Scheme 
50). 
 
Scheme 57. Oxygen-18 labelled proposed mechanism 
The total synthesis of the enantiomer of the natural product have been achieved in 4 steps and 
13% overall yield from simple starting materials, aldehyde 164 and enone 142. The concise 
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approach significantly reduced the number of steps to such targets. Comparing with previous 
total syntheses of blepharocalyxin D where 17 and 15 steps32,41 were required, it will give access 
to a library of dimeric diarylheptanoids for biological assessment (Scheme 58).  
 
Scheme 58. Total synthesis of (+)-blepharocalyxin D.
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2. Synthesis of Pleuromutilin Biosynthetic Intermediates  
2.1 Introduction 
2.1.1 Use of pleuromutilins as antibiotics 
Antibiotic resistance is an increasing problem worldwide, endangering the efficacy of antibiotics, 
which have transformed medicine and saved millions of lives.69 The first cases of methicillin-
resistant Staphylococcus aureus (MRSA) were identified in the United Kingdom in 1962 and in 
the United States in 1968.70 Unfortunately, nowadays resistance has been observed to nearly all 
antibiotics that have been developed.71 Although the pharmaceutical industry has introduced 
new antibiotics to solve the resistance problem, bacterial infections have again become a 
threat.72 Among Gram-positive pathogens, a global pandemic of resistant S. aureus and 
Enterococcus species currently poses the biggest threat.73 The global spread of drug resistance 
among common respiratory pathogens, including Streptococcus pneumonia and Mycobacterium 
tuberculosis, is epidemic.73 MRSA infections can be very serious and are among the most 
frequently occurring of all antibiotic-resistance threats. Enterococci cause a wide range of 
illnesses, mostly among patients in hospitals or other health care settings, including 
bloodstream, surgical-site and urinary tract infections.71 S. pneumoniae can cause serious and 
sometimes life-threatening infections. It is a major cause of bacterial pneumonia and meningitis, 
as well as bloodstream, ear and sinus infections.74 
Rapidly emerging resistant bacteria threaten the extraordinary medical advances that have been 
achieved with antibiotics.75 Hence, it is very important to develop new antibiotics for the 
treatment of bacterial infections, including resistant strains. 
Pleuromutilin is a diterpene fungal metabolite which was first reported by Kavanagh in 1951.76 
It was isolated from two basidiomycetes species, Pleurotus mutilis (now known as Clitopilus 
scyphoides) and Pleurotus passeckeranius (now known as Clitopilus passeckeranius), although it 
has now been found to be produced by 11 different Clitopilus strains.77 In the early 1960s 
structural elucidation studies were published giving the molecular formula of pleuromutilin as 
C22H34O5 and assigning three of the five oxygen-bearing centres as two non-phenolic hydroxyl 
groups and one hindered carbonyl group.78 Independent work by Arigoni79 and Birch80 
culminated in publication of the full and correct structure of (+)-pleuromutilin and provided first 
insights into the biosynthesis. This work revealed the unique tricyclic diterpenoid core of 
pleuromutilin, which consists of fused 5-,6- and 8-membered rings and eight stereocentres. The 
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numbering of pleuromutilin shown in Figure 38 was described by Arigoni and has become 
convention throughout pleuromutilin chemistry. Further evidence for the structure was 
established by Bonavia81 on the basis of X-ray and ORD data to establish the final 
stereochemistry. 
 
Figure 38. Structure of (+)-pleuromutilin with standard numbering  
Initial antibacterial studies by Kavanagh82 showed pleuromutilin was active against Gram-
positive bacteria, including all tested Staphylococcus, Streptococcus and Enterococcus strains. 
Around this time, Brandl and Knauseder83 found that pleuromutilin was also active against 
resistant bacteria such as penicillin- and streptomycin-resistant staphylococci and was highly 
active against Mycoplasma spp. 
Thousands of pleuromutilin derivatives have been prepared by modification of the C-14 side 
chain or tricyclic core,84–86 but only sulfanylacetyl derivatives, most of which contain a basic 
amine residue on the C-14 extension, have advanced into or beyond Phase I clinical studies. 
Tiamulin 175 (Denegard) (Figure 39) was the first antibiotic developed at Sandoz in 1975.87 It is 
highly active against many Gram-positive bacteria and is used as a prophylactic and therapeutic 
treatment for bacterial infections in farm animals.88 In 1999, Novartis launched valnemulin 176 
(Econor)89,90 which has broad spectrum activity against Gram-positive pathogens. Valnemulin 
has superior antimicrobial activity, against many of the same strains, than tiamulin.91 Although 
it is primarily used in veterinary medicine, valnemulin has been used in humans to treat life-
threatening drug-resistant Mycoplasma infections in immune-compromised patients.92 
 
Figure 39. Structures of tiamulin and valnemulin 
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In 1982, azamulin 177 (Figure 40) intended for human use was synthesised by Berner93 and 
disclosed by GlaxoSmithKline. Azamulin was reported to have good oral bioavailability at dosage 
levels appropriate for clinical use, despite its extensive metabolism by cytochrome P450 
oxidation. However, azamulin did not progress beyond a Phase I clinical trial because it was 
found to be a strong and irreversible inhibitor of CYP3A.85 It was not until 2007 that the first 
pleuromutilin, retapamulin 178 (Altargo) for clinical use was introduced. Retapamulin shows 
excellent potency against S. aureus and S pyrogenes.94 It is used as a topical, short-term 
treatment for skin and soft tissue infections including impetigo and small infected lacerations, 
abrasions, or sutured wounds.95  
 
Figure 40. Structures of Azamulin and Retapamulin 
Nabriva Therapeutics has extensively investigated C-14 derivatives of (+)-pleuromutilin and 
identified lefamulin 179 (BC-3781) as potentially a drug suitable for systemic use in humans 
(Figure 41).85 Lefamulin 179 has shown promising activity96 for a number of clinical applications 
including acquired bacterial pneumonia, acute bacterial skin infections (Phase 2 completed) and 
sexually transmitted infections (Phase 1 completed), among others. Lefamulin exhibits excellent 
potency against a broad spectrum of Gram-positive bacteria, especially drug- and multidrug-
resistant isolates.97 Nabriva have also developed BC-7013,98 a novel topical pleuromutilin, which 
recently completed Phase 2 clinical trials for the treatment of uncomplicated skin infections.96 
BC-7013 is highly active against Gram-positive bacteria that cause skin and ocular infections and 
has also demonstrated potent activity against Chlamydia trachomatis, the leading cause of 
blindness in the world, and Propionibacterium acnes, the causative agent of acne.99 
 
Figure 41. Structures of lefamulin and BC-7013 




2.1.2 Total syntheses of pleuromutilin 
Pleuromutilin has received significant attention from the synthetic community not only because 
of its bioactivity but also its unusual carbon skeleton bearing three fused rings and eight 
stereocenters. The first total synthesis of ()-pleuromutilin was completed by Gibbons.100 His 
approach to the tricyclic system was based on a sequential Michael strategy which rapidly 
assembled the hydrindane core (Scheme 59). 
  
Scheme 59. Key step in the Gibbons synthesis of pleuromutilin100 
Shortly after, Boeckman101 reported the second route to the target which utilised an anionic oxy-
Cope rearrangement to form the eight-membered ring (Scheme 60).  
 
Scheme 60. Key step in the Boeckman synthesis of pleuromutilin101 
In 2013 Procter and co-workers102 reported the first enantioselective synthesis of (+)-
pleuromutilin. The key step of the synthesis was the SmI2-mediated cascade cyclisation to form 
the 5,6,8-trycyclic core, constructing four contiguous stereocentres and two new rings in a single 
step84 (Scheme 61).  
 
Scheme 61. Key step in the Procter synthesis of (+)-pleuromutilin102 
In 2017, Herzon and co-workers103 developed an enantioselective synthetic route that relies on 
the convergent union of a complex hydridane derivate with a bifunctional C-11-C-13 synthon.  





Scheme 62. Key step in the Herzon synthesis of (+)-pleuromutilin103 
The most recent enantioselective synthesis of (+)-pleuromutilin was reported by Reisman and 
co-workers104 which employs an allylborate addition as the key step to establish the C-12 
stereocenter leading to (+)-pleuromutilin in 18 steps. 
 
Scheme 63. Key step in the Reisman synthesis of (+)-pleuromutilin104 
Due to the many steps required for the total synthesis of pleuromutilin, the low yields and the 
high costs, total synthesis have not been used for large-scale production of the antibiotic. Hence, 
it appears that despite the efforts of several groups, total synthesis of pleuromutilin does not 
seem to be a cost-effective alternative to purification of the antibiotic fungal cultures. 
 
2.1.3 Biosynthesis of (+)-pleuromutilin 
In the 1960s the first investigations into the biosynthesis of pleuromutilin were undertaken by 
Birch,80 who confirmed the structure for pleuromutilin proposed by Arigoni,79 as well as proving 
through incorporation of 14C-labelled acetic and mevalonic acids that pleuromutilin was a 
diterpene. In 1976 Knauseder and Brandl83 carried out a large-scale fermentation of C. 
passeckerianus with the aim of isolating possible intermediates during the biosynthesis of 
pleuromutilin. At the end of the fermentation, pleuromutilin 174, mutilin 181, 14-O-acetyl 
mutilin 182, and a series of pleuromutilin esters were isolated from the dried mycelium. It was 
proposed that mutilin 181 and 14-O-acetyl-mutilin 182 could be the products of a secondary 
pathway that would branch from the main pathway of the antibiotic and would terminate with 
14-O-acetyl-mutiln. 




Figure 42. Structures of mutilin 181, 14-O-acetyl-mutilin 182 and 3-deoxo-11-dehydroxy-mutilin 183  
In 1979, Hasler and co-workers105 reported the isolation of the metabolite 3-deoxo-11-
dehydroxy-mutilin 183 from extracts of P. mutilus (Figure 42). They proposed that this 
metabolite would be a precursor of pleuromutilin by feeding a 14C-labelled sample of the 
compound, prepared from naturally obtained substances, to a culture of the fungus and then 
isolating 14C-pleuromutilin. They also produced evidence that mutilin 181 and 3-deoxo-mutilin 
184 would be two precursors of pleuromutilin, therefore going against the hypothesis of 
Knauseder and Brandl83 that mutilin could be the end-product of a secondary pathway. 
In 2007, Tsukagoshi and co-workers106 fed into a culture of the fungus Clitopilus pseudo-pinsitus, 
2H-labelled samples of mutilin 181, 3-deoxo-mutilin 184 and 3-deoxo-11-dehydroxy 183 and 
then isolated 2H-pleuromutilin from the corresponding mycelial cultures, proving as Hasler105 
proposed, their role as biosynthetic intermediates. From these results, the proposed 
pleuromutilin biosynthetic pathway is shown in Scheme 64.  
 
Scheme 64. Proposed biosynthetic pathway to pleuromutilin106 
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More recently Bailey´s group107 in the Department of Biological Science at the University of 
Bristol working in collaboration with our group have conducted further studies on the 
biosynthesis of pleuromutilin in C. passeckerianus. The gene cluster responsible for the 
biosynthesis of pleuromutilin was identified in this fungus leading to a patent,108 where the 
sequence of the putative gene cluster was revealed. Seven genes were proposed to be involved 
in the production of pleuromutilin. Firstly, there is a specific geranylgeranyl diphosphate 
synthase gene (GGS) responsible for providing geranylgeranyl diphosphate (GGPP) for the 
biosynthesis of pleuromutilin. Then, there are six other genes adjacent to GGS with potential 
roles in secondary metabolite biosynthesis (Scheme 65). These included a gene encoding a 
cyclase (Cyc) which commonly catalyses the cyclisation of GGPP to give the proposed first cyclic 
intermediate 183, as well as genes encoding acetyl transferase (ATF), short-chain 
dehydrogenase/reductase (SDR) and three cytochrome P450s (P450-1, P450-2 and P450-3). It 
was confirmed by Bailey and co-workers107 by Northern blot analyses and gene silencing 
experiments that these seven genes were putatively involved in the biosynthesis of the 
antibiotic. 
 
Scheme 65. Proposed biosynthetic pathway of pleuromutilin in which the seven cloned genes are 
shown over arrows. 
Heterologous expression of the seven genes in the secondary host Aspergillus oryzae (GGS, Cyc, 
P450-1, P450-2, P450-3, ATF and SDR from the native produced C. passeckerianus) recreated the 
biosynthesis of the antibiotic and demonstrated that these genes formed the pleuromutilin gene 
cluster. 
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2.2 Aim of the Project 
To confirm the proposed biosynthetic pathway and determine the function of each individual 
gene Fabrizio Alberti, a former PhD student in Bailey´s group, performed stepwise heterologous 
expression of genes from the pleuromutilin cluster in A. oryzae and isolated the products. In a 
collaborative project, my aim was to synthesise three of the putative metabolites 181, 183 and 
184 (Figure 43) to give standards for comparison with the isolated products.109 This work has 
been published in Nature Communications (Heterologous expression reveals the biosynthesis of 
the antibiotic pleuromutilin and generates bioactive semi-synthetic derivatives F. Alberti, K. 
Khairudin, E. Rodriguez-Venegas, J. A. Davies, P. M. Hayes, C. L. Willis. A. M. Bailey and G. D. 
Forster, Nat Commun., 2017, 8, 1831.) 
 
 
Figure 43. Synthetic targets 
 
2.3 Results and Discussion 
Concurrent with my work, Alberti continued to investigate the biosynthetic pathway of 
pleuromutilin by introduction of the cytochrome P450-1 gene along with GGS and Cyc producing 
3-deoxo-mutilin 184 into A. oryzae. This diol had been previously reported by Hasler105 and by 
comparison with their spectral data, confirmed 184 to be the second intermediate in the 
biosynthetic pathway of pleuromutilin. An A. oryzae transformant strain was then constructed 
harbouring GGS, Cyc, P450-1 and P450-2 from C. passeckerianus which gave 3-dihydro-mutilin 
185. This triol was novel and had not been reported in the literature, thus was one of my 
synthetic targets. Next, Alberti added the cDNA of the SDR gene to an A. oryzae host that also 
contained GGS, Cyc, P450-1 and P450-2 and this system showed the production of mutilin 181 
which was first observed by Knauseder and Brandl83 in C. passeckerianus and had been 
hypothesised to be a precursor of pleuromutilin by both Hasler105 and Tsukagoshi.106 Mutilin 181 
was also synthesised during my research project as described below.  
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Pleuromutilin is produced industrially via large-scale fermentation of Clitopilus passeckerianus 
however, it is not commercially available for research purposes at a reasonable price. Instead, a 
far more cost-effective source was tiamulin hydrogen fumarate 187 which is available as 
Denegard, a solution containing 12.5% of tiamulin hydrogen fumarate (w/v) in aqueous 
solution. To begin, a solution of Denegard was concentrated in vacuo with toluene to azeotrope 
off the water to give tiamulin salt 187 in  99% purity (Scheme 66). Reaction of 186 with 
potassium hydroxide gave mutilin 181 in 73% yield confirming the structure of the product from 
an A. oryzae transformant strain harbouring GGS, Cyc, P450-1 and P450-2 and SDR. 
Tiamulin salt 187 was treated with NaBH4 to give diol 188 in 41% yield after purification by 
column chromatography. Diol 188 was heated to reflux in a solution of 5% potassium hydroxide 
in methanol to hydrolyse the side chain giving triol 185. The structure was determined by 
spectroscopic methods and the configuration of the 3-hydroxy group determined by X-ray 
crystallography (X-ray by Jonathan Davies, PhD student in the group). 
 
 
Scheme 66. Synthesis of mutilin 181 and triol 185 
 
Comparison of the 1H and 13C NMR spectra of natural and synthetic triol 185 (Figure 44 & Figure 
45) illustrates the excellent correlation between them, supporting the proposed structure of the 
secondary metabolite 185 produced by the A. oryzae transformant strain harbouring GGS, Cyc, 
P450-1 and P450-2. 




Figure 44. 1H NMR spectra of natural (top) and synthetic triol 184 (bottom) 
 
Figure 45. 13C NMR spectra of natural (top) and synthetic triol 184 (bottom) 
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At this stage, the structures of three of the intermediates 184, 185 and 181 in the proposed 
biosynthetic pathway to pleuromutilin (Scheme 65) were now confirmed, and so attention was 
turned to the first putative cyclic intermediate 183. This is proposed to be generated from 
geranylgeranyl pyrophosphate as shown in Scheme 67. Arigoni79,110 and Birch80 proposed that 
the class II terpene synthase domain of Cyc promotes ring contraction during the protonation-
dependent cyclisation of GGPP giving I. The class I terpene synthase domain then catalyses 
formation of the eight-membered ring through ionisation-dependent dephosphorylation and a 




Scheme 67. Outline of cyclisation to the pleuromutilin tricyclic scaffold 79,80,110 
 
To investigate this step in the biosynthesis of the antibiotic, the cDNA of GGS and Cyc were co-
expressed in A. oryzae by Alberti. However, reverse-phase HPLC using a gradient of H2O 
containing 0.05% of formic acid and CH3CN containing 0.045% formic acid failed to detect any 
new product.109 It was speculated that the non-polar product was not being eluted from the 
column. Hence the extract was examined by thin-layer chromatography (TLC) and a new spot 
was apparent. Preparative TLC was used to purify 14-alcohol 183, yielding 5 mg from 1 L of 
culture. To confirm the structure of product 183 a synthetic standard was required, hence 14-
alcohol 183 was prepared by partial synthesis diol 188 (Scheme 68). This could be achieved by 
removing the 3- and 11-alcohols as well as hydrolyse the C-14 side chain to the alcohol. 
 




Scheme 68. Proposed synthesis towards alcohol 183 
 
Diol 188 was treated with MsCl and Et3N (Scheme 69). Unfortunately, desired mesylate 189 was 
not observed and alkene 191 was isolated in 50% yield. The trisubstituted alkene was evident 
from both the 13C NMR ( 152.4 for C-4 &  126.4 for C-3) and 1H-NMR spectra ( 5.55 for 3-H). 
 
Scheme 69. Reaction of diol 188 with MsCl 
 
Following this disappointing result, a stepwise sequence was investigated. Mutilin 181 was 
treated with TESCl in the presence of imidazole giving mono- and di-protected silyl ethers 192 
and 193 in 47% and 34% yield respectively. To verify that mono-protection had occurred at the 
required 14-hydroxyl group, acetylation of 192 under standard conditions gave acetate 194 in 
56% yield (Scheme 70). 




Scheme 70. Synthesis of silyl ethers 192, 193 and acetate 194 
Comparison of the 1H NMR spectra (Figure 46) between 192 and 194 showed the downfield shift 
of the signal assigned to 11-H to δ4.87 ppm when acetylated in 194, compared to δ3.34 ppm in 
alcohol 192, confirming the TES protection of alcohol at C-14. 
 
Figure 46. Diagnostic signals of 1H NMR spectra of alcohol 192 and acetate 194 
With the protection on the correct hydroxyl group achieved, alcohol 192 was treated with MsCl 
and Et3N to give mesylate 195 in only 30% yield along with 15% starting material 192 recovered 
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(Scheme 71). Reduction of mesylate 195 with LiAlH4 led to reduction of the-ketone as expected 
but no deoxygenation at C-11 occurred. Further conditions were investigated including LiAlH4 
under reflux, LiBH4 and NaBH4/LiCl but each time only alcohol 196 was obtained. Changing the 
leaving group to a tosylate was investigated by reaction of alcohol 195 with TsCl and pyridine, 
but the 11-hydroxyl group was too hindered to allow the addition of the tosylate group.  
 
Scheme 71. Synthesis of sulfonate ester 195 and alcohol 196 
Tsukagoshi and co-workers106 have reported the synthesis of a deuterated analogue of the 
required alcohol 183 via a Barton McCombie deoxygenation reaction. Thus, following this 
literature approach, ketone 192 was treated with NaBH4 to give diol 197 (Scheme 72). As the 
Barton McCombie deoxygenation proceeds through a free radical mechanism, the 19,20-alkene 
required protection. Therefore, mono-protected diol 197 was converted to triol 198 via 
hydroboration-oxidation using borane dimethylsulfide (BMS), NaOH and H2O2. Then, the new 
primary alcohol 198 was protected with addition of pivaloyl chloride to obtain pivalate ester 199 
in 71% yield. 
 
Scheme 72. Synthesis of diol 199 
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With the required protecting groups in place, the deoxygenation was investigated. Thus, diol 
199 was reacted with phenyl thionochloroformate in the presence of NaHMDS producing 
thiocarbonyl ester 200 in 96% yield (Scheme 73). Treatment of thiocarbonyl ester 200 with 
Bu3SnH and Et3B produced a 3:2 inseparable mixture of required 3,11-deoxy product 202 and 
alkene 203 in 53% yield. Furthermore, partially deoxygenated product 201 was isolated in 11% 
yield which was reduced to 202 using further Bu3SnH and Et3B radical conditions. In order to 
assist with the purification of the required 3,11-deoxy compound 202, the mixture of 202 and 
203 was treated with mCPBA to epoxidise the alkene. After purification by column 
chromatography the desired product 202 was isolated in 35% over the two steps, the epoxide 
was observed in the 1H NMR of the crude mixture but not isolated. 
 
Scheme 73. Synthesis of deoxygenated compound 202 
With the desired deoxygenated product 202 in hand, it was necessary to regenerate the 19,20-
alkene (Scheme 74). Thus, pivaloyl ester 202 was reduced with DIBALH to give alcohol 204 in 
quantitative yield. The terminal alkene was reincorporated via a Grieco elimination by treatment 
of alcohol 204 with nitrophenylselenocyanate and tributylphosphine to form a selenide which 
upon oxidation with H2O2 led to elimination to alkene 205 in 50% yield. Finally, silyl ether 205 
was deprotected using HF-pyridine to give alcohol 183 in 43% yield. 




Scheme 74. Synthesis of target alcohol 183 
Having synthesised alcohol 183, its 1H and 13C NMR spectra were compared with those of the 
natural product isolated from the extracts of A. oryzae by Alberti (Figure 47 & Figure 48). The 
excellent correlation between their NMR spectra confirmed the structure of the natural product 
as being this the first precursor in the biosynthetic pathway of pleuromutilin. 
 
Figure 47. 1H NMR spectra of natural (top) and synthetic product (bottom)  183 






Figure 48. 13C NMR spectra of natural (top) and synthetic product (bottom)  183  
 
Heterologous expression of the cDNA of an acetyl-transferase (ATF) gene along with GGS, Cyc, 
P450-1, P450-2 and SDR in A. oryzae produced 14-O-acetyl mutilin 186 proving that ATF is 
catalysing esterification of the hydroxyl group from C-14 in mutilin 181. At this point the A. 
oryzae 6-gene transformant strain producing 14-O-acetyl mutilin 186 was only lacking the gene 
P450-3 in comparison with the A. oryzae 7-gene transformant that produced pleuromutilin 174. 
Hence, it can be inferred from this that cytochrome P450-3 catalyses conversion of 14-O-acetyl-
mutilin 181 to pleuromutilin 174 thus, completing the elucidation of the biosynthetic pathway 
of pleuromutilin shown in Scheme 75. 




Scheme 75. Proposed biosynthetic pathway of pleuromutilin  
2.4 Conclusions 
Three intermediates in the biosynthesis of pleuromutilin were synthesised (Scheme 76). Triol 
185 was prepared in two steps from tiamulin 187. Its 1H and 13C NMR spectra were compared 
with those of the natural 3-dihydro-mutilin 185 isolated from extracts of the culture of A. oryzae, 
when the transformant contained GGS, Cyc, P450-1, and P450-2 genes, showing excellent 
correlation between them. 
Mutilin 181, which was previously reported by Egger111 and confirmed by Alberti112 to be a 
precursor in the biosynthetic pathway of the antibiotic pleuromutilin, was prepared in one steps 
from tiamulin 187.  
Alcohol 183 was required to confirm the structure of the first cyclic intermediate, 3-deoxo-11-
dehydroxy-mutilin 183, isolated from the extracts of A. oryzae when the transformant 
harboured only GGS and Cyc genes. A synthetic route to alcohol 183 has been developed. 
Hydrolysis of tiamulin gave mutilin 181, which was protected as the 14-monosilyl ether 192. The 
regiocontrol in the protection step was confirmed by conversion of alcohol 192 to acetate 194 
which showed a characteristic downfield shift of the signal assigned to 11-H in the 1H-NMR 
spectrum. Following reduction of the 3-ketone to alcohol 197, the 19,20-alkene was temporarily 
protected via hydroboration and selective esterification of the resultant primary alcohol giving 
199. The 3- and 11-hydroxy groups were removed via radical reduction, then pivoyl ester 202 
was reduced to alcohol 204. Following dehydration then deprotection of the silyl ether 205, the 
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target alcohol 183 was isolated. The 1H and 13C NMR spectra of the synthetic material and 
product isolated from extract of A. oryzae with the GGS and Cyc genes were compared showing 
excellent correlation between them, thus confirming the structure of the natural product. 
 





3. Experimental  
3.1 General experimental 
All reagents were sourced from commercial suppliers and were used without further 
purification. Where anhydrous conditions were necessary, standard Schlenk syringe-septa 
techniques were used with flame dried glassware under positive pressure of nitrogen. THF, Et2O, 
hexane and CH2Cl2 were dried by passing through a modified Grubbs system of alumina columns, 
manufactured by Anhydrous Engineering. All stated temperatures below ambient are the 
temperatures of the cooling baths, unless otherwise stated. Flash column chromatography was 
performed using silica gel 60 (Fisher Scientific or Aldrich) and a suitable eluent. TLC was 
performed with aluminium backed silica TLC plates (Merck-Kieselgel 60 F254) with suitable 
solvent system and was visualised using UV fluorescence (254 & 366 nm) and/or developed with 
potassium permanganate.  
Infra-red spectra were recorded on a Perkin Elmer Spectrum 100 FTIR with an ATR accessory and 
frequencies are reported in wavenumbers (cm-1). 1H and 13C NMR spectra were recorded using, 
Joel ECS 400 MHz, Varian 400-MR (400 MHz), Bruker Advance III HD 500 Cryo (500 MHz) 
spectrometers at ambient temperature. Chemical shifts (δ) are quoted in parts per million (ppm) 
and coupling constants (J) are in Hertz (Hz). Residual solvent peaks were used as the internal 
reference for proton and carbon chemical shifts. HRMS ESI were performed on either a Bruker 
Daltonics Apex 4, 7 Telsa FTICR or microTOF II. Samples were submitted in MeOH or CH2Cl2. 
Optical rotation ([α]TD) was measured on a Bellingham and Stanley Ltd. ADP220 polarimeter 
and is quoted in (°ml)(g dm)-1. All HPLC purifications and analyses were performed on an Agilent 
1260 Infinity II LC System using either a Waters SunFire Prep silica column or a Regis 





3.2 Experimental procedures chapter 1 
1-(4-Methoxyphenyl)-6-trimethylsilylhex-5-yn-3-ol     85 
 
3-(Trimethylsilyl)propargyl bromide (1.09 g, 5.71 mmol) was added to a suspension of In powder 
(0.66 g, 5.71 mmol) and InBr3 (0.16 g, 0.46 mmol) in THF (5.7 mL) under nitrogen. After stirring 
for 10 min aldehyde 84 (0.75 g, 4.57 mmol) was added. The mixture was heated to reflux for 20 
h, then, 1M HCl solution (10 mL) was added and the mixture was extracted with EtOAc (3 × 15 
mL). The combined organic layers were dried over MgSO4 and solvent evaporated in vacuo. The 
residue was purified by column chromatography using 5-20% EtOAc in petroleum ether 40-60 
°C to give alcohol 85 as a colourless oil (0.82 g, 65%).νmax (neat)/cm-1: 3855, 3672, 3473, 2933, 
1601, 1510; δH (400 MHz, CDCl3) 7.12 (2H, d, J 9, Ar), 6.83 (2H, d, J 9, Ar), 3.79 (3H, s, OCH3), 3.74 
(1H, m, 3-H), 2.78 – 2.60 (2H, m, 1-H2), 2.47 (1H, dd, J 17, 5, 4-HH), 2.37 (1H, dd, J 17, 7, 4-HH), 
1.82 (2H, m, 2-H2), 0.16 (9H, s, Si(CH3)3); δC (100 MHz, CDCl3) 157.9, 133.8, 129.4, 113.9, 103.1 
(C-5), 87.9 (C-6), 69.1 (C-3), 55.3 (OCH3), 38.1 (C-2), 31.0 (C-1), 29.0 (C-4), 0.15 (Si(CH3)3); Found 
(ESI) 299.1443 [MNa+] (C16H24O2SiNa requires 299.1438).  
(Z)-1-(4-methoxyphenyl)-6-trimethylsilylhex-5-en-3-ol     86 
 
DIBALH (1 M, 8.5 mL, 8.46 mmol) was added dropwise to a solution of alcohol 85 (0.90 g, 3.25 
mmol) in anhydrous Et2O (5 mL) under nitrogen at 0 °C. The reaction mixture was stirred at room 
temperature for 16 h, then MeOH (50 mL) and Rochelle’s salt solution (50 mL) were added and 
the aqueous phase was extracted with Et2O (3 × 100 mL). The combined organic layers were 
washed with water (50 mL) and a saturated solution of brine (50 mL). The combined organic 
layers were dried over MgSO4 and solvent evaporated in vacuo. The residue was purified by 
column chromatography using 5-10% EtOAc in petroleum ether 40-60 °C to give alcohol 86 as a 
colourless oil (0.47 g, 52%). νmax (neat)/cm-1: 3668, 2976, 2836, 1733, 1609, 1511; δH (400 MHz, 
CDCl3) 7.13 (2H, d, J 9, Ar), 6.83 (2H, d, J 9, Ar), 6.31 (1H, m, 5-H), 5.69 (1H, d, J 14, 6-H), 3.79 (3H, 
s, OCH3), 3.68 (1H, m, 3-H), 2.76 (1H, m, 1-HH), 2.65 (1H, m, 1-HH), 2.35 – 2.29 (2H, m, 4-H2), 




133.2 (C-6), 129.4, 113.9, 70.6 (C-3), 55.3 (OCH3), 41.4 (C-4), 38.8 (C-2), 31.2 (C-1), 0.34 (Si(CH3)3); 
Found (ESI) 301.1585 [MNa+] (C16H26O2SiNa requires 301.1594). 
7-(p-Chlorophenyl)-3-(p-methoxyphenethyl)-3,4-dihydro-2H-pyran     87 
 
p-Chlorobenzaldehyde (0.33 g, 2.37 mmol) and a solution of alcohol 86 (0.33 g, 1.185 mmol) in 
anhydrous CH2Cl2 (1.8 mL) were added to a solution of BiBr3 (0.027 g, 0.06 mmol) in CH2Cl2 (10 
mL) under nitrogen. After stirring for 15 h the reaction mixture was filtered through silica gel 
and the solvent was evaporated in vacuo. The residue was treated with NaBH4 (0.09 g, 2.37 
mmol) in MeOH (10 mL) for 0.5 h to reduce any residual aldehyde. Water (10 mL) was added 
and the solution was extracted with EtOAc (3 × 25 mL). The combined organic layers were dried 
over MgSO4 and the solvent evaporated in vacuo. The residue was purified by column 
chromatography using 2% Et2O in petroleum ether 40-60 °C to give dihydropyran 87 as a 
colourless oil (0.225 g, 58%). νmax (neat)/cm-1: 3434, 2932, 1689, 1611, 1590, 1511; δH (400 MHz, 
CDCl3) 7.33 (4H, s, Ar), 7.12 (2H, d, J 9, Ar), 6.83 (2H, J 9, Ar), 5.91 (1H, ddt, J 10, 6, 2, 5-H), 5.70 
(1H, ddt, J 10, 3, 1, 6-H), 5.11 (1H, m, 7-H), 3.79 (3H, s, OCH3), 3.69 (1H, m, 3-H), 2.79 – 2.64 (2H, 
m, 1-H2), 2.13 (1H, m, 4-HH), 2.05 – 1.89 (2H, m, 4-HH, 2-HH), 1.79 (1H, m, 2-HH); δC (100 MHz, 
CDCl3) 157.8, 140.4, 134.2, 133.5, 129.8 (C-6), 129.4, 128.7, 128.6, 125.3 (C-5), 113.8, 76.9 (C-7), 
73.4 (C-3), 55.3 (OCH3), 37.7 (C-2), 30.9 (C-4), 30.7 (C-1). Found (ESI) 351.1128 [MNa+] 
(C20H21O2ClNa requires 351.1122).  
1-Phenylhex-5-en-3-ol     89 
 
Allyl magnesium chloride (28.5 mL, 0.57 mol) was added dropwise to a solution of 
hydrocinnamaldehyde 35 (5.0 mL, 0.38 mol) in anhydrous THF (126 mL), at −78 °C and stirred 
for 2.5 h. Semi-saturated solution of NH4Cl (100 mL) was added and aqueous layer extracted 
with EtOAc (3 × 100 mL). The combined organic layers were dried over MgSO4 and solvent 
evaporated in vacuo. The residue was purified by column chromatography using 20% EtOAc in 
petroleum ether 40-60 °C as eluent to give alcohol 89 as a colourless oil (6.4 g, 95%). δH (400 
MHz, CDCl3) 7.31 – 7.26 (2H, m, Ar), 7.22 – 7.17 (3H, m, Ar), 5.83 (1H, m, 5-H), 5.17 (1H, m, 6-




(1H, m, 4-HH), 2.19 (1H, m, 4-HH), 1.79 (2H, m, 2-H2), 1.67 (1H, br s, OH); δC (100 MHz, CDCl3) 
142.1, 134.7 (C-5), 128.5, 128.5, 125.9, 118.4 (C-6), 70.0 (C-3), 42.1 (C-4) 38.5 (C-2), 32.1 (C-1). 
Spectroscopic data in accord with the literature.113 
(E)-7-Acetoxy-1,7-diphenylhept-5-en-3-ol     90 
 
A solution of alcohol 89 (0.25 g, 1.42 mmol) and 1-phenylallyl acetate (0.44 g, 2.48 mmol) in 
anhydrous Et2O (14 mL) was degassed with N2 for 10 min. Then Grubbs catalyst 2nd generation 
(GII) (0.03 g, 0.035 mmol) and CuI (8.0 mg, 0.042 mmol) were added and the mixture was heated 
with stirring to reflux. After 2 h, the solvent was evaporated in vacuo. The residue was purified 
by column chromatography using 20% EtOAc in petroleum ether 40-60 °C as eluent to give 
alcohol 90 as a 1:1 mixture of diastereomers as a colourless oil (0.452 g, 95%). Data given for the 
mixture νmax (neat)/cm-1: 3025, 2922, 1737, 1494, 1452; δH (400 MHz, CDCl3) 7.38 – 7.27 (7H, m, 
Ar), 7.20 – 7.17 (3H, m, Ar), 6.22 (1H, m, 7-H), 5.76 (2H, m, 5-H, 6-H), 3.68 (1H, m, 3-H), 2.79 (1H, 
m, 1-HH), 2.67 (1H, m, 1-HH), 2.31 (1H, m, 4-HH), 2.20 (1H, m, 4-HH), 2.09 & 2.05 (3H, s, COCH3), 
1.76 (2H, m, 2-H2). δC (100 MHz, CDCl3) 170.2 & 170.1 (COCH3), 142.0, 139.5, 139.4, 132.1 & 
132.0 (C-5), 130.1 & 129.9 (C6), 128.7, 128.5, 128.5, 128.2, 126.9, 125.9, 76.3 & 76.1 (C-7), 70.2 
& 70.0 (C-3), 40.6 & 40.5 (C-4), 38.5 (C-2), 32.0 (C-1), 21.4 (COCH3).; Found (ESI) 347.1605 [MNa+] 
(C21H24O3Na requires 347.1617). 
(E)-7-Acetoxy-3-tert-butoxycarbonyloxy-1,7-diphenylhept-5-ene     91 
 
Et3N (0.124 mL, 0.89 mmol), DMAP (0.016 g, 0.137 mmol) and Boc2O (0.60 g, 2.74 mmol) were 
added to a solution of alcohol 90 (0.22 g, 0.68 mmol) in anhydrous CH2Cl2 (6.8 mL). The reaction 
mixture was stirred for 3.5 h, then the solvent was evaporated in vacuo. The residue was purified 
by column chromatography using 10% EtOAc in petroleum ether 40-60 °C as eluent to give a 1:1 
mixture of diastereomers of acetate 91 as a colourless oil (0.29 g, 99%). Data given for the 
mixture. νmax (neat)/cm-1: 2930, 1734, 1455, 1368; δH (400 MHz, CDCl3) 7.38 – 7.25 (7H, m, Ar), 
7.20 – 7.13 (3H, m, Ar), 6.23 (1H, m, 7-H), 5.73 (2H, m, 5-H, 6-H), 4.73 (1H, m, 3-H), 2.74 – 2.57 
(2H, m, 1-H2), 2.40 (2H, m, 4-H2), 2.09 & 2.08 (3H, s, COCH3), 1.86 (2H, m, 2-H2), 1.49 & 1.47 (9H, 




(C-6), 128.6, 128.5, 128.4, 128.1, 127.1, 127.0, 126.0, 82.0 (OC(CH3)3), 75.9 (C-7), 75.8 (C-3), 37.2 
(C-4), 35.6 (C-2), 31.6 (C-1), 27.9 (OC(CH3)3), 21.4 (COCH3); Found (ESI) 447.2138 [MNa+] 
(C26H32O5Na requires 447.2142). 
(E)-4-Phenethyl-6-styryl-1,3-dioxan-2-one     92 
 
FeCl3·6H2O (2.0 mg, 0.012 mmol) was added to a solution of acetate 91 (0.05 g, 0.12 mmol) in 
MeCN (1.12 mL) under nitrogen. The reaction mixture was stirred for 5.5 h, then the solvent was 
evaporated in vacuo. The residue was purified by column chromatography using 30% petroleum 
ether 40-60 °C in EtOAc to give carbonate 92 as a mixture of diastereomers 2.5:1 as a colourless 
oil (0.21 g, 58%). Data given for the mixture. νmax (neat)/cm-1: 3026, 2923, 1737, 1378; δH (400 
MHz, CDCl3) 7.41 – 7.17 (10H, m, Ar), 6.71 (0.73H, d, J 16, 7-H), 6.69 (0.27H, d, J 16, 7-H), 6.16 
(0.73H, dd, J 16, 7, 6-H), 6.15 (0.27H, dd, J 16, 7, 6-H), 5.22 (0.27, q, J 5, 5-H), 5.03 (0.73H, dddd, 
J 11, 7, 3, 1, 5-H), 4.55 (0.27H, spt, J 5, 3-H), 4.47 (0.73H, m, 3-H), 2.94 – 2.70 (2H, m, 1-H2), 2.20 
– 2.04 (2.27H, m, 4-HH, 2-HH, 4-H2), 2.01 – 1.81 (1.73H, m, 4-HH, 2-HH); δC (100 MHz, CDCl3) 
150.0 (CO), 140.4, 135.5, 133.7 & 113.5 (C-7), 128.8, 128.7, 128.6, 128.5, 126.9, 126.8, 126.4, 
125.1 & 125.0 (C-6), 79.0 & 76.6 (C-5), 77.6 & 75.3 (C-3), 37.0 & 36.7 (C-6), 33.8 & 31.8 (C-4), 
31.0 & 30.7 (C-7). 
(E)-1,7-Diphenylhept-1-ene-3,5-diol     88 
 
A solution of carbonate 92 (0.02 g, 0.065 mmol) in MeOH (1.3 mL) was treated with K2CO3 (0.06 
g, 0.45 mmol). After stirring the mixture for 1.5 h, EtOAc (2 mL) and a saturated solution of NH4Cl 
(2 mL) were added. The mixture was extracted with EtOAc (3 × 5 mL). The combined organic 
layers were dried over MgSO4 and solvent evaporated in vacuo to give diol 88 as a colourless oil 
as an 88:12 mixture of diastereomers (0.013 g, 73%). Data for the major diastereomer. δH (400 
MHz, CDCl3) 7.39 – 7.17 (10H, m, Ar), 6.60 (1H, d, J 16, 7-H), 6.23 (1H, dd, J 16, 7, 6-H), 4.56 (1H, 
m, 5-H), 3.97 (1H, m, 3-H), 2.84 – 2.65 (2H, m, 1-H2), 1.90 – 1.79 (2H, m, 2-H2), 1.78 – 1.74 (2H, 




126.6, 126.0, 73.9 (C-5), 71.8 (C-3), 43.5 (C-4), 39.8 (C-2), 31.9 (C-1). Spectroscopic data in accord 
with the literature.114 
Treatment of racemic diol 88 with TMSOTf  
 
Starting diol 88 (0.25 mg, 0.88 mmol) was dissolved in CH2Cl2 (9 mL) under nitrogen and the 
solution was cooled to 0 °C. TMSOTf (8 μL, 0.045 mmol) was added and the mixture was stirred 
at this temperature for 4.5 h. Water (8 mL) was added and the two phases separated, the 
aqueous layer was extracted with CH2Cl2 (3 × 8 mL). The combined organic layers were dried 
over MgSO4 and solvent evaporated in vacuo. The crude product was purified by column 
chromatography. Elution with 1% EtOAc in petroleum ether 40-60 °C gave syn-dihydropyran 93 
(4.6 mg, 2% yield) and anti-dihydropyran 94 (34 mg, 15 % yield), elution with 5% EtOAc in 
petroleum ether 40-60 °C gave blepharocalyxin analogue 95 (26 mg, 11% yield) and finally using 
20% EtOAc in petroleum ether 40-60 °C a further mixture of dimeric diarylheptanoids (63 mg, 
27% yield) was obtained. 
()-Syn-3-phenethyl-7-phenyl-3,4-dihydro-2H-pyran     93. A colourless oil. νmax (neat)/cm-1 
3058, 2931, 2931, 1718, 1689; δH (400 MHz, CDCl3) 7.44 – 7.18 (10H, m, Ar), 5.92 (1H, m, 5-H), 
5.79 (1H, m, 6-H), 5.17 (1H, m, 7-H), 3.74 (1H, m, 3-H), 2.89 – 2.74 (2H, m, 1-H2), 2.18 (1H, m, 4-
HH), 2.08 – 1.97 (2H, m, 4-HH, 2-HH), 1.85 (1H, m, 2-HH); δC (100 MHz, CDCl3) 142.3, 141.9, 130.3 
(C-6), 128.7, 128.6, 128.4, 127.8, 127.6, 125.8, 124.9 (C-5), 77.7 (C-7), 73.4 (C-3), 37.6 (C-2), 31.7 
(C-4), 31.0 (C-1). Found (ESI) 287.1419 [MNa+] (C19H20ONa requires 287.1406). 
()-Anti-3-phenethyl-7-phenyl-3,4-dihydro-2H-pyran     94. A colourless oil. νmax (neat)/cm-1 
3025, 2917, 2857, 1690, 1598, δH (400 MHz, CDCl3) 7.46 – 7.34 (5H, m, Ar), 7.18 – 7.10 (3H, m, 
Ar), 6.93 – 6.90 (2H, m, Ar), 6.09 – 6.00 (2H, m, 5-H, 6-H), 5.32 (1H, s, 7-H), 3.54 (1H, m, 3-H), 
2.74 (1H, m, 1-HH), 2.52 (1H, m, 1-HH), 2.14 – 1.98 (2H, m, 4-H2), 1.89 (1H, m, 2-HH), 1.69 (1H, 




(C-5), 125.6, 74.2 (C-7), 66.4 (C-3), 37.6 (C-2), 31.7 (C-4), 31.2 (C-1). Found (ESI) 287.1407 [MNa+] 
(C19H20ONa requires 287.1406). Spectroscopic data in accord with the literature.115 
()-Trans-3,9-phenylethyl-7-phenyl-5((E)-phenethenyl)-2,8-dioxabicyclo[4.4.0]decane     95. A 
colourless oil. νmax (neat)/cm-1 3025, 2919, 2854, 1687, 1601; δH (400 MHz, CDCl3) 7.50 – 7.06 
(17H, m, Ar), 6.99 (1H, m, Ar), 6.73 (2H, m, Ar), 5.82 (1H, d, J 16, 2’-H), 5.14 (1H, dd, J 16, 9, 1’-
H), 4.02 (1H, d, J 10, 7-H), 3.55 (1H, m, 9-H), 3.46 (1H, m, 3-H), 3.38 (1H, m, 1-H), 2.83 – 2.67 (4H, 
m, 2”-H2, 2”’-H2), 2.20 (1H, m, 5-H), 2.08 (1H, m, 10-HH), 2.02 – 1.63 (6H, m, 6-H, 10-HH, 1”-H2, 
1”’-H2), 1.55 (1H, m, 4-HH), 1.30 (1H, m, 4-HH); δC (100 MHz, CDCl3) 142.1, 141.0, 137.4, 134.1 
(C-1’), 128.5, 128.5, 128.3 (C-2’), 128.3, 128.2, 128.0, 128.0, 127.8, 126.5, 125.8, 125.7, 125.7, 
83.3 (C-7), 79.1 (C-1), 75.7 (C-9), 75.0 (C-3), 50.6 (C-6), 41.9 (C-5), 40.3 (C-4), 38.1 (C-10), 37.6, 
37. 5 (C-1” & C-1”’), 31.6, 31.3 (C-2” & C-2”’); Found (ESI) 551.2906 [MNa+] (C38H40O2Na requires 
551.2920). 
 
3-(4-(Benzenesulfonyloxyphenyl)propional     98 
 
A suspension of acid 97 (8 g, 48.15 mmol), benzyl bromide (9.89 g, 57.78 mmol) and potassium 
hydrogen carbonate (7.23 g, 72.22 mmol) in acetone (50 mL) was heated to reflux for 12 h. 
Solvent was removed in vacuo, then CH2Cl2 (30 mL) and water (30 mL) were added. The phases 
were separated, and the aqueous phase was extracted with CH2Cl2 (2 × 30 mL). The combined 
organic layers were dried over MgSO4 and the solvent evaporated in vacuo. The residue was 
purified by column chromatography using 10% of ethyl acetate in petroleum ether 40-60 °C to 
give benzyl ester as a pale-yellow oil (10.98 g, 89%).  
Benzene sulfonyl chloride (8 g, 45.10 mmol) and triethylamine (4.35 mL, 42.92 mmol) were 
added dropwise to a stirring solution of benzyl ester (11 g, 42.92 mmol) in CH2Cl2 (72 mL) under 
nitrogen at 0 °C. After 5 min of stirring, the reaction mixture was allowed to warm to room 
temperature and stirred for 21 h. Saturated solution of NH4Cl (70 mL) was added and the mixture 
was stirred for 10 min. The aqueous phase was extracted with CH2Cl2 (2 × 70 mL). The combined 




purified by column chromatography using 5-10% ethyl acetate in petroleum ether 40-60 °C to 
give benzyl ester as a white solid (16.55 g, 99%).  
DIBALH (1 M, 11 mL, 11 mmol) was added dropwise to a solution of benzyl ester (2.12 g, 10.84 
mmol) at −78 °C, under nitrogen, then stirred for 3 h. The reaction was allowed to warm to room 
temperature, then quenched with Rochelle’s salt solution (350 mL) and stirred overnight. The 
reaction mixture was extracted with CH2Cl2 (2 × 400 mL). The combined organic layers were 
dried over MgSO4 and the solvent evaporated in vacuo. The residue was purified by column 
chromatography using 10% EtOAc in petroleum ether 40-60 °C to yield aldehyde 98 as a 
colourless oil (5.79 g, 70%). δH (400 MHz, CDCl3) 9.79 (1H, t, J 2, 1-H), 7.85 – 7.80 (2H, m, OSO2Ph), 
6.66 (1H, m, OSO2Ph), 7.56 – 7.49 (2H, m, OSO2Ph), 7.12 – 7.08 (2H, m, Ar), 6.91 – 6.87 (2H, m, 
Ar), 2.91 (2H, t, J 7, 3-H2), 2.75 (2H, t, J 7, 2-H2); δC (100 MHz, CDCl3) 201.0 (C-1), 148.0, 139.7, 
135.5, 134.3, 129.6, 129.2, 128.5, 122.5, 45.0 (C-2), 27.4 (C-3). Spectroscopic data in accord with 
the literature.41  
 
(S, E) 1-(4’-Benzenesulfonyloxyphenyl)-hept-5-en-3-ol     99 
 
Nokami reagent 36 (5.1 g, 24.1 mmol) and p-toluenesulfonic acid hydrate (0.23 g, 1.2 mmol) 
were added to a solution of aldehyde 98 (3.5 g, 12.05 mmol) in CH2Cl2 (80 mL) under nitrogen. 
The reaction mixture was stirred at room temperature for 22 h. Water (80 mL) was added and 
the phases were separated. The aqueous phase was extracted with CH2Cl2 (3 × 100 mL). The 
combined organic layers were dried over MgSO4 and the solvent evaporated in vacuo. The 
residue was purified by column chromatography using 20% EtOAc in petroleum ether 40-60 °C 
to yield alcohol 99 as a colourless oil (3.67 g, 88%). [𝛼]D
25
 −8.0 (c. 1.0 CHCl3) Lit41 [𝛼]𝐷
20 −11.0 (c 
1.0 CHCl3); δH (400 MHz, CDCl3) 7.86 – 7.80 (2H, m, OSO2Ph), 7.71 – 7.60 (2H, m, OSO2Ph), 7.57 
– 7.46 (2H, m, OSO2Ph), 7.10 (2H, d, J 9, Ar), 6.87 (2H, d, J 9, Ar), 5.55 (1H, m, 6-H), 5.4 (1H, m, 5-
H), 3.56 (1H, m, 3-H ), 2.76 (1H, m, 1-HH), 2.64 (1H, m, 1-HH), 2.22 (1H, m, 2-HH), 2.09 (1H, m, 
2-HH), 1.76 – 1.61 (5H, m, 7-H3, 4-H2). δC (100 MHz, CDCl3) 147.7, 141.5, 135.6, 134.2, 129.6, 
129.5, 129.2, 128.6, 126.8, 122.2, 70.0 (C-3), 40.9 (C-2), 38.2 (C-4), 31.5 (C-1), 18.1 (C-7). 





(S)-5-(4’-Benzenesulfonyloxyphenyl)-3-(tertbutyldimethylsilyloxy)-pentanal     100 
 
TBSCl (4.7 g, 31.18 mmol), imidazole (5.3 g, 77.94 mmol) and DMAP (0.32 g, 2.60 mmol) were 
added to a solution of alcohol 99 (9 g, 26 mmol) in dry CH2Cl2 (135 mL) under nitrogen. The 
reaction mixture was stirred at room temperature for 15 h, then quenched with the addition of 
water (70 mL). The phases were separated, and the aqueous phase was extracted with CH2Cl2 (2 
× 100 mL). The combined organic layers were washed with a saturated solution of brine (50 mL), 
dried over MgSO4 and the solvent evaporated in vacuo. The residue was purified by column 
chromatography using 1% EtOAc in petroleum ether 40-60 °C to yield corresponding silyl ether 
as a colourless oil (10.73 g, 90%).  
Silyl ether (2 g, 4.34 mmol) was dissolved in THF (45 mL) and N-methylmorpholine N-oxide (1.17 
g, 8.68 mmol) and osmium tetroxide (3 crystals) were added under nitrogen. The reaction 
mixture was stirred at room temperature for 9 h, then quenched with a saturated solution of 
Na2SO3 (50 mL). The phases were separated, and the aqueous phase was extracted with EtOAc 
(3 × 100 mL). The combined organic layers were dried over MgSO4 and the solvent evaporated 
in vacuo to give a pale-yellow oil. Then, NaIO4 (2.14 g, 10.0 mmol) was added to a solution of the 
crude oil in THF (200 mL) and water (200 mL). The reaction mixture was stirred for 4 h, then 
quenched with a saturated solution of NaHCO3 (200 mL). The aqueous phase was extracted with 
EtOAc (3 × 200 mL). The combined organic layers were dried over MgSO4 and the solvent 
evaporated in vacuo. The residue was purified by column chromatography using 20% EtOAc in 
petroleum ether 40-60 °C to yield aldehyde 100 as a pale-yellow oil (1.87 g, 96%). δH (400 MHz, 
CDCl3) 9.80 (1H, t, J 2, 1-H), 7.88 – 7.78 (2H, m, OSO2Ph), 7.66 (1H, m, OSO2Ph), 7.56 – 7.48 (2H, 
m, OSO2Ph), 7.07 (1H, d, J 9, Ar), 6.88 (1H, d, J 9, Ar), 4.22 (1H, p, J 6, 3-H), 2.69 – 2.59 (2H, m, 2-
H2,), 2.57 (2H, ddd, J 6, 4, 2, 5-H2), 1.83 – 1.76 (2H, m, 4-H2), 0.88 (9H, s, SiC(CH3)3), 0.06 (3H, s, 
SiCH3), 0.05 (3H, s, SiCH3); δC (100 MHz, CDCl3) 201.8 (C-1), 147.8, 141.0, 135.6, 134.2, 129.4, 
129.2, 128.6, 122.4, 67.6 (C-3), 50.9 (C-2), 39.4 (C-4), 30.9 (C-5) 25.3 (SiC(CH3)3), 18.1 (SiC(CH3)3), 






(S)-1-(4’-Benzenesulfonyloxyphenyl)-hept-6-ene-3,5-diol     101 
 
Vinyl magnesium chloride (3.35 mL, 1 M in THF, 3.35 mmol) was added to a solution of aldehyde 
100 (1 g, 2.23 mmol) in dry THF (7 mL) at −78 °C under nitrogen. The reaction mixture was stirred 
at this temperature for 3 h, then quenched with the addition of a saturated solution of NH4Cl (7 
mL). The aqueous phase was extracted with EtOAc (3 × 10 mL). The combined organic layers 
were dried over MgSO4 and the solvent evaporated in vacuo to give vinyl alcohol as a 3:2 mixture 
of diastereomers as a pale-yellow oil (1.06 g, 99%).νmax (neat)/cm-1: 3436, 2953, 2929, 2857, 
1502; δH (400 MHz, CDCl3) 7.88 – 7.80 (2H, m, OSO2Ph), 7.68 (1H, m, OSO2Ph), 7.58 – 7.47 (2H, 
m, OSO2Ph), 7.11 – 7.03 (2H, m, Ar), 6.92 – 6.83 (2H, m, Ar), 5.84 (1H, dd, J 10, 6, 6-H), 5.26 (1H, 
dt, J 17, 2, 7-HH), 5.10 (1H, dt, J 10, 1, 7-HH), 4.27 (1H, m, 3-H), 3.97 (1H, m, 5-H), 2.61 (2H, m, 
1-H2), 1.90 – 1.64 (4H, m, 2-H2, 4-H2), 0.91 (9H, s, SiC(CH3)3), 0.09 (3H, s, SiCH3), 0.07 (3H, s, SiCH3); 
δC (100 MHz, CDCl3) 147.6, 141.3, 140.8 (C-6), 135.5, 134.1, 129.3, 129.1, 128.5, 122.2, 114.3 (C-
7), 71.5 (C-3), 71.3 (C-5), 43.2 (C-4), 39.3 (C-2), 30.4 (C-1), 25.8 (SiC(CH3)3), 17.9 (SiC(CH3)3), −4.1 
(SiCH3), −4.6 (SiCH3); Found (ESI) 499.1945 [MNa+] (C25H36O5SNa requires 499.1950). 
TBAF (19.72 mL, 1 M in THF, 19.72 mmol) was added to a solution of the mixture of 
diastereomers of silyl ether (1.98 g, 3.94 mmol) in dry THF (20 mL) under nitrogen. The reaction 
mixture was stirred at room temperature for 2 h, then quenched with water (20 mL). The 
aqueous phase was extracted with EtOAc (4 × 25 mL). The combined organic layers were dried 
over MgSO4 and the solvent evaporated in vacuo. The residue was purified by column 
chromatography using 30% EtOAc in petroleum ether 40-60 °C to yield diol 101 as a 3:2 mixture 
of diastereomers as a yellow oil (0.98 g, 66%).νmax (neat)/cm-1: 3354, 2938, 2929, 1501, 1449; δH 
(400 MHz, CDCl3) 7.88 – 7.78 (2H, m, OSO2Ph), 7.67 (1H, m, OSO2Ph), 7.58 – 7.46 (2H, m, 
OSO2Ph), 7.15 – 7.04 (2H, m, Ar), 6.90 – 6.85 (2H, m, Ar), 5.87 (1H, ddd, J 17, 10, 6, 6-H), 5.24 
(1H, dt, J 17, 1, 7-HH), 5.11 (1H, dt, J 10, 1, 7-HH), 4.36 (1H, m, 5-H), 3.87 (1H, m, 3-H), 2.80 – 
2.57 (2H, m, 1-H2), 1.85 – 1.60 (4H, m, 2-H2, 4-H2); δC (100 MHz, CDCl3) 147.7, 141.3, 140.7 (C-6), 
140.5, 134.2, 129.6, 129.6, 129.2, 128. 6, 122.7, 114.8 (C-7), 74.0 (C-5), 71.4 (C-3), 43.0 (C-4), 




(S)-1-(4’-Benzenesulfonyloxyphenyl)-7-phenylhept-6-ene-3,5-diol     102 
 
Styrene (0.95 g, 2.62 mmol) and Grubbs catalyst 2nd Generation (0.067 g, 0.079 mmol) were 
added to a solution of the mixture of diastereomer of diol 101 (0.48 g, 1.32 mmol) in dry CH2Cl2 
(20 mL) under nitrogen. The stirring reaction mixture was heated to reflux for 3 h. The solvent 
was evaporated in vacuo. The residue was purified by column chromatography using 30% EtOAc 
in petroleum ether 40-60 °C to yield diol 102 as a 5:2 mixture of diastereomers as a pale-yellow 
oil (0.41 g, 35%). Data for major diastereomer. νmax (neat)/cm-1: 3353, 3028, 2919, 1501, 1449; 
δH (400 MHz, CDCl3) 7.89 – 7.78 (2H, m, OSO2Ph), 7.66 (1H, m, OSO2Ph), 7.56 – 7.49 (2H, m, 
OSO2Ph), 7.25 (4H, m, Ar), 7.28 – 7.21 (1H, m, Ar), 7.13 – 7.06 (2H, m, Ar), 6.93 – 6.83 (2H, m, 
Ar), 6.59 (1H, d, J 15, 7-H), 6.22 (1H, dd, J 16, 7, 6-H), 4.55 (1H, q, J 7, 5-H), 3.93 (1H, m, 3-H), 
2.84 – 2.59 (2H, m, 1-H2), 1.87 – 1.69 (4H, m, 2-H2, 4-H2); δC (100 MHz, CDCl3) 147.7, 141.2, 136.5, 
135.6, 134.2, 131.7 (C-6), 130.4 (C-7), 129.6, 129.2, 128.7, 128.6, 127.9, 126.6, 122.3, 73.8 (C-5), 
71.4 (C-3), 43.3 (C-4), 39.5 (C-2), 31.1 (C-1); Found (ESI) 461.1398 [MNa+] (C25H26O5SNa requires 
461.1393). 
(S)-1-(4’-Benzenesulfonyloxyphenyl)-7-phenylhept-6-ene-5-one-3-ol.     103 
 
MnO2 (0.42 g, .958 mmol) was added to a solution of diol 102 in CH2Cl2. The reaction mixture 
was stirred at room temperature for 3 h, then filtered through celite and the solvent evaporated 
in vacuo. The residue was purified by column chromatography using 30-50% EtOAc in petroleum 
ether 40-60 °C to yield ketone 103 as a pale-yellow oil (0.27 g, 64%). [𝛼]𝐷
21 +3.5 (c 1.0 CHCl3); 
νmax (neat)/cm-1: 3453, 3062, 2926, 1705, 1648, 1606, 1501; δH (400 MHz, CDCl3) 7.85 – 7.81 (2H, 
m, OSO2Ph), 7.68 – 7.63 (1H, m, OSO2Ph), 7.59 – 7.48 (5H, m, OSO2Ph, Ar, 7-H), 7.46 – 7.35 (3H, 
m, Ar), 7.11 (1H, m, Ar), 6.88 (2H, m, Ar), 6.71 (1H, d, J 16, 6-H), 4.10 (1H, m, 3-H), 3.34 (1H, s, 
OH), 2.93 – 2.62 (4H, m, 2-H2, 4-H2), 1.83 (1H, m, 2-HH), 1.71 (1H, m, 2-HH); δC (100 MHz, CDCl3) 
200.8 (C-5), 147.8, 143.9 (C-7), 141.2, 135.6, 134.2, 134.2, 131.0, 129.7, 129.2, 129.1, 128.6, 
128.5, 126.3 (C-6), 122.3, 67.0 (C-3), 46.9 (C-4), 38.0 (C-2), 31.2 (C-1); Found (ESI) 459.1226 





(+)-(3S,5S,E)-1-(4’-Benzenesulfonyloxyphenyl)-7-phenylhept-6-ene-3,5-ol      104 
 
Diethyl methoxy borane (0.034 mL, 0.254 mmol) was added to a solution of hydroxyketone 103 
(0.101g, 0.231 mmol) in a mixture of THF (8 mL) and MeOH (2 ml), at −78 °C, under N2. The 
mixture was stirred at this temperature for 30 min, then NaBH4 (0.01, 0.28 mmol) was added. 
The mixture reaction was stirred for 5 h then quenched with 2.5M NaOH solution (4 mL) and 
hydrogen peroxide (2 mL). The aqueous phase was extracted with EtOAc (3 × 10 mL). The 
combined organic layers were dried over MgSO4 and the solvent evaporated in vacuo to yield 
syn-diol 104 as single diastereomer as a colourless oil (0.10 mg, 99%). [𝛼]𝐷
21 +3.0 (c 1.0 CHCl3); 
νmax (neat)/cm-1: 3286, 2916, 1502, 1449, 1372; δH (400 MHz, CDCl3) 7.86 – 7.80 (2H, m, OSO2Ph), 
7.69 – 7.63 (1H, m, OSO2Ph), 7.55 – 7.48 (2H m, OSO2Ph), 7.39 – 7.28 (4H, m, Ar), 7.26 – 7.21 
(1H, m, Ar), 7.13 – 7.08 (2H, m, Ar), 6.91 – 6.83 (2H, m, Ar), 6.59 (1H, d, J 16, 7-H), 6.21 (1H, dd, 
J 16, 7, 6-H), 4.54 (1H, q, J 7, 5-H), 3.92 (1H, m, 3-H), 2.82 – 2.59 (2H, m, 1-H2), 1.84 – 1.68 (4H, 
m, 2-H2, 4-H2); δC (100 MHz, CDCl3) 147.8, 141.2, 136.5, 135.6, 134.2, 131.7 (C-6), 130.4 (C-7), 
129.6, 129.2, 128.7, 128.6, 127.9, 126.6, 122.3, 73.8 (C-5), 71.4 (C-3), 43.4 (C-4), 39.5 (C-2), 31.1 
(C-1); Found (ESI) 461.1395 [MNa+] (C25H26O5SNa requires 461.1393). 
(−)-(3S,5R,E)-1-(4’-Benzenesulfonyloxyphenyl)-7-phenylhept-6-ene-3,5-diol      106 
 
Glacial acetic acid (10 mL) was added to a solution of Me4NHB(OAc)3 (603 mg, 2.29 mmol) in 
anhydrous acetonitrile (10 mL) and the mixture stirred at room temperature under an 
atmosphere of nitrogen for 30 min. The borohydride solution was then added by cannula to a 
solution of hydroxyketone 103 (0.125 mg, 0.286 mmol) in dry acetonitrile (10 mL) at −20 °C and 
stirred for 3 h. The reaction was quenched with saturated solution of Rochelle’s salt (20 mL) and 
allowed to warm to room temperature whilst vigorously stirring for 1 h. The reaction mixture 
was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with aqueous 
NaHCO3 (7 × 20 mL). The combined organic layers were dried over MgSO4 and the solvent 
evaporated in vacuo. The residue was purified by column chromatography using 20-40% EtOAc 
in petroleum ether 40-60 °C to yield anti-diol 106 as a 7:1 mixture of diastereomers as a 
colourless oil (0.107, 85%). [𝛼]𝐷




1371; δH (400 MHz, CDCl3) 7.87 – 7.77 (2H, m, OSO2Ph), 7.68 – 7.62 (1H, m, OSO2Ph), 7.54 – 7.47 
(2H, m, OSO2Ph), 7.39 – 7.28 (4H, m, Ar), 7.25 – 7.21 (1H, m, Ar), 7.12 – 7.05 (2H, m, Ar), 6.92 – 
6.83 (2H, m, Ar), 6.61 (1H, d, J 16, 7-H), 6.26 (1H, dd, J 16, 6, 6-H), 4.65 (1H, q, J 6, 5-H), 3.97 (1H, 
m, 3-H), 2.80 – 2.57 (2H, m, 1-H2), 1.87 – 1.68 (4H, m, 2-H2, 4-H2); δC (100 MHz, CDCl3) 147.8, 
141.2, 136.6, 135.6, 134.2, 131.8 (C-6), 130.3 (C-7), 129.6, 129.2, 128.6, 128.6, 127.9, 126.5, 
122.3, 70.7 (C-5), 68.6 (C-3), 42.8 (C-4), 39.1 (C-2), 31.5 (C-1) ); Found (ESI) 461.1393 [MNa+] 
(C25H26O5SNa requires 461.1393). 
Treatment of 3,5-syn-diol 104 with TMSOTf 
 
Diol 104 (0.11 g, 0.25 mmol) in anhydrous CH2Cl2 (2.5 mL) under nitrogen and the solution was 
cooled to 0 °C. TMSOTf (2 μL, 0.012 mmol) was added and the mixture stirred at this 
temperature for 5 h. Water (2.5 mL) was added and the two phases separated, the aqueous 
layer was extracted with CH2Cl2 (3 × 3 mL). The combined organic layers were dried over MgSO4 
and solvent evaporated in vacuo. The crude product was purified by column chromatography. 
Elution with 1% EtOAc in petroleum ether 40-60 °C gave syn-dihydropyran 107 (13 mg, 12%) and 
anti-dihydropyran 108 (5 mg, 5 % yield), elution with 5% EtOAc in petroleum ether 40-60 °C gave 
blepharocalyxin analogue 109 (17.6 mg, 17% yield) and finally using 20% EtOAc in petroleum 
ether 40-60 °C a further mixture of dimeric diarylheptanoids (14.6 mg, 14% yield) was obtained. 





Diol 106 (0.13 g, 0.29 mmol) in anhydrous CH2Cl2 (3 mL) under nitrogen and the solution was 
cooled to 0 °C. TMSOTf (2.6 μL, 0.014 mmol) was added and the mixture stirred at this 
temperature for 5 h. Water (2 mL) was added and the two phases separated, the aqueous layer 
was extracted with CH2Cl2 (3 × 3 mL). The combined organic layers were dried over MgSO4 and 
solvent evaporated in vacuo. The crude product was purified by column chromatography. 
Elution with 1% EtOAc in petroleum ether 40-60 °C gave syn-dihydropyran 107 (6 mg, 5%) and 
anti-dihydropyran 108 (19 mg, 15 % yield), elution with 5% EtOAc in petroleum ether 40-60 °C 
gave blepharocalyxin analogue 109 (38 mg, 31% yield) and finally using 20% EtOAc in petroleum 
ether 40-60 °C a further mixture of dimeric diarylheptanoids (17.4 mg, 14% yield) was obtained. 
(3S,7S)-3-(p-phenyl benzenesulfonate)-7-phenyl-3,4-dihydro-2H-pyran     107. A colourless oil. 
νmax (neat)/cm-1 3062, 2925, 2859, 1689, 1501: δH (400 MHz, CDCl3) 7.84 – 7.81 (2H, m, Ar), 7.68 
– 7.63 (1H, m Ar), 7.54 – 7.49 (2H, m, Ar), 7.39 – 7.33 (4H, m, Ar), 7.31 – 7.27 (1H, m, Ar), 7.12 – 
7.07 (2H, m, Ar). 6.89 – 6.86 (2H,m, Ar), 5.90 (1H, m, 5-H), 5.75 (1H, m, 6-H), 5.10 (1H, m, 7-H), 
3.65 (1H, m, 3-H), 2.82 – 2.66 (2H, m, 1-H2), 2.13 (1H, m, 4-HH), 2.03 – 1.87 (2H, m, 4-HH, 2-HH), 
1.77 (1H, m, 2-HH); δC (100 MHz, CDCl3) 147.7, 141.7, 141.4, 135.6, 134.2, 130.2 (C-6), 129.6, 
129.1, 128.6, 128.6, 127.8, 127.2, 124.7 (C-5), 122.2, 77.7 (C-7), 73.2 (C-3), 37.3 (C-2), 31.0 (C-1), 
31.0 (C-4). Found (ESI) 443.1283 [MNa+] (C25H24O4SNa requires 443.1288). 
(3S,7R)-3-(p-phenyl benzenesulfonate)-7-phenyl-3,4-dihydro-2H-pyran     108. A colourless oil. 
νmax (neat)/cm-1 3032, 2925, 2863, 1691, 1501; δH (400 MHz, CDCl3) 7.82 – 7.79 (2H, m, Ar), 7.68 
– 7.64 (1H, m Ar), 7.53 – 7.49 (2H, m, Ar), 7.40 – 7.29 (5H, m, Ar), 6.76 – 6.70 (4H, m, Ar), 6.04 
(1H, m, 5-H), 5.99 (1H, m, 6-H), 5.27 (1H, s (br), 7-H), 3.43 (1H, m, 3-H), 2.65 (1H, m, 1-HH), 2.46 
(1H, dt, J 14, 8, 8, 1-HH), 2.06 (1H, ddq, J 17, 10, 2, 4-HH), 1.96 (1H, m, 4-HH), 1.81 (1H, m, 2-HH), 
1.60 (1H, m, 2-HH); δC (100 MHz, CDCl3) 147.5, 141.3, 141.0, 135.6, 134.1, 129.7, 129.1, 128.6, 
128.5, 128.4, 127.8, 127.4 (C-6), 126.1 (C-5), 122.0, 74.3 (C-7), 65.9 (C-3), 37.2 (C-2), 31.2 (C-1), 
30.9 (C-4). Found (ESI) 443.1280 [MNa+] (C25H24O4SNa requires 443.1287). 
(1R,3S,5S,6S,7S,9S)-3,9-(p-phenylbenzenesulfonate)-7-phenyl-5((E)-phenethenyl)-2,8-
dioxabicyclo[4.4.0]decane     109. A colourless oil. νmax (neat)/cm-1 3026, 2924, 1502; δH (500 
MHz, CDCl3) 7.85 – 7.81 (4H, m, Ar), 7.68 – 7.63 (2H, m, Ar), 7.54 – 7.50 (4H, m, Ar), 7.33 – 7.03 
(11H, m, Ar), 6.97 (1H, m, Ar), 6.89 – 6.84 (4H, m, Ar), 6.71 – 6.7 (2H, m, Ar), 5.81 (1H, d, J 16, 2’-
H), 5.11 (1H, dd, J 16, 9, 1’-H), 3.98 (1H, d, J 10, 7-H), 3.49 (1H, m, 9-H), 3.42 (1H, m, 3-H), 3.34 
(1H, m, 1-H), 2.76 – 2.59 (4H, m, 2”-H2, 2”’-H2), 2.18 (1H, m, 5-H), 1.99 (1H, m, 10-HH), 1.88 (1H, 




(1H, m, 4-HH), 1.32 (1H, m, 4-HH); δC (100 MHz, CDCl3) 147.61, 147.60, 141.2, 140.8 (C-1’), 137.3, 
135.6, 135.5, 134.1, 133.9, 129.6, 129.5, 128.5, 128.2 (C-2’), 128.1, 128.0, 127.8, 126.6, 125.8, 
122.1, 122.0, 83.4 (C-7), 79.1 (C-1), 75.6 (C-3), 74.8 (C-9), 50.6 (C-6), 41.9 (C-5), 40.3 (C-4), 38.1 
(C-10), 37.4 (C-1’’), 37.2 (C-1’’’), 31.0 (C-2”), 30.1 (C-2’’’); Found (ESI) 863.2665 [MNa+] 
(C50H48O8S2Na requires 863.2683). 
 
()-(1E, 3S*,5R*)-1,7-Diphenylhept-1-ene-3,5-diol     112 
 
Cinnamaldehyde (0.48 mL 3.78 mmol), benzylacetone (0.68 mL, 4.54 mmol) and MgI2 (1.26 g, 
4.54 mmol) were dissolved in anhydrous CH2Cl2 (20 mL) under nitrogen and the flask protected 
from light. N,N-Diisopropylethylamine (0.85 mL, 4.92 mmol) was added by syringe pump at 0.85 
mL/min. The reaction mixture was stirred for 1 h at room temperature and quenched with 
saturated solution of NaHCO3 (15 mL). The mixture was extracted with CH2Cl2 (3 × 15 mL). The 
organic phase was dried over MgSO4 and the solvent evaporated in vacuo. The residue was 
purified by column chromatography using 10% EtOAc in petroleum ether 40-60 °C to give an 
inseparable 10:1 mixture of regioisomers. Me4NHB(OAc)3 (4.23g, 20 mmol) was dissolved in dry 
MeCN (12 mL) and glacial acetic acid (12 mL) under nitrogen. The mixture was stirred for 30 min 
at room temperature, then cooled to −40 °C and a solution of the mixture of regioisomers (0.70 
mg, 2.5 mmol) in dry MeCN (3.5 mL) was added. The reaction mixture was warmed −20 °C and 
stirred overnight. The reaction was quenched with Rochelle’s salt solution (20 mL). The aqueous 
phase was extracted with CH2Cl2 (2 × 25 mL) and the combined organic layers were washed with 
NaHCO3(aq) (3 × 25 mL). The organic phase was dried over MgSO4, and solvent evaporated in 
vacuo. The residue was purified by column chromatography using 10-20% EtOAc in petroleum 
ether 40-60 °C to give diol 112 as pale-yellow oil (0.48 g, 45% over two steps). δH (400 MHz, 
CDCl3) 7.39 – 7.16 (10H, m, Ar), 6.63 (1H, d, J 16, 1-H), 6.28 (1H, dd, J 16, 6, 2-H), 4.67 (1H, q, J 5, 
3-H), 4.03 (1H, m, 5-H), 2.81 (1H, m, 7-HH), 2.69 (1H, m, 7-HH), 1.94 – 1.75 (4H, m, 6-H2, 4-H2); 
δC (100 MHz, CDCl3) 142.0, 136.7, 132.0 (C-2), 130.3 (C-1), 128.8, 128.6, 128.5, 127.9, 126.6, 
126.0, 70.8 (C-3), 69.1 (C-5), 42.8 (C-4), 39.4 (C-6), 32.3 (C-7). Spectroscopic data in accord with 





()-(E)-5-Methoxy-1,7-diphenylhept-6-en-3-one     118 
 
Silver(I) oxide (3.10 g, 13.4 mmol) and MeI (2.28 mL, 53.5 mmol) were added to a solution of β-
hydroxyketone 112 (1.5 g, 5.35 mmol) in dry Et2O (27 mL) under nitrogen. The reaction was 
protected from light and stirred for 3 days. The reaction mixture was then filtered through celite, 
washed with EtOAc (100 mL) and concentrated in vacuo. The crude product was purified by 
column chromatography using 2-10 % EtOAc in petrol ether 40-60 °C to afford β-methoxy ketone 
118 (0.949 g, 60 %) as a pale-yellow oil. νmax (neat)/cm-1 3060 (w), 3026 (w), 2929 (w), 2822 (w), 
1713 (s), 1677 (s); δH (400 MHz, CDCl3) 7.14 – 7.42 (10H, m, Ar), 6.59 (1H, d, J 16, 7-H), 6.04 (1H, 
dd, J 16, 8, 6-H), 4.19 – 4.28 (1H, m, 5-H), 3.29 (3H, s, OCH3), 2.73 – 2.95 (5H, m, 1-H2, 2-H2, 4-
HH), 2.54 (1H, dd, J 16, 5, 4-HH); δC (100 MHz, CDCl3) 207.5 (C-3), 132.7 (C-7), 128.5, 128.4 (C-6), 
128.3, 127.9, 126.5, 126.0, 78.3 (C-5), 56.5 (OCH3), 49.0 (C-4), 45.5 (C-2), 29.4 (C-1); Found (ESI) 
317.1513 [MNa+] (C20H22NaO2 requires 317.1512). 
 
()-(E)-5-methoxy-1,7-diphenylhept-6-en-3-ol     119 
 
NaBH4 (0.843 g, 31.9 mmol) was carefully added to a solution of 118 (0.94 g, 3.19 mmol) in 1:1 
THF:MeOH (110 mL) at 0 °C. After 30 minutes the reaction was allowed to warm to room 
temperature and stirred for 3 h. The reaction was quenched by the addition of saturated NH4Cl 
solution (55 mL). The aqueous phase was extracted with EtOAc (3 × 50 mL). The combined 
organic layers were dried over MgSO4 and the solvent evaporated in vacuo. The crude product 
was purified by column chromatography using 10 % EtOAc in petrol ether 40-60 °C to yield 
alcohol 119 (0.94 g, 99 %) as a colourless oil and a 3:2 mixture of diastereomers. νmax (neat)/cm-1: 
3412 (br), 3025 (w), 2929 (w), 2858 (w) , 1494 (s); δH (400 MHz, CDCl3) 7.15 – 7.41 (10H, m, Ar), 
6.57 (1H, dd, J 16, 7-H), 6.13 (1H, dd, J 16, 8, 6-H), 3.78 – 4.10 (2H, m, 3-H, 5-H), 3.34 (3H, s, 
OCH3), 2.59 – 2.88 (2H, m, 1-H), 1.63 – 1.89 (4H, m, 2-H, 4-H); δC (100 MHz, CDCl3) 142.4, 136.3, 
132.9 (C-7), 129.2 (C-6), 128.8, 128.5, 126.7, 128.1, 125.9, 83.7 (C-5), 70.9 (C-3), 56.3 (OCH3), 




()-(6E, 3S*,5R*)-(E)-5-acetoxy-1,7-diphenylhept-6-en-3-ol     121 and ()-(6E, 3S*,5R*)-(E)-5-
acetoxy-1,7-diphenylhept-6-en-3-ol      122 
 
Diol 116 (1 g, 3.54 mmol) was dissolved in dry CH2Cl2 (20 mL) and pyridine (0.3 mL, 3.54 mmol) 
and acetyl chloride (0.20 mL, 2.83 mmol) were added dropwise under nitrogen. The reaction 
was stirred at room temperature for 25 min. Water (10 mL) was added and the aqueous phase 
extracted with CH2Cl2 (3 × 10 mL). The organic phase was dried over MgSO4 and solvent removed 
in vacuo. The residue was purified by column chromatography using 5-40% EtOAc in petroleum 
ether 40-60 °C to give a 3:1 mixture of monoacetylated compounds. The mixture of acetates was 
dissolved in CH2Cl2 (22 mL) and MnO2 (1.25 g, 33.83 mmol) was added. The reaction mixture was 
stirred at room temperature overnight. The crude reaction was filtered through celite and the 
solvent removed in vacuo. The residue was purified by column chromatography using 5-15% 
EtOAc in petroleum ether 40-60 °C to give alcohol 121 (0.51 g, 45% over two steps) and ketone 
122 (0.19 g, 16%) as colourless oils. Alcohol 121 νmax (neat)/cm-1: 3442, 3025, 2922, 2858, 1732; 
δH (400 MHz, CDCl3)7.41 – 7.20 (10H, m, Ar), 6.65 (1H, d, J 16, 1-H), 6.22 (1H, dd, J 16, 7, 2-H), 
5.73 (1H, m, 3-H), 3.64 (1H, m, 5-H), 2.86 (1H, m, 7-HH), 2.72(1H, m, 7-HH) 2.13 (3H, s, CH3), 
1.92-1.74 (4H, m, 6-H2, 4-H2); δC (100 MHz, CDCl3) 171.5 (CO), 142.03, 136.1, 132.1 (C-1), 128.6, 
128.5, 128.4, 128.1, 127.4 (C-2) 126.6, 125.8, 72.1 (C-3), 66.7 (C-5), 43.1 (C-6), 38.8 (C-4), 32.1 
(C-7), 21.2 (CH3); Found (ESI) 347.1611[MNa+] (C21H24O3Na requires 347.1618). Ketone 122. δH 
(400 MHz, CDCl3) 7.57 (1H, d, J 16, 7-H), 7.56 – 7.53 (2H, m, Ar), 7.42 – 7.38 (3H, m, Ar), 7.31 – 
7.26 (2H, m, Ar), 7.22 – 7.16 (3H, m, Ar), 6.72 (1H, d, J 16, 6-H), 5.38 (1H, p, J 6, 3-H), 3.07 (1H, 
dd, J 15, 6, 4-HH), 2.85 (1H, dd, J 15, 6, 4-HH), 2.77 – 2.63 (2H, qt, J 14, 8, 1-H2), 2.32 –1.97 (2H, 
td, J 8, 6, 2-H2), 2.02 (3H, s, CH3); δC (100 MHz, CDCl3) 196.9 (CO), 170.5, 143.5 (C-7), 141.2, 134.3, 
130.7, 129.0, 128.5, 128.4, 128.3, 126.0 (C-6), 70.6 (C-3), 45.1 (C-4), 35.7 (C-1), 31.7 (C-2), 21.1 
(CH3). 
(1E, 3S*, 5R*)-1-(p-methoxyphenyl)-7-phenylhept-1-ene-3,5-diol     126 
 
p-Methoxycinnamaldehyde 123 (2.50 g, 15.41 mmol), benzylacetone (2.74 g, 18.49 mmol) and 




protected from light. N,N-Diisopropylethylamine (3.49 mL, 20.01 mmol) was added dropwise. 
The reaction mixture was stirred at room temperature for 2 h, quenched by the addition of 
saturated NaHCO3 solution (80 mL). The aqueous phase was extracted with CH2Cl2 (3 × 80 mL). 
The combined organic layers were dried over MgSO4 and solvent evaporated in vacuo. The 
residue was purified by column chromatography using 5-20% EtOAc in petroleum ether 40-60 
°C to give and inseparable mixture 16:1 of regioisomers as orange oil. Me4NHB(OAc)3 (13.66 g, 
64.48 mmol) was dissolved in dry MeCN (50 mL) and glacial acetic acid (50 mL) and the mixture 
stirred for 30 min at room temperature under nitrogen. The solution was cooled down to −40 
°C and a solution of the regioisomer mixture (4 g, 12.89 mmol) in dry MeCN (12.5 mL) was added 
dropwise, then the mixture was warmed to −20 °C and stirred overnight. The reaction was 
quenched with the addition of 0.5N sodium tartare solution (80 mL) and diluted with CH2Cl2 (30 
mL). The aqueous phase was extracted with CH2Cl2 (3 × 30 mL), the organic layers were washed 
with saturated NaHCO3 solution (5 × 50 mL), dried over MgSO4, and solvent evaporated in vacuo. 
The residue was purified by column chromatography using 10-40% EtOAc in petroleum ether 
40-60 °C to give diol 126 as bright orange oil (1.78 g, 37% over two steps). νmax (neat)/cm-1: 3369 
(br), 3029 (w), 2916 (w), 2836 (w), 1607 (m), 1513 (s); δH (400 MHz, CDCl3) 7.34 – 7.26 (4H, m, 
Ar), 7.21 – 7.16 (3H, m, Ar), 6.86 (2H, d, J 9, Ar), 6.56 (2H, d, J 16, 1-H), 6.14 (1H, dd, J 16, 6, 2-
H), 4.63 (1H, m, 3-H), 4.04 (1H, m, 5-H), 3.81 (3H, s, OCH3), 2.80 (1H, m, 7-HH), 2.68 (1H, m, 7-
HH), 1.93 – 1.74 (4H, m, 4-H2, 6-H2); δC (100 MHz, CDCl3) 159.4 , 142.1 , 129.9 (C-2), 129.7 (C-1), 
129.4 , 128.6 , 128.5 , 127.8 , 126.0 , 114.2 , 71.0 (C-3), 69.0 (C-5), 55.4 (OCH3), 42.9 (C-4), 39.3 
(C-6), 32.3 (C-7); Found (ESI) 335.1617 [MNa+] (C25H26O5SNa requires 335.1624). 
Treatment of racemic diol 126 with TMSOTf  
 
Diol 126 (0.40 mg, 1.28 mmol) was dissolved in CH2Cl2 (2.5 mL) under nitrogen and the solution 




temperature for 1 h. Water (3 mL) was added and the two phases separated, the aqueous layer 
was extracted with CH2Cl2 (3 × 3 mL). The combined organic layers were dried over MgSO4 and 
solvent evaporated in vacuo. The crude product was purified by column chromatography. 
Elution with 5% EtOAc in petroleum ether 40-60 °C gave syn-dihydropyran 127 (9 mg, 2% yield), 
elution with 10% EtOAc in petroleum ether 40-60 °C gave blepharocalyxin analogue 128 (86 mg, 
23% yield) and finally using 30% EtOAc in petroleum ether 40-60 °C a further mixture of dimeric 
diarylheptanoids (121 mg, 32% yield) was obtained . 
(3S,7S)-3-phenethyl-7-(p-methoxyphenyl)-3,4-dihydro-2H-pyran     127. A colourless oil. νmax 
(neat)/cm-1: 3063, 3026, 2929, 2841, 1678, 1599; δH (400 MHz, CDCl3) 7.33 – 7.26 (4H, m, Ar), 
7.22 – 7.17 (3H, m, Ar), 6.90 (2H, d, J 9, Ar), 5.91 (1H, m, 5-H), 5.74 (1H, m, 6-H), 5.10 (1H, m, 7-
H), 3.81 (3H, s, OCH3), 3.70 (1H, m, 3-H), 2.86 – 2.70 (2H, m, 1-H2), 2.14 (1H, m, 4-HH), 2.04 – 
1.93 (2H, m, 4-HH, 2-HH), 1.81 (1H, m, 2-HH); δC (100 MHz, CDCl3) 159.2, 142.2, 133.9 (C-6), 
130.3, 128.5, 128.5, 128.3, 125.7, 124.8 (C-5), 113.9, 77.1 (C-7), 73.3 (C-3), 55.3 (OCH3), 37.4 (C-
2), 31.6 (C-1), 31.0 (C-4). Found (ESI) 295.1691 [MH+] (C20H22O2 requires 295.1693). 
()-(1R*,3S*,5S*,6S*,7S*,9S*)-3,9-di(phenethyl)-5-(E)-(p-methoxyphen)ethenyl-7-(p-
methoxy)phenyl-2,8-dioxabicyclo[4.4.0]decane     128. A white solid. νmax (neat)/cm-1: 3024, 
2911, 2844, 1603, 1512; δH (500 MHz, CDCl3) 7.33 – 7.28 (5H, m, Ar), 7.23 – 7.19 (7H, m, Ar), 6.76 
– 6.70 (4H, m, Ar), 5.75 (1H, d, J 16, 2’-H), 5.03 (1H, dd, J 16, 9, 1’-H), 4.00 (1H, d, J 10, 7-H), 3.80 
(3H, s, OCH3), 3.57 (1H, m, 9-H), 3.52 (3H, m, OCH3), 3.47 (1H, m, 3-H), 3.38 (1H, m, 1-H), 2.81 
(1H, m, 2”-HH), 2.76 – 2.70 (3H, 2’’’-H2, 2’’-HH), 2.16 (1H, m, 5-H), 2.09 (1H, ddd, J 12, 4, 2, 10-
HH), 2.00 (1H, m, 1’’’-HH), 1.94 – 1.81 (2H, m, 1’’-HH, 1’’’-HH), 1.75 – 1.61 (3H, m, 1’’-HH, 10-HH, 
6-H), 1.57 (1H, m, 4-HH), 1.33 (1H, m, 4-HH); δC (125 MHz, CDCl3) 159.1, 158.4, 142.2, 133.3, 
132.2 (C-1’), 130.5, 128.5, 128.5, 128.3, 128.3, 127.0 (C-2’), 126.8, 125.7, 125.7, 113.3, 82.8 (C-
7), 79.2 (C-1), 75.8 (C-3), 74.9 (C-9), 55.3 (OCH3), 54.9 (OCH3), 50.1 (C-6), 42.0 (C-5), 40.4 (C-4), 
38.2 (C-10), 37.7, 37.5 (C-1” & C-1”’), 31.6, 31.4 (C-2” & C-2”’); Found (ESI) [MNa+] 611.3157 
(C40H44O4Na requires 611.3132). 
(E)-3-(4-(Trifluoromethyl)phenyl)-2-ene-1-propanol     128 
 
4-(Trifluoromethyl)cinnamic acid 127 (0.5 g, 2.31 mmol) was dissolved in anhydrous THF (8 mL) 




chloroformate (0.30 mL, 3.00 mmol) was added dropwise and the reaction was stirred at this 
temperature for 0.5 h. The mixture was filtered through celite and washed with EtOAc (15 mL). 
The filtrate was concentrated in vacuo and dissolved in MeOH (16 mL). NaBH4 (0.22 g, 5.78 
mmol) was added in portions at −78 °C and the solution was stirred for 1.5 h. The reaction was 
quenched with the addition of NH4Cl(aq) (16 mL) and the mixture extracted with EtOAc ( 3 × 20 
mL). The crude reaction was concentrated and suspended in CH2Cl2 (25 mL) and MnO2 (3.61 g, 
41.55 mmol) was added and the reaction stirred for 2h. The mixture was filtered through celite 
and rinse with CH2Cl2. The solvent was removed in vacuo to give compound 128 as white solid 
(0.39 g, 84%). δH (400 MHz, CDCl3) 9.76 (1H, d, J 7.5, 1-H), 7.72 – 7.66 (4H, m, Ar), 7.51 (1H, d, J 
16, 3-H), 6.78 (1H, dd, J 16, 7.5, 2-H); δC (100 MHz, CDCl3) 193.1 (C-1), 150.2 (C-3), 130.5 (C-2), 
128.6 , 126.1 (q, J 4, CF3). Spectroscopic data in accord with the literature.117 
(1E, 3S*, 5R*)-1-(p-trifluoromethylphenyl)-7-phenylhept-1-ene-3,5-diol    131 
 
Aldehyde 128 (1.40 g, 6.99 mmol), benzylacetone (1.26 mL, 8.39 mmol) and MgI2 (2.34 g, 8.39 
mmol) were dissolved in CH2Cl2 (35 mL) under nitrogen and the flask protected from light. N,N-
Diisopropylethylamine (1.58 mL, 9.09 mmol) was added by syringe pump at 0.85 ml/min. The 
mixture was stirred at room temperature for 2 h and quenched with the addition of NaHCO3(aq) 
(35 mL). The mixture was extracted with CH2Cl2 (2 × 25 mL). The organic phase was dried over 
MgSO4 and solvent removed in vacuo. The residue was purified by column chromatography 
using 5% EtOAc in petroleum ether 40-60 °C to give an inseparable 20:1 mixture of regioisomers 
(1.55 g). Me4NHB(OAc)3 (8.2 g, 38.65 mmol) was dissolved in dry MeCN (20 mL) and glacial acetic 
acid (20 mL) under nitrogen. The solution was cooled to −40 °C and a solution of the mixture of 
regioisomers in MeCN (10 mL) was added. The reaction mixture was allowed to warm to −20 °C 
and stirred overnight. The reaction was quenched with Rochelle’s salt solution (20 mL). The 
aqueous phase was extracted with CH2Cl2 (2 × 25 mL) and the combined organic layers were 
washed with NaHCO3(aq) repeatedly (8 × 10 mL). The organic phase was dried over MgSO4 and 
solvent removed in vacuo. The residue was purified by column chromatography using 5-40% 
EtOAc in petroleum ether 40-60 °C to give diol 131 as a colourless oil (0.51 g, 20% over two 
steps). νmax (neat)/cm-1: 3287, 2943, 1614; δH (400 MHz, CDCl3) 7.57 (2H, d, J 8, Ar), 7.45 (2H, d, 
J 8, Ar), 7.31 – 7.25 (2H, m, Ar), 7.22 – 7.17 (3H, m. Ar), 6.67 (1H, d, J 16, 1-H), 6.36 (1H, dd, 16, 




(4H, m, 6-H2, 4-H2); δC (100 MHz, CDCl3) 141.8, 140.3, 134.8 (C-2), 128.6, 128.6 (C-1), 128.5 126.7, 
126.1, 125.7 (q, J 4, CF3), 70.4 (C-3), 69.1 (C-5), 42.6 (C-4), 39.3 (C-7), 32.2 (C-6). δF (400 MHz, 
CDCl3) −62.39. 
(−)-(R,E)-5-Hydroxy-1,7-diphenylhept-1-en-3-one     138 
 
(+)-Ipc2BCl (5 g, 15.59 mmol) was dissolved in Et2O (100 mL) under nitrogen and cooled to 0 °C. 
Et3N (5.9 mL, 42.51 mmol) and a solution of ketone 114 (2.7 g, 18.42 mmol) in Et2O (100 mL) 
were added. The reaction mixture was stirred at this temperature for 2h, cooled to −78 °C and 
a solution of hydrocinnamaldehyde 35 in Et2O (20 mL) was added dropwise. The temperature 
was increased to −30 °C and the reaction stirred overnight. The reaction mixture was allowed to 
warm to room temperature and stirred for 5 h, quenched with the addition of NaHCO3 solution 
(200 mL) and the aqueous phase was extracted with Et2O (3 × 200 mL). The combined organic 
layers were washed with saturated solution of brine (20 mL), dried over MgSO4 and solvent 
removed in vacuo. The residue was purified by column chromatography using 5-30% EtOAc in 
hexane to give hydroxyketone 138 as a colourless oil (2.1 g, 53%, er 95.5).[α]𝐷
21 −27 (c. 3.0 CHCl3): 
δH (400 MHz, CDCl3) 7.58 – 7.54 (3H, m, 1-H, Ar), 7.42 – 7.40 (3H. m, Ar), 7.31 – 7.17 (5H, m, Ar), 
6.72 (1H, d, J 16, 2-H), 4.17 (1H, m, 5-H), 3.32 (1H, d, J 3, OH), 2.91 – 2.70 (4H, m, 4-H2, 7-H2), 
1.95 – 1.87 (1H, m, 6-HH), 1.82 – 1.73 (1H, m, 6-HH); δC (100 MHz, CDCl3) 200 (C=O), 143.6 (C-1), 
141.9, 130.8, 129.0, 128.5, 128.4, 126.2 (C-2), 125.8, 67.5 (C-5), 46.8 (C-7), 38.1 (C-6), 31.8 (C-7). 
(E)-4-(p-Methoxyphenyl)but-3-en-2-one     142 
 
Anisaldehyde (1.22 mL, 10.0 mmol) was dissolved in acetone (7.4 mL, 0.1 mol) and water (2 ml) 
was added. The solution was cooled to 0 °C and a solution of 10% NaOH(aq) (5 mL) was added 
dropwise. After stirring at room temperature for 2 h, 2M HCl was added until neutralise the 
solution. The solid was filtered, washed with water and dried to give enone 142 as a white solid 
(1.58 g, 90%) mp 73-75; δH (400 MHz, CDCl3) 7.49 (2H, d, J 9, Ar), 7.47 (1H, d, J 16, 1-H), 6.92 (2H, 
d, J 9, Ar), 6.61 (2H, d, J 16, 2-H), 3.84 (3H, s, OCH3), 2.36 (3H, s, 4-H3); δC (100 MHz, CDCl3) 198.5 
(CO), 161.7, 143.3 (C-1), 130.0, 127.16, 125.1 (C-2), 114.5, 55.5 (OCH3), 27.5 (CH3) Spectroscopic 




(-)-(R,E)-5-Hydroxy-1-(4-methoxyphenyl)-7-phenylhept-1-en-3-one     125 
 
(+)-Ipc2BCl (2.31 g, 7.20 mmol) was dissolved in anhydrous Et2O (80 mL) and cooled to 0 °C under 
nitrogen. Et3N (2.70 mL, 19.73 mmol) and a solution of enone 142 (1.5 g, 8.51 mmol) in Et2O (80 
mL) were added. The reaction mixture was stirred for 2.5 h and cooled to −78 °C and a solution 
of dihydrocinnamaldehyde 35 (0.86 mL, 6.55 mmol) in Et2O (15 mL) was added dropwise. The 
temperature was increased to −20 °C and the reaction stirred overnight. The reaction mixture 
was allowed to warm to room temperature and stirred for 4 h, quenched with the addition of 
NaHCO3 solution (135 mL). The aqueous phase was extracted with Et2O (3 × 200 mL) and the 
combined organic layers were dried over MgSO4 and solvent removed in vacuo. The residue was 
purified by column chromatography using 5-30% EtOAc in hexane to give hydroxyketone 125 as 
a white solid (0.59 g, 30%, er 96:4). mp 61-63 °C; [𝛼]𝐷
22−45.0 (c. 1.0 CHCl3); νmax (neat)/cm-1: 3447, 
3025, 2936, 2839, 1629, 1596; δH (400 MHz, CDCl3) 7.52 (1H, d, J 16, 1-H), 7.52 – 7.48 (2H, m, 
Ar), 7.31 – 7.17 (5H, m, Ar), 6.94 – 6.90 (2H, m, Ar), 6.60 (1H, d, J 16, 2-H), 4.15 (1H, m, 5-H), 3.85 
(3H, s, OCH3), 2.90 – 2.83 (2H, m, 4-HH, 7-HH), 2.79 – 2.70 (2H, m, 4-HH, 7-HH), 1.90 (1H, m, 6-
HH), 1.77 (1H, m, 6-HH); δC (100 MHz, CDCl3) 201.0 (CO), 162.0, 143.6 (C-1), 142.1, 130.3, 128.6, 
128.5, 126.9, 126.0, 124.2 (C-2), 114.6, 67.4 (C-5), 55.6 (OCH3), 46.7 (C-7), 38.3 (C-6), 32.0 (C-4); 
Found (ESI) 311.1638 [MNa+] (C20H22O3 requires 311.1642). 
 
(+)-(3S, 5R, E)-1-(4-Methoxyphenyl)-7-phenylhept-1-ene-3,5-diol   126 
 
Me4NHB(OAc)3 (3.06 g, 14.43 mmol) was dissolved in a 1:1 mixture of MeCN:AcOH (30 mL) under 
nitrogen and the solution was cooled to −40 °C. β-hydroxyketone 125 (0.56 g, 1.80 mmol) was 
dissolved in MeCN (2 mL) and added to the reaction mixture, which was warmed to −20 °C and 
stirred overnight. 0.5 N Rochelle’s salt solution (15 mL) was added and the mixture diluted with 
CH2Cl2 (15 mL). The aqueous layer was extracted with CH2Cl2 (3 × 25 mL). The combined organic 
layers were washed repeatedly with NaHCO3(aq). The organic phase was dried with MgSO4 and 




EtOAc in hexane to give anti-diol 126 as a light-yellow oil (0.46 g, 82%). [𝛼]𝐷
22+4.0 (c. 1.0 CHCl3); 
δH (400 MHz, CDCl3) 7.33 – 7.25 (4H, m, Ar), 7.22 – 7.16 (3H, m, Ar), 6.86 (2H, d, J 9 Ar), 6.56 (1H, 
d, J 16, 1-H), 6.14 (1H, dd, J 16, 6, 2-H), 4.63 (1H, q, J 6, 3-H), 4.01 (1H, m, 5-H), 3.81 (3H, s, OCH3), 
2.81 (1H, m, 7-HH), 2.68 (1H, m, 7-HH), 2.51 (2H, s(br), 2OH), 1.93 – 1.74 (4H, m, 4-H2, 6-H2); δC 
(100 MHz, CDCl3) 159.5, 142.1, 129.9 (C-1), 129.7 (C-2), 129.5, 128.6, 128.5, 127.8, 126.0, 114.2, 
71.0 (C-3), 69.0 (C-5), 55.5 (OCH3), 42.9 (C-4), 39.3 (C-6), 32.3 (C-7). Found (ESI) [MNa+] 335.1624 
(C20H24O3Na requires 335.1618).  
 
Treatment of diol (+)-126 with TMSOTf  
 
Diol (+)-126 (0.50 mg, 0.16 mmol) was dissolved in dry CH2Cl2 (0.5 mL) under nitrogen and the 
solution was cooled to 0 °C. TMSOTf (1.5 μL, 0.008 mmol) was added with microsyringe and the 
mixture was stirred at this temperature for 10 min. Water (0.5 mL) was added and the two 
phases separated, the aqueous layer was extracted with CH2Cl2 (3 × 1 mL). The combined organic 
layers were dried over MgSO4 and solvent evaporated in vacuo. The crude product was purified 
by HPLC using a Waters SunFire Prep silica column with a flow of 1 mL/min and a gradient of 
EtOAc with hexane starting from 2% for 4 min, 5% for 10 min, 8% for 10 min,15% for 10 min and 
30% for 10 min isolating blepharocalyxin analogue (+)-128 (6.5 mg, 14% yield), 143 (1.4 mg, 3% 





(+)-(1S, 3R, 5R, 6R, 7R, 9R)-3,9-di(phenethyl)-7-p-methoxyphenyl-5-(E)-(p-
methoxyphen)ethenyl-2,8-dioxabicyclo[4.4.0]decane     (+)-128 
 
[𝛼]𝐷
23 +110.0 (c. 1.0, CHCl3); All data in accordance with racemic product. 
(1R, 3R, 5S, 6S, 7S, 9R)-3,9-di(phenethyl)-7-p-methoxyphenyl-5-(E)-(p-methoxy)phenethenyl-
2,8-dioxabicyclo[4.4.0]decane     143 
      
A colourless oil. νmax (neat)/cm-1 3026, 2927, 2856, 1607, 1511; δH (500 MHz, CDCl3) 7.32 – 7.17 
(12H, m, Ar), 6.72 – 6.66 (6H, m, Ar), 5.72 (1H, d, J 16, 2’-H), 5.01 (1H, dd, J 16, 9, 1’-H), 4.25 (1H, 
d, J 11, 7-H), 4.19 (1H, dt, J 11, 6, 9-H), 4.00 (1H, dt, J 11, 6, 3-H), 3.85 (1H, td, J 11, 4, 1-H), 3.77 
(3H, m, OCH3), 3.52 (3H, m OCH3), 2.77 – 2.59 (4H, m, 2”-H2, 2”’-H2), 2.37 – 2.21 (3H, m, 1’’-HH, 
5-H, 1’’’-HH), 2.01 (1H, td, J 12, 6, 10-HH), 1.85 – 1.70 (5H, m, 10-HH, 1’’-HH, 1”’-HH, 4-HH, 6-H), 
1.46 (1H, m, 4-HH); δC (125 MHz, CDCl3) 159.1, 158.4, 142.0, 133.1, 132.0 (C-1’), 130.4, 129.7, 
128.5, 128.4, 127.2 (C-2’), 126.8, 125.9, 113.8, 113.3, 75.7 (C-7), 72.9 (C-9), 72.0 (C-3), 66.7 (C-
1), 55.3 (OCH3), 55.0 (OCH3), 51.5 (C-6), 37.5 (C-5), 37.0 (C-4), 35.6 (C-10), 33.6 (C-1’’’), 32.8 (C-
1’’), 32.6, 32.4 (C-2”’ & C-2’’); Found (ESI) 611.3132 [MNa+] (C40H44O4Na requires 611.3132). 
(1R, 3R, 5R, 6S, 7S, 9R)-3,9-di(phenethyl)-7-p-methoxyphenyl-5-(E)-(p-methoxy)phenethenyl-
2,8-dioxabicyclo[4.4.0]decane     144 




A colourless oil. νmax (neat)/cm-1: 3026, 2928, 2856, 1607, 1510; δH (500 MHz, CDCl3) 7.28 – 7.21 
(8H, m, Ar), 7.19 – 7.14 (6H, m, Ar), 6.89 – 6.85 (4H, m, Ar), 6.33 (1H, dd, J 16, 9, 1’-H), 6.02 (1H, 
d, J 16, 2’-H), 4.27 (1H, d, J 11, 7-H), 4.17 (2H, m, 9-H, 1-H), 3.94 (1H, m, 3-H), 3.84 (3H, m, OCH3), 
3.81 (3H, m, OCH3), 2.74 – 2.67 (2H, m, 2’’-HH, 2’’’-HH), 2.65 – 2.57 (2H, m, 2”-HH, 2”’-HH), 2.26 
– 2.19 (3H, m, 5-H, 1’’-HH, 1’’’-HH), 2.14 (1H, m, 4-HH), 2.00 – 1.75 (5H, m, 10-H2, 6-H, 1’’-HH, 
1’’’-HH), 1.58 (1H, m, 4-HH); δC (125 MHz, CDCl3) 159.4, 159.1, 141.9, 131.8 (C-1’), 131.3, 130.2, 
129.2, 128.5, 128.4, 128.3, 127.7 (C-2’), 127.2, 125.9, 125.8,114.1, 113.7, 73.4 (C-7), 73.1 (C-9), 
71.6 (C-3), 62.7 (C-1), 55.4 (OCH3), 55.3 (OCH3), 48.7 (C-6), 36.12 (C-4 & C-1’’’), 35.8 (C-10), 35.6 
(C-5), 33.4 (C-1”), 32.9 (C-2”’), 32.5 (C2’’); Found (ESI) 589.3292 [MH+] (C40H45O4 requires 
589.3312). 
 
(1R, 3S, 5S, 6S, 7S, 9R)-3,9-di(phenethyl)-7-p-methoxyphenyl-5-((E)-p-methoxyphenethenyl)-
2,8-dioxabicyclo[4.4.0]decane    145 
       
A colourless oil. νmax (neat)/cm-1: 3026, 2931, 2856, 1607, 1511; δH (500 MHz, CDCl3) 7.30 – 7.26 
(4H, m, Ar), 7.20 – 7.16 (8H, m, Ar), 6.72 – 6.64 (6H, m, Ar), 5.74 (1H, d, J 16, 2’-H), 5.01 (1H, dd, 
J 16, 9, 1’-H), 4.23 (1H, d, J 10, 7-H), 4.19 (1H, m, 9-H), 3.76 (3H, m, OCH3), 3.58 (1H, m, 1-H), 3.50 
(3H, m OCH3), 3.45 (1H, m, 3-H), 2.80 – 2.58 (4H, m, 2”-H2, 2”’-H2), 2.30 – 2.04 (3H, m, 10-HH, 5-
H, 1’’-HH), 1.96 (1H, m, 1’’-HH), 1.89 – 1.79 (2H, m, 10-HH, 1’’’-HH), 1.73 – 1.66 (2H, m, 1”’-HH, 
6-H), 1.58 (1H, m, 4-HH), 1.32 (1H, m, 4-HH); δC (125 MHz, CDCl3) 159.1, 158.4, 142.1, 142.0, 
133.2, 132.1 (C-1’), 130.4, 129.6, 128.4, 128.4, 128.4, 128.3, 127.1 (C-2’), 126.8, 125.8, 125.7, 
113.7, 113.3, 75.9 (C-7 & C-9), 75.2 (C-1), 72.8 (C-3), 55.2 (OCH3), 54.9 (OCH3), 51.1 (C-6), 42.3 
(C-5), 40.2 (C-4), 37.7 (C-1’’’), 35.4 (C-1”), 33.4 (C-10), 32.5 (C-2”’), 31.6 (C2’’); Found (ESI) 





(1S, 3S, 5R, 6R, 7R, 9R)-3,9-di(phenethyl)-7-p-methoxyphenyl-5-((E)-p-methoxyphenethenyl)-
2,8-dioxabicyclo[4.4.0]decane     146 
      
A colourless oil. νmax (neat)/cm-1: 3025, 2936, 2830, 1610, 1510; δH (500 MHz, CDCl3) 7.32 – 7.24 
(6H, m, Ar), 7.22 – 7.16 (6H, m, Ar), 6.73 – 6.64 (6H, m, Ar), 5.70 (1H, d, J 16, 2’-H), 4.99 (1H, dd, 
J 16, 9, 1’-H), 3.99 (1H, d, J 10, 7-H), 3.99 (1H, m, 3-H), 3.77 (3H, s, OCH3), 3.61 (1H, m, 1-H), 3.54 
(1H, m, 9-H), 3.51 (3H, m, OCH3), 2.79 – 2.64 (4H, m, 2’’-H2, 2’’’-H2), 2.38 – 2.25 (2H, m, 5-H, 1’’-
HH), 1.99 – 1.89 (2H, m, 10-HH, 1’’’-HH), 1.84 – 1.69 (3H, m, 4-HH, 1’’-HH, 1’’’-HH), 1.64 (1H, q, 
J 10, 6-H), 1.56 (1H, m, 10-HH), 1.43 (1H, m, 4-HH); δC (125 MHz, CDCl3) 159.0, 158.4, 142.2, 
142.1, 133.2, 132.2 (C-1’), 130.5, 129.7, 128.5, 128.5, 128.4, 128.3, 127.0 (C-2’), 126.8, 125.9, 
125.7, 113.6, 113.4, 82.7 (C-7), 75.0 (C-9), 71.8 (C-3), 70.6 (C-1), 55.3 (OCH3), 54.9 (OCH3), 51.5 
(C-6), 38.3 (C-10), 37.5 (C-1’’’), 37.2 (C-5), 37.2 (C-4), 32.7 (C-1’’), 32.3, 31.4 (C-2’’ & C-2’’’). Found 
(ESI) 589.3309 [MH+] (C40H44O4 requires 589.3312). 
 





Diol 126 (0.40 mg, 1.28 mmol) was dissolved in CH2Cl2 (2.5 mL) under nitrogen and the solution 
was cooled to 0 °C. TMSOTf (12 μL, 0.064 mmol) was added and the mixture was stirred at this 
temperature for 1 h. Water (3 mL) was added and the two phases separated, the aqueous layer 
was extracted with CH2Cl2 (3 × 3 mL). The combined organic layers were dried over MgSO4 and 
solvent evaporated in vacuo. . The crude product was purified by HPLC using a Waters SunFire 
Prep silica column with a flow of 1 mL/min and a gradient of EtOAc with hexane starting from 
2% for 4 min, 5% for 10 min, 8% for 10 min,15% for 10 min and 30% for 10 min isolating 
blepharocalyxin analogue 128 (44.6 mg, 15% yield), 143 (13 mg, 3% yield), 144 (26 mg, 7% yield), 
145 (42 mg, 11% yield), 146 (44 mg, 12% yield), 147 (26 mg, 7% yield), 148 (16 mg, 4% yield), 
149 (12 mg, 1% yield). 
 
(1S*,3S*,5S*,6S*,7S*,9R*)-3,9-di(phenethyl)-7-p-methoxyphenyl-5-((E)-p-methoxyphenethenyl)-
2,8-dioxabicyclo[4.4.0]decane     147 
      
A colourless. νmax (neat)/cm-1 3024, 2918, 2851, 1607, 1509; δH (500 MHz, CDCl3) 7.40 – 7.36 (2H, 
m, Ar), 7.30 – 7.25 (7H, m, Ar), 7.21 – 7.16 (5H, m, Ar), 6.89 – 6.86 (2H, m, Ar), 6.83 – 6.80 (2H, 
m, Ar), 6.52 (1H, d, J 16, 2’-H), 5.82 (1H, dd, J 16, 9, 1’-H), 5.15 (1H, s, 7-H), 4.32 (1H, m, 1-H), 
3.81 (3H, s, OCH3), 3.79 (3H, s, OCH3), 3.73 (1H, m, 3-H), 3.40 (1H, m, 9-H), 2.97 – 2.86 (2H, m, 5-
H, 2’’-HH), 2.79 (1H, m, 2’’’-HH), 2.68 (1H, m, 2’’’-HH), 2.59 (1H, m, 2’’-HH), 2.37 (1H, dd, J 11, 5, 
6-H), 2.08 (1H, q, J 12, 10-HH), 1.94 (1H, m, 1’’’-HH), 1.88-1.69 (4H, m, 1’’-H2, 4-HH, 1’’’-HH), 1.52 
(1H, m, 10-HH), 1.42 (1H, q, J 12, 4-HH); δC (100 MHz, CDCl3) 158.9, 158.6, 142.2, 142.2, 132.2, 
131.2 (C-2’), 130.6 (C-1’), 130.0, 128.6, 128.4, 128.3, 128.3, 128.2, 127.3, 125.8, 125.7, 113.9, 
113.8, 74.4 (C-7), 69.4 (C-1), 69.1 (C-9), 67.4 (C-3), 55.3 (2OCH3), 40.1 (C-6), 39.2 (C-4), 38.2 (C-
1’’ & C-1’’’), 37.1 (C-5), 32.0 (C-2’’), 31.9 (C-10), 31.7 (C-2’’’); Found (ESI) 611.3168 [MNa+] 






2,8-dioxabicyclo[4.4.0]decane     148 
      
A colourless oil. νmax (neat)/cm-1 3026, 2925, 2857, 1608, 1511; δH (500 MHz, CDCl3) 7.32 – 7.29 
(2H, m, Ar), 7.29 – 7.24 (5H, m, Ar), 7.20 – 7.16 (5H, m, Ar), 7.05 – 7.02 (2H, m, Ar), 6.88 – 6.85 
(2H, m, Ar), 6.79 – 6.76 (2H, m, Ar), 5.74 (1H, d, J 16, 2’-H), 5.66 (1H, dd, J 16, 7, 1’-H), 4.50 (1H, 
d, J 11, 7-H), 4.23 (1H, q, J 3, 1-H), 3.96-3.87 (2H, m, 3-H, 9-H), 3.77 (3H, s, OCH3), 3.78 (3H, s, 
OCH3), 2.79 – 2.73 (2H, m, 2’’-HH, 2’’’-HH), 2.71 – 2.63 (2H, m, 2’’-HH, 2’’’-HH), 2.10 – 2.01 (2H, 
m, 5-H, 10-HH), 1.90 – 1.83 (3H, m, 6-H, 1’’-HH, 1’’’-HH), 1.81 – 1.72 (3H, m, 4-HH, 1’’-HH, 1’’’-
HH), 1.67 (1H, m, 10-HH), 1.59 (1H, m, 4-HH); δC (125 MHz, CDCl3) 159.3, 158.7, 142.5, 142.2, 
133.1, 132.0 (C-2’), 130.3, 129.4, 128.5, 128.5, 128.3, 128.2, 127.6 (C-1’), 127.0, 125.7, 125.6, 
113.8, 113.7, 80.12 (C-7), 72.6, 71.9 (C-3 & C-9), 63.6 (C-1), 55.3 (2OCH3), 45.3 (C-6), 37.7, 37.1 
(C-1’’ & C-1’’’), 37.0 (C-10), 36.0 (C-5), 32.0, 31.6 (C-2’’ & C-2’’’), 31.2 (C-4); Found (ESI) 611.3113 
[MNa+] (C40H44O4Na requires 611.3132). 
(1S*,3S*,5S*,6R*,7R*,9R*)-3,9-di(phenethyl)-7-p-methoxyphenyl-5-((E)-p-methoxyphenethenyl)-
2,8-dioxabicyclo[4.4.0]decane    149 
       
A colourless oil. νmax (neat)/cm-1 3026, 2925, 2853, 1609, 1511; δH (500 MHz, CDCl3) 7.27 – 7.21 
(8H, m, Ar), 7.18 – 7.15 (6H, m, Ar), 6.89 – 6.84 (4H, m, Ar), 6.33 (1H, dd, J 16, 10, 1’-H), 5.99 (1H, 
d, J 16, 2’-H), 4.01 (1H, d, J 10.5, 7-H), 3.98 – 3.92 (2H, m, 1-H, 3-H), 3.83 (3H, s, OCH3), 3.81 (3H, 
m, OCH3), 3.49 (1H, m, 9-H), 2.75 – 2.59 (4H, m, 2’’H2, 2’’’H2), 2.29 – 2.20 (2H, m, 5-H, 1’’’-HH), 
2.14 (1H, m, 10-HH), 1.99 – 1.92 (2H, m, 4-HH, 1’’-HH), 1.86 – 1.76 (3H, m, 6-H, 1’’-HH, 1’’’-HH), 
1.59 – 1.50 (2H, m, 10-HH, 4-HH); δC (100 MHz, CDCl3) 159.3, 159.1, 142.1, 142.0, 131.6 (C-2’), 




7), 74.8 (C-9), 71.7 (C-3), 66.4 (C-1), 55.4 (OCH3), 55.3 (OCH3), 48.5 (C-6), 38.6 (C-4), 37.5 (C-1’’), 
36.3 (C-10), 36.1 (C-1’’’), 35.5 (C-5), 32.9, 31.4 (C-2’’ and C-2’’’); Found (ESI) 611.3167 [MNa+] 
(C40H44O4Na requires 611.3132). 
[18O]-Dihydrocinnamaldehyde   150 
 
Dihydrocinnamaldehyde 35 (1 g, 7.45 mmol) was dissolved in d3-acetonitrile (0.8 mL) and water-
18O (0.15 mL, 8.20 mmol) was added. The reaction mixture was stirred for 2 h and diluted with 
CH2Cl2 (10 mL). The solution was dried over MgSO4 and the solvent removed in vacuo to give 
aldehyde 150 as a colourless oil in quantitative yield. δH (400 MHz, CD3CN) 9.73 (1H, s, 1-H), 
7.31–7.18 (5H, m, Ar), 2.91 (2H, t, J 7.5, 3-H2). 2.74 (2H, t, J 7.5, 2-H2); δC (100 MHz, CD3CN) 
203.14 (C16OH), 203.09 (C18OH), 141.9, 129.4, 129.2, 127.0, 45.6 (C-2), 28.6 (C-3). 
[5-18O]-(+)-(1E, 3S, 5R)-1,7-Diphenylhept-1-ene-3,5-diol    152 
 
Benzylacetone 114 (0.80 g, 5.51 mmol) was dissolved in Et2O (50 mL) and cooled to 0 °C under 
nitrogen. Et3N (1.54 mL, 11.01 mmol) and a solution of (+)-Ipc2BCl (4 mL, 1.2 M, 4.77 mmol) were 
added dropwise and stirred for 2 h. The reaction mixture was cooled to −78 °C and a solution of 
label [18O]-dihydrocinnamaldehyde 150 in THF (2.5 mL) was added dropwise. The temperature 
was increased to −30 °C and the reaction stirred overnight. The reaction mixture was allowed to 
warm to room temperature and stirred for 3 h, quenched with the addition of NaHCO3 solution 
(50 mL) and the aqueous phase was extracted with CH2Cl2 (3 × 50 mL). The combined organic 
layers were dried over MgSO4 and the solvent removed in vacuo. The residue was purified by 
column chromatography using 5-30% EtOAc in hexane to give the corresponding β-
hydroxyketone in 96:4 er. Me4NHB(OAc)3 (2.03 g, 7.70 mmol) was dissolved in a 1:1 mixture of 
MeCN:AcOH (8 mL) and stirred for 30 min. The solution was cooled to −20 °C and a solution of 
hydroxyketone (0.27 g, 0.96 mmol) in MeCN (2.0 mL) was added to the reaction mixture and 
stirred overnight. Semi-saturated Rochelle’s salt solution (10 mL) was added and the aqueous 
layer was extracted with CH2Cl2 (3 × 15 mL). The combined organic layers were washed 
repeatedly with NaHCO3(aq). The organic phase was dried with MgSO4 and solvent removed in 




give [5-18O]-diol 152 as a colourless oil (0.17 g, 17% over two steps, dr 88:12). [α]D22 +5.0 (c. 1.0 
CHCl3); δH (400 MHz, CDCl3) 7.38–7.17 (10H, m, Ar), 6.63 (1H, m, J 16, 1-H), 6.28 (1H, dd, J 16, 6, 
2-H), 4.67 (1H, m, 3-H), 4.03 (1H, m, 5-H), 2.80 (1H, m, 7-HH), 2.69 (1H, m, 7-HH), 2.47 (1H, s(br), 
OH), 2.36 (1H, s(br), OH), 1.93–1.75 (4H, m, 4-H2, 6-H2); δC (100 MHz, CDCl3) 142.0, 136.7, 132.0 
(C-2), 130.2 (C-1), 128.7, 128.6, 128.5, 127.9, 126.6, 126.1, 70.8 (C-3), 69.07 (C-16OH), 68.04 (C-
18OH), 42.8 (C-4), 39.4 (C-6), 32.3 (C-7). 
[18O]-(1R,3S,5S,6S,7S,9S)-3,9-diphenylethyl-7-phenyl-5-(E)-phenethenyl-2,8-
dioxabicyclo[4.4.0]decane     153  
 
Diol 152 (0.10 mg, 0.35 mmol) was dissolved in anhydrous CH2Cl2 (1 mL) under nitrogen and the 
solution was cooled to 0 °C. TMSOTf (3.2 μL, 0.018 mmol) was added by microsyringe and the 
mixture was stirred at this temperature for 1.5 h. Water (1 mL) was added and the two phases 
separated, the aqueous layer was extracted with CH2Cl2 (3 × 1 mL). The combined organic layers 
were dried over MgSO4 and solvent evaporated in vacuo. The crude product was purified by 
column chromatography. Elution with 2.5% EtOAc in petroleum ether 40-60 °C gave 
blepharocalyxin analogue [18O]-153 as a colourless oil (7.8 mg, 8% yield). δH (400 MHz, CDCl3) 
7.30–7.25 (4H, m, Ar), 7.20–7.15 (6H, m, Ar), 7.12–7.05 (2H, m, Ar), 6.98 (1H, m, Ar), 6.72 (2H, 
m, Ar), 5.81 (1H, d, J 16, 2’-H), 5.14 (1H, dd, J 16, 9, 1’-H), 4.01 (1H, d, J 10, 7-H), 3.55 (1H, m, 9-
H), 3.45 (1H, m, 3-H), 3.37 (1H, m, 1-H), 2.81–2.67 (4H, m, 2”-H2, 2”’-H2), 2.19 (1H, m, 5-H), 2.07 
(1H, m, 10-HH), 1.97 (1H, m, 1”’-HH) 1.91–1.78 (2H, m, 1”’-HH, 1”-HH), 1.73–1.63 (6H, m, 6-H, 
10-HH, 1”- HH), 1.55 (1H, m, 4-HH), 1.33 (1H, m, 4-HH); δC (100 MHz, CDCl3) 142.1, 141.0, 137.4, 
134.1 (C-1’), 128.5, 128.5, 128.3 (C-2’), 128.3, 128.2, 128.0, 127.9, 127.8, 126.5, 125.8, 125.7, 
125.7, 83.39 & 83.37 (C-7), 79.13 & 79.11 (C-1), 75.77 & 75.74 (C-9), 75.02 & 75.00 (C-3), 50.6 
(C-6), 41.9 (C-5), 40.3 (C-4), 38.1 (C-10), 37.6, 37. 5 (C-1” & C-1”’), 31.6, 31.3 (C-2” & C-2”’). Found 
(ESI) 551.2939 [MNa+] (C38H40O2 requires 551.2921 & Found (ESI) 555.3005 [MNa+] (C38H4018O2 
requires 555.3021).  





Me4NHB(OAc)3 (3.63 g, 17.12 mmol) was dissolved in a 1:1 mixture of MeCN:AcOH (36 mL) under 
nitrogen and the solution cooled to −40 °C. Hydroxyketone 138 (0.6 g, 2.14 mmol) was dissolved 
in MeCN (2.5 mL) and added to the reaction mixture, which was allowed to warm to −20 °C and 
stirred overnight. Rochelle’s salt solution 0.5 N (30 mL) was added. The aqueous layer was 
extracted with CH2Cl2 (3 × 10 mL). The combined organic layers were washed repeatedly with 
NaHCO3(aq). The organic phase was dried with MgSO4 and solvent removed in vacuo. The residue 
was purified by column chromatography using 2-30% EtOAc in hexane to give diol (+)-116 as a 
white solid (0.51 g, 84%). mp 75-77; [α]𝐷
23 +5.0 (c. 3.0 CHCl3); δH (400 MHz, CDCl3) 7.39 – 7.16 
(10H, m, Ar), 6.63 (1H, m, J 16, 1-H), 6.28 (1H, dd, J 16 6, 2-H), 4.67 (1H, m, 3-H), 4.03 (1H, m, 5-
H), 2.84 – 2.65 (1H, m, 7-HH), 2.73 – 2.65 (1H, m, 7-HH), 2.45 (1H, d, J 4, OH), 2.34 (1H, d, J 4 
OH), 1.94 – 1.75 (4H, m, 4-H2, 6-H2); δC (100 MHz, CDCl3) 141.9 , 136.6 , 131.8 (C-2), 130.1 (C-1), 
128.6, 128.5, 128.4, 127.7, 126.5, 125.9, 70.7 (C-3), 68.9 (C-5), 42.7 (C-4), 39.2 (C-6), 32.1 (C-7).  
Treatment of diol (+)-116 with TMSOTf  
 
Diol (+)-116 (0.40 mg, 1.46 mmol) was dissolved in CH2Cl2 (3 mL) under nitrogen and the solution 
was cooled to 0 °C. TMSOTf (13 μL, 0.073 mmol) was added and the mixture was stirred at this 
temperature for 1.5 h. Water (3 mL) was added and the two phases separated, the aqueous 
layer was extracted with CH2Cl2 (3 × 3 mL). The combined organic layers were dried over MgSO4 
and solvent evaporated in vacuo. The crude product was purified by HPLC using Waters SunFire 
Prep silica column with a flow of 1 mL/min and a gradient of EtOAc with hexane isolating 
blepharocalyxin analogue 95 (79 mg, 20% yield), 154 (20 mg, 5% yield), 155 (10 mg, 2.5% yield), 
156 (10 mg, 2.5% yield), 157 (20.5 mg, 5% yield), tetrahydropyran 158 (19.2 mg, 7% yield), 1,5-





dioxabicyclo[4.4.0]decane     154 
 
A colourless oil. νmax (neat)/cm-1 3025, 2926, 2853, 1495; δH (500 MHz, CDCl3) 7.31 – 7.26 (7H, 
m, Ar), 7.21 – 7.15 (9H, m, Ar), 7.13 – 7.08 (3H, m, Ar), 7.03 – 6.99 (1H, m, Ar), 6.72 (2H, d, J 9, 
Ar), 5.85 (1H, d, J 16, 2’-H), 5.18 (1H, dd, J 16, 9, 1’-H), 4.30 (1H, d, J 10, 7-H), 4.23 (1H, m, 9-H), 
3.62 (1H, td, J 11, 4.5, 1-H), 3.49 (1H, m, 3-H), 2.82 – 2.60 (4H, m, 2”-H2, 2”’-H2), 2.32 – 2.19 (2H, 
m, 1’’’-HH, 5-H), 2.11 (1H, td, J 12, 6, 10-HH), 1.99 (1H, dd, 13, 4.5, 10HH), 1.94 – 1.67 (4H, m, 
1”’-HH, 1’’H2, 6-H), 1.58 (1H, m, 4-HH), 1.36 (1H, q, J 12, 4-HH); δC (125 MHz, CDCl3) 142.2, 142.1, 
141.0, 137.45, 134.1 (C-1’), 128.7, 128.6, 128.5, 128.4, 128.4 (C-2’), 128.2, 128.1, 128.0, 126.64, 
126.0, 125.9, 125.8, 76.6 (C-7), 76.0 (C-3), 75.2 (C-1), 73.0 (C-9), 50.7 (C-6), 42.5 (C-5), 40.2 (C-
4), 37.7 (C-1’’), 35.4 (C-10), 33.5 (C-1”’), 32.6 (C-2”’), 31.7 (C2’’); Found (ESI) 551.2922 [MNa+] 
(C38H40O2Na requires 551.2921). 
 
(1R,3R,5R,6S,7S,9R)-3,9-phenylethyl-7-phenyl-5-(E)-phenethenyl-2,8-
dioxabicyclo[4.4.0]decane     155 
 
A colourless oil. δH (500 MHz, CDCl3) 7.37 – 7.22 (14H, m, Ar), 7.19 – 7.13 (6H, m, Ar), 6.50 (1H, 
dd, J 16, 10, 1’-H), 6.09 (1H, d, J 16, 2’-H), 4.32 (1H, d, J 10, 7-H), 4.20 (2H, m, 9-H, 1-H), 3.95 (1H, 
m, 3-H), 2.75 – 2.67 (2H, m, 2’’-HH, 2’’’-HH), 2.65 – 2.58 (2H, m, 2”-HH, 2”’-HH), 2.30 – 2.20 (3H, 
m, 5-H, 1’’-HH, 1’’’-HH), 2.15 (1H, m, 4-HH), 2.03 – 1.92 (2H, m, 10-HH, 6-H), 1.90 – 1.77 (3H, m, 
10-HH, 1’’-HH, 1’’’-HH) 1.59 (1H, m, 4-HH); δC (125 MHz, CDCl3) 141.9, 139.1, 137.3, 132.6 (C-2’), 
129.9 (C-1’),  128.7, 128.5, 128.4, 128.4, 128.3, 128.1, 128.0, 127.4, 126.1, 125.9, 125.8, 73.9 (C-
7), 73.2 (C-9), 71.6 (C-3), 62.6 (C-1), 48.7 (C-6), 36.14 (C-4 & C-1’’), 35.8 (C-10), 35.5 (C-5), 33.4 





dioxabicyclo[4.4.0]decane     156 
 
A colourless oil. νmax (neat)/cm-1 3025, 2930, 2859, 1733, 1602, 1495; δH (500 MHz, CDCl3) 7.32 
– 7.15 (15H, m, Ar), 7.12 – 7.07 (2H, m, Ar), 7.02 (1H, m, Ar), 6.73 – 6.70 (2H, m, Ar), 5.81 (1H, d, 
J 16, 2’-H), 5.16 (1H, dd, J 16, 10, 1’-H), 4.30 (1H, d, J 10, 7-H), 4.20 (1H, m, 9-H), 4.00 (1H, m, 3-
H), 3.87 (1H, m, 1-H), 2.79 – 2.57 (4H, m, 2’’-H2, 2’’’-H2), 2.43 – 2.20 (3H, m, 5-H, 1’’’-HH, 1’’-HH), 
2.02 (1H, m, 10-HH), 1.88–1.72 (5H, m, 6-H, 10-HH, 1’’’-HH, 1’’-HH, 4-HH), 1.47 (2H, m, 4-HH); δC 
(125 MHz, CDCl3) 142.0, 142.0, 140.8, 137.3, 134.0 (C-1’), 128.6, 128.5, 128.4, 128.2 (C-2’), 128.0, 
127.8, 126.6, 125.9, 125.8, 76.4 (C-7), 72.9 (C-9), 71.9 (C-3), 66.6 (C-1), 51.0 (C-6), 37.6 (C-5), 
36.9 (C-4), 35.6 (C-10), 33.6 (C-1’’’), 32.9 (C-1’’), 32.5, 32.4 (C-2’’’ and C-2’’); Found (ESI) 551.2910 
[MNa+] (C38H40O2Na requires 551.2921).  
 (1R,3R,5R,6S,7S,9R)-3,9-phenylethyl-7-phenyl-5-(E)-phenethenyl-2,8-
dioxabicyclo[4.4.0]decane     157 
      
νmax (neat)/cm-1 3025, 2918, 2851, 1601, 1494; δH (500 MHz, CDCl3) 7.37 – 7.35 (2H, m, Ar), 7.33 
– 7.26 (6H, m, Ar), 7.24 – 7.18 (7H, m, Ar), 7.14 – 7.10 (3H, m, Ar), 6.70 – 6.68 (2H, m, Ar), 5.99 
(1H, d, J 16, 2’-H), 5.21 (1H, dd, J 16, 8, 1’-H), 5.02 (1H, d, J 11, 7-H), 4.02 (1H, q, J 7, 9-H), 3.90 
(1H, s, 1-H), 3.47 (1H, m, 3-H), 2.90 (1H, m, 2’’-HH), 2.82 – 2.62 (3H, m, 2’’-HH, 2’’’-H2), 2.57 – 
2.50 (2H, m, 5-H, 1’’’-HH), 2.25 – 2.12 (3H, m, 6-H, 1’’’-HH, 10-HH), 2.03 – 1.96 (2H, m, 10-HH, 
1’’-HH), 1.88 (1H, m, 1’’-HH), 1.61 – 1.50 (2H, m, 4-H2); δC (125 MHz, CDCl3) 142.6, 142.3, 141.9, 
137.3, 133.9 (C-1’), 128.7, 128.5, 128.4, 128.3, 128.3, 128.0, 127.9, 127.3 (C-2’), 126.3, 126.0, 
125.7, 125.6, 76.6 (C-3), 75.2 (C-1), 71.8 (C-9), 69.8 (C-7), 44.3 (C-6), 43.7 (C-5), 38.2 (C-1’’), 34.9 
(C-1’’’), 34.1 (C-10), 32.9 (C-2’’’), 32.8 (C-4), 31.7 (C-2’’); Found (ESI) 551.2907 [MNa+] 





tetrahydropyran    158 
       
A colourless oil. νmax (neat)/cm-1 3025, 2925, 2852, 1713, 1495,; δH (500 MHz, CDCl3) 7.30 – 7.10 
(20H, m, Ar), 6.43 (1H, d, J 16, 2’’’-H), 6.00 (1H, dd, J 16, 9, 1’’’-H), 3.74 (1H, td, J 10, 3, 2-H), 3.31 
(1H, m, 6-H), 2.92 – 2.76 (4H, m, 4’-H2, 1’’-HH, 3’-HH), 2.72 – 2.52 (4H, m, 3’-HH, 2’’’’-H2, 1’-HH), 
2.48 – 2.43 (2H, m, 1’-HH, 1’’-HH), 2.26 (1H, m, 4-H), 1.75 (1H, m, 1’’’’-HH), 1.70 – 1.60 (3H, m, 
1’’’’-HH, 3-HH, 5-HH), 1.34 (1H, m, 5-HH); δC (125 MHz, CDCl3) 209.0 (CO), 142.1, 141.2, 140.5, 
137.2, 133.6 (C-2’’’), 131.2 (C-1’’’), 129.1, 128.5, 128.4, 128.4, 128.3, 128.3, 127.2, 126.1, 126.0, 
125.7, 78.53 (C-2), 75.3 (C-6), 47.6 (C-1’), 46.0 (C-4’), 46.0 (C-3), 45.0 (C-4), 39.0 (C-5), 37.8 (C-
1’’’’), 35.8 (C-1’’), 31.7 (C-2’’’’), 29.5 (C-4’); Found (ESI) 551.2935 [MNa+] (C38H40O2Na requires 
551.2921). 
 
(3R,5R, 10R, 11S)-3,10-diphenethyl-5,11-di((E)-styryl)-1,5-dioxocane      159 
       
νmax (neat)/cm-1 3025, 2926, 2855, 1495; δH (500 MHz, CDCl3) 7.42 – 7.39 (4H, m, Ar), 7.35 – 7.31 
(4H, m, Ar), 7.29 – 7.24 (4H, m, Ar), 7.18 – 7.17 (3H, m, Ar), 7.13 – 7.10 (3H, m, Ar), 7.05 – 7.03 
(2H, m, Ar), 6.71 (1H, d, J 16, 2’-H), 6.58 (1H, d, J 16, 2’’’-H), 6.35 (1H, dd, J 16, 7, 1’’’-H), 6.30 (1H, 
dd, J 16, 5, 1’-H), 4.52 (1H, m, 6-H), 4.16 (1H, m, 2-H), 4.00 (1H, m, 4-H), 3.84 (1H, m, 8-H), 2.90 
– 2.81 (2H, m, 2’’’’-HH, 2’’-HH), 2.71 – 2.59 (2H, m, 2’’’’-HH, 2’’-HH), 2.15 (1H, m, 3-HH), 2.00 – 
1.85 (2H, m, 1’’-HH, 1’’’’-HH), 1.83 – 1.77 (3H, m, 7-HH, 1’’’’-HH, 3-HH), 1.68 (1H, m, 7-HH), 1.61 
(1H, m, 1’’-HH); δC (125 MHz, CDCl3) 142.3, 142.0, 137.0, 136.8, 132.5 (C-1’’’), 131.9 (C-1’), 129.4 
(C-2’’’), 128.6 (C-2’), 128.6, 128.6, 128.5, 128.4, 128.4, 128.3, 127.6, 127.4, 126.4, 126.4, 125.7, 
125.7, 82.6 (C-2), 79.6 (C-8), 76.8 (C-4), 68.6 (C-6), 42.3 (C-7), 41.8 (C-3), 38.6 (C-1’’’), 37.1 (C-




[1-2H]-Dihydrocinnamaldehyde    160 
 
LiAl2H4 (0.56 g, 13.32 mmol) was suspended in dry Et2O (10 mL) and a solution of 
dihydrocinnamic acid (1.0 g, 6.66 mmol) in dry Et2O (7 mL) was added at 0 °C under nitrogen. 
The mixture was stirred at room temperature for 1 h and diluted with Et2O (20 mL). Water was 
added dropwise at 0 °C until all LiAl2H 4 was quenched. The suspension was filtered through celite 
and the filtrate dried over MgSO4 and the solvent removed in vacuo to give corresponding 
alcohol as colourless liquid (0.93 g, 99%). The alcohol was dissolved in dry CH2Cl2 (8 mL) under 
nitrogen. A solution of 15% wt of Dess-Martin periodinane in CH2Cl2 (2.71 mL, 1.31 mmol) was 
added and the mixture stirred at room temperature overnight. The solvent was removed in 
vacuo and the solid dissolved in Et2O. The solution was filtered through celite and the solvent 
from filtrate removed in vacuo. The residue was purified by column chromatography using 2.5% 
EtOAc in hexane as eluent to give aldehyde 160 as a light-yellow liquid (0.1 g, 63%). δH (400 MHz, 
CDCl3) 7.32 – 7.27 (2H, m, Ar), 7.23 – 7.20 (3H, m, Ar), 2.97 (2H, t, J 7, 3-H2), 2.78 (2H, t, J 7, 2-
H2); δC (100 MHz, CDCl3) 140.4, 128.7, 128.4, 126.4, 45.2 (C-2), 28.2 (C-3). Spectroscopic data in 
accord with the literature.119 
[5-2H]-(R,E)-5-hydroxy-1,7-phenylhept-1-en-3-one     161 
 
(+)-Ipc2BCl (4.76 mL, 4.99 mmol, 1.05 M in hexane) was dissolved in dry Et2O (50 mL) and cooled 
to 0 °C. Et3N (0.53 mL, 3.82 mmol) and a solution of 4-phenyl-3-buten-2-one 135 (0.73 g, 5.0 
mmol) in dry Et2O (10 mL) were added and the mixture stirred at 0 °C for 30 min. The mixture 
was cooled to −78 °C and a solution of aldehyde 160 (0.45 g, 3.33 mmol) in dry Et2O (7 mL) was 
added dropwise and the mixture stirred for 30 min at −78 °C. The mixture was allowed to warm 
to −25 °C and stirred overnight. Saturated solution of NaHCO3(aq) (50 mL) was added and the 
aqueous layer extracted with Et2O (3 x 50 mL). The combined organic layers were dried over 
MgSO4 and solvent removed in vacuo. The residue was purified by column chromatography 
using 5-15% EtOAc in petroleum ether 40-60 °C as eluent to give hydroxyketone 161 as a 
colourless oil (0.78 g, 83%). δH (400 MHz, CDCl3) 7.56 – 7.54 (3H, m, 1-H, Ar), 7.42 – 7.40 (3H. m, 




6-HH), 1.77 (1H, m, 6-HH); δC (100 MHz, CDCl3) 200.1 (CO), 143.7 (C-1), 141.9, 134.2, 130.8, 
129.0, 128.4, 126.3 (C-2), 125.9, 46.7 (C-7), 38.1 (C-6), 31.8 (C-7).  
[3,5-2H2]-(5R, E)-1,7-Diphenylhept-1-ene-3,5-anti-diol     162 
 
Hydroxyketone 161 (0.35 g, 1.24 mmol) was dissolved in a mixture 1:1 THF:MeOH and cooled to 
0 °C. NaB2H4 (0.52 g, 12.4 mmol) was added portionwise and the mixture stirred at room 
temperature for 1 h. A semi-saturated solution of NH4Cl (6 mL) was added. The aqueous layer 
was extracted with EtOAc (3 x 10 mL) and the combined organic layers dried over MgSO4 and 
solvent removed in vacuo. The residue was purified by column chromatography using 10-50% 
EtOAc in hexane as eluent to give a mixture of diastereomers 162 as a colourless oil (0.22 g, 
63%). δH (400 MHz, CDCl3) 7.39 – 7.16 (10H, m, Ar), 6.63 (1H, m, 1-H), 6.28 (1H, m, 2-H), 2.91 – 
2.66 (2H, m, 7-H2), 1.94 – 1.75 (4H, m, 6-H2, 4-H2); δC (100 MHz, CDCl3) 142.0, 136.7, 132.0 (C-2), 
130.3 (C-1), 128.8, 128.6, 128.5, 127.9, 126.6, 126.0, 42.8 (C-4), 39.4 (C-6), 32.3 (C-7).  
Treatment of [3,5-2H2]-diol 162 with TMSOTf  
 
[3,5-2H2]-Diol 162 (0.22 mg, 1.28 mmol) was dissolved in CH2Cl2 (1.5 mL) under nitrogen and the 
solution was cooled to 0 °C. TMSOTf (7 μL, 0.039 mmol) was added and the mixture was stirred 
at this temperature for 1 h. Water (1 mL) was added and the two phases separated, the aqueous 
layer was extracted with CH2Cl2 (3 × 3 mL). The combined organic layers were dried over MgSO4 




Prep silica column with a flow of 1 mL/min and a gradient of EtOAc with hexane isolating syn-
dihydropyran 93 (7 mg, 3%), anti-dihydropyran 94 (2.3 mg, 1%), blepharocalyxin analogue 95 
(8.3 mg, 4% yield), 163 (2.6 mg, 1.2% yield), 157 (3.5 mg, 1.7% yield), 156 (4.3 mg, 2% yield). 
[3,5-2H2]-Syn-3-phenethyl-7-phenyl-3,4-dihydro-2H-pyran     93. A colourless oil. δH (400 MHz, 
CDCl3) 7.41 – 7.34 (4H, m, Ar), 7.31 – 7.27 (3H, m, Ar), 7.22 – 7.17 (3H, m, Ar), 5.76 (1H, s(br), 6-
H), 5.15 (1H, s(br), 7-H), 2.85 – 2.72 (2H, m, 1-H2), 2.15 (1H, m, 4-HH), 2.03 – 1.95 (2H, m, 4-HH, 
2-HH), 1.83 (1H, ddd, J 14, 9, 7, 2-HH). 
[3,5-2H2]-Anti-3-phenethyl-7-phenyl-3,4-dihydro-2H-pyran     94. A colourless oil. δH (400 MHz, 
CDCl3) 7.42 – 7.10 (8H, m, Ar), 6.90 – 6.89 (2H, m, Ar), 6.00 (1H, s, 6-H), 5.3 (1H, s, 7-H), 2.74 (1H, 
m, 1-HH), 2.52 (1H, m, 1-HH), 2.14 – 1.98 (2H, m, 4-H2), 1.89 (1H, m, 2-HH), 1.69 (1H, m, 2-HH). 
[1,3,5,9-2H4]-(1S*,3R*,5R*,6R*,7R*,9R*)-3,9-phenylethyl-7-phenyl-5-(E)-phenethenyl-2,8-
dioxabicyclo[4.4.0]decane     95. A colourless oil. δH (500 MHz, CDCl3) 7.30 – 7.07 (17H, m, Ar), 
6.98 (1H, m, Ar), 6.72 (2H, m, Ar), 5.81 (1H, d, J 16, 2’-H), 5.13 (1H, d, J 16, 1’-H), 4.01 (1H, d, J 
10, 7-H), 2.81 – 2.67 (4H, m, 2”-H2, 2”’-H2), 2.06 (1H, d, J 12, 10-HH), 1.96 (1H, m, 1”-HH), 1.89 – 
1.78 (2H, m, 1”-HH, 1”’-HH), 1.72-1.65 (3H, m, 6-H, 10-HH, , 1”’-HH), 1.53 (1H, d, J 13, 4-HH), 
1.32 (1H, d, J 13, 4-HH); δC (120 MHz, CDCl3) 142.1, 140.5, 137.4, 134.1 (C-1’), 128.5, 128.5, 128.3 
(C-2’), 128.3, 128.2, 127.9, 128.9, 127.8, 126.5, 125.8, 125.7, 125.7, 83.3 (C-7), 50.5 (C-6), 40.1 
(C-4), 37.9 (C-10), 37.5, 37. 3 (C-1” & C-1”’), 31.6, 31.3 (C-2” & C-2”’). 
[1,3,5,9-2H4]-(1S*,3S*,5R*,6R*,7R*,9R*)-3,9-phenylethyl-7-phenyl-5-(E)-phenethenyl-2,8-
dioxabicyclo[4.4.0]decane     163. A colourless oil. δH (500 MHz, CDCl3) 7.32 – 7.07 (18H, m, Ar), 
6.73 – 6.71 (2H, m, Ar), 5.77 (1H, d, J 16, 2’-H), 5.12 (1H, d, J 16, 1’-H), 4.03 (1H, d, J 10, 7-H), 
2.78 – 2.64 (4H, m, 2’’-H2, 2’’’-H2), 2.33 (1H, m, 1’’-HH), 1.95 (1H, m, 1’’’-HH), 1.89 (1H, d, J 12, 
10-HH) 1.82 – 1.69 (5H, m, 4-HH, 1’’-HH, 1’’’-HH, 6-H, 10-HH), 1.42 (1H, d, J 14, 4-HH); δC (125 
MHz, CDCl3) 142.1, 142.0, 137.4, 134.1 (C-1’), 128.6,128.5,128.5,128.4, 128.3, 128.2, 128.0, 
127.9, 127.8, 126.5 (C-2’), 125.9, 125.8, 125.7, 83.2 (C-7), 20.9 (C-6), 38.1 (C-10), 37.3 (C-1’’’), 
36.9 (C-4), 32.7 (C-1’’), 32.9, 31.3 (C-2’’ & C-2’’’) 
[1,3,5,9-2H4]-(1R*,3S*,5S*,6S*,7S*,9R*)-3,9-phenylethyl-7-phenyl-5-(E)-phenethenyl-2,8-
dioxabicyclo[4.4.0]decane     157. A colourless oil. δH (500 MHz, CDCl3) 7.37 – 7.26 (5H, m, Ar), 
7.20 – 7.14 (10H, m, Ar), 7.11 – 7.06 (3H, m, Ar), 7.00 (1H, m, Ar), 6.71 – 6.69 (2H, m, Ar), 5.83 
(1H, d, J 16, 2’-H), 5.16 (1H, d, J 16, 1’-H), 4.28 (1H, d, J 10, 7-H), 2.80 – 2.59 (4H, m, 2’’-H2, 2’’’-




1’’-HH, 6-H, , 1’’’-HH, 4-HH), 1.69 (1H, m, 1’’-HH), 1.34 (1H, d, J 14, 4-HH); δC (100 MHz, CDCl3) 
142.1, 142.0, 140.9, 137.3, 134.0 (C-1’), 128.6, 128.5, 128.4, 128.3 (C-2’), 128.1, 128.0, 127.8, 
126.5, 125.9, 125.8, 125.7, 76.5 (C-7), 51.4 (C-6), 39.9 (C-5), 37.6 (C-4), 35.1 (C-10), 33.3, 32.5 (C-
1’’’ & C-1’’), 31.6, 29.7 (C-2’’’ & C-2’’). 
[1,3,5,9-2H4]-(1R*,3R*,5S*,6S*,7S*,9R*)-3,9-phenylethyl-7-phenyl-5-(E)-phenethenyl-2,8-
dioxabicyclo[4.4.0]decane     156. A colourless oil. δH (500 MHz, CDCl3) 7.34 – 7.15 (15H, m, Ar), 
7.11 – 7.07 (3H, m, Ar), 7.02 (1H, m, Ar), 6.72-6.70 (2H, m, Ar), 5.80 (1H, d, J 16, 1’-H), 5.15 (1H, 
d, J 16, 2’-H), 4.29 (1H, d, J 10, 7-H), 2.77 – 2.57 (4H, m, 2’’-H2, 2’’’-H2), 2.34 – 2.20 (2H, m, 1’’-
HH, 1’’’-HH), 2.15 (1H, d, J 14, 4-HH), 1.83 – 1.73 (5H, m, 10-H2, 6-H, 1’’-HH, 1’’’-HH) 1.44 (1H, d, 
J 14, 4-HH); δC (125 MHz, CDCl3) 142.0, 141.9, 140.8, 137.3, 133.9 (C-2’), 128.6, 128.5, 128.4, 
128.2, 128.0 (C-1’), 127.9, 126.6, 125.9, 125.8, 76.3 (C-7), 50.8 (C-6), 36.6 (C-4), 35.4 (C-1’’), 33.5 
(C-10), 32.8 (C-1”’), 32.5, 32.4 (C-2”’ & C2’’).  
(−)-(1E,5R)-5-Hydroxy-1,7-bis(4-methoxyphenyl)hept-1-en-3-one   165 
 
Enone 142 (0.34 g, 1.96 mmol) was dissolved in THF (25 mL) under nitrogen and the solution 
cooled to 0 °C. Et3N (0.55 mL, 3.91 mmol) and (+)-Ipc2BCl (1.42 mL, 1.2 M in hexane, 1.70 mmol) 
were added. After 2.5 h, the reaction mixture was cooled to −78 °C and a solution of p-
methoxyphenylpropanal 164 (0.21 g, 1.30 mmol) was added dropwise. The temperature was 
increased to −30 °C and the reaction stirred overnight. The reaction mixture was allowed to 
warm to room temperature and stirred for 4 h, quenched with the addition of NaHCO3 solution 
(50 mL) and the aqueous phase was extracted with Et2O (3 × 50 mL). The combined organic 
layers were dried over MgSO4 and solvent removed in vacuo. The residue was purified by column 
chromatography using 10-40% EtOAc in hexane to give β-hydroxyketone 165 as white solid (0.20 
g, 42%, er 9:1). mp 110-112 °C; [α]D22−23.5 (c. 0.17 CHCl3) δH (400 MHz, CDCl3) 7.52 (1H, d, J 16, 1-
H), 7.52–7.48 (2H, m, Ar-H), 7.19–7.12 (2H, m, Ar-H), 6.94–6.90 (2H, m, Ar-H), 6.85–6.81 (2H, m, 
Ar-H), 6.60 (1H, d, J 16, 2-H), 4.14 (1H, m, 5-H), 3.85 (3H, s, OCH3), 3.79 (3H, s, OCH3), 2.88–2.64 
(4H, m, 4-H2, 7-H2), 1.87 (1H, m, 6-HH), 1.74 (1H, m, 6-HH); δC (100 MHz, CDCl3) 201.0 (CO), 162.0, 
157.9, 143.6 (C-1), 134.2, 130.3, 129.5, 127.0, 124.2 (C-2), 114.6, 114.0, 67.4 (C-5), 55.6 (OCH3), 





(+)-(1E, 3S, 5R,)-1,7-bis(p-methoxy)phenylhept-1-ene-3,5-diol   166 
 
Me4NHB(OAc)3 (1.23 g, 4.70 mmol) was dissolved in a 1:1 mixture of MeCN:AcOH (10 mL) under 
nitrogen and stirred for 30 min. The solution was cooled to −20 °C and a solution of 
hydroxyketone 165 (0.20 g, 0.59 mmol) in MeCN (5 mL) was added to the reaction mixture and 
stirred overnight. Semi-saturated Rochelle’s salt solution (15 mL) was added and the mixture 
diluted with CH2Cl2 (10 mL). The aqueous layer was extracted with CH2Cl2 (3 × 10 mL). The 
combined organic layers were washed repeatedly with NaHCO3(aq). The organic phase was dried 
with MgSO4 and solvent removed in vacuo. The residue was purified by column chromatography 
using 10-40% EtOAc in hexane to give diol 166 as a white solid (0.19 g, 39% over two steps, dr 
75:25). mp 82-84 °C; [α]D22+2.0 (c. 1.0 CHCl3); δH (400 MHz, CDCl3) 7.31 (2H, d, J 9, Ar-H), 7.11 (2H, 
d, J 9, Ar), 6.87–6.80 (5H, m, Ar-H) 6.56 (1H, d, J 16, 1-H), 6.13 (1H, dd, J 16, 6, 2-H), 4.62 (1H, q, 
J 6, 3-H), 4.01 (1H, m, 5-H), 3.81 (3H, s, OCH3), 3.78 (3H, s, OCH3), 2.77–2.60 (2H, m, 7-H2), 1.89–
1.71 (4H, m, 4-H2, 6-H2); δC (100 MHz, CDCl3) 159.5, 157.9, 134.1 (C-1), 129.8 (C-2), 129.7, 129.4, 
127.8, 114.2, 114.0, 71.0 (C-3), 69.0 (C-5), 55.4 (OCH3), 42.9 (C-4), 39.5 (C-6), 31.3 (C-7). Found 
(ESI) [MNa+] 365.1714 (C21H26O4Na requires 365.1723). 
(+)-Blepharocalyxin D tetramethyl ether   167  
 
(+)-Diol 166 (0.10 mg, 0.29 mmol) was dissolved in CH2Cl2 (1 mL) and the solution was cooled to 
0 °C. TMSOTf (3.4 μL, 0.019 mmol) was added by microsyringe and the mixture was stirred at 
this temperature for 0.5 h. Water (0.5 mL) was added and the two phases separated, the 
aqueous layer was extracted with CH2Cl2 (3 × 1 mL). The combined organic layers were dried 
over MgSO4 and solvent evaporated in vacuo. The crude product was purified by column 
chromatography. Elution with 2.5% EtOAc in petroleum ether 40-60 °C gave blepharocalyxin 
analogue 167 (31 mg, 33% yield). []D +93.3 (c.0.3, CHCl3); [Lit. for the enantiomer32 [α]D22 −90.4 
(c.0.32, CHCl3)]; δH (500 MHz, Acetone-D6) 7.11 – 7.05 (4H, m, Ar), 6.87 – 6.77 (6H, m, Ar), 6.72 




(3H, s, OCH3), 3.78 (3H, s, OCH3), 3.76 (3H, s, OCH3), 3.51 (1H, m, 9-H), 3.48 (3H, s, OCH3), 3.42 
(1H, m, 3-H), 3.34 (1H, m, 1-H), 2.73 – 2.60 (4H, m, 2”-H2, 2”’-H2), 2.11 (1H, m, 5-H), 2.04 (1H, m, 
10-HH), 1.92 (1H, m, 1”’-HH), 1.87 – 1.73 (7H, m, 1”-H2, 1”’- HH), 1.68 – 1.58 (6-H, 10-HH), 1.53 
(1H, m, 4-HH), 1.30 (1H, m, 4-HH); δC (100 MHz, Acetone-D6) 159.0, 158.4, 157.7, 157.6, 134.2, 
134.2, 133.3, 132.2 (C-1’), 130.5, 129.4, 129.3, 126.9 (C-2’), 129.8, 113.7, 133.7, 113.3, 82.8 (C-
7), 79.2 (C-1), 75.7 (C-3), 74.9 (C-9), 55.2 (OCH3), 54.9 (OCH3), 51.1 (C-6), 42.0 (C-5), 40.4 (C-4), 
38.1 (C-10), 37.9, 37.7 (C-1” & C-1”’), 30.7, 30.4 (C-2” & C-2”’). Spectroscopic data in accord with 
the literature for the enantiomer32  
(+)-Blepharocalyxin D 
 
Propanethiol (0.28 mL, 3 mmol) was dissolved in HMPA (2 mL) and cooled to 0 °C under nitrogen. 
nButyllithium (1.9 mL, 1.54 Μ in hexane, 3 mmol) was added dropwise and stirred for 1 h. The 
reaction mixture was warmed to room temperature and the hexane was removed in vacuo. A 
solution of tetramethyl ether 167 (25.4 mg, 0.037 mmol) in HMPA (1 mL) was added dropwise 
to the resulting solution of lithium propanethiolate. The reaction mixture was heated to 180 °C 
for 1 h before cooling to room temperature. Water (20 mL) was added and the mixture extracted 
with EtOAc (3 × 20 ml). The organic phase was dried over MgSO4 and solvent removed in vacuo. 
The residue was purified by column chromatography using 2-10% methanol in chloroform to 
give (+)-blepharocalyxin D as a pale yellow solid (0.21 g, 99%). []D +80.3 (c. 0.7 MeOH) [Lit. For 
the enantiomer41 [α]D22 −79.2 (c.0.23, MeOH)]; δH (500 MHz, Acetone-D6) 7.04 – 7.00 (6H, m, Ar), 
6.76 – 6.72 (6H, m, Ar), 6.68 – 6.58 (4H, m, Ar), 5.82 (1H, d, J 16, 2’-H), 5.07 (1H, d, J 16, 8, 1’-H), 
3.99 (1H, d, J 10, 7-H), 3.52 (1H, m, 9-H), 3.46 (1H, m, 3-H), 3.37 (1H, m, 1-H), 2.69 – 2.52 (4H, m, 
2”-H2, 2”’-H2), 2.20 (1H, m, 5-H), 2.00 (1H, m, 10-HH), 1.83 – 1.49 (7H, m, 1”-H2, 1”’-H2, 4-HH, 6-
H, 10-HH), 1.29 (1H, m, 4-HH); δC (125 MHz, Acetone-D6) 157.8, 156.9, 156.3, 133.9, 133.8, 133.7, 
133.0 (C-1’), 130.6, 130.2, 130.2, 128.0 (C-2’), 127.8, 115.9, 115.6, 83.6 (C-7), 80.0 (C-1), 76.3 (C-
3), 75.5 (C-9), 52.1 (C-6), 42.5 (C-5), 41.6 (C-4), 39.9 (C-10), 39.2, 39.1 (C-1” & C-1”’), 31.4, 31.3 




Benzyl 3-(p-tert-butyldimethylsilyloxyphenyl)propanal     171 
 
Ester 169 (0.67 g, 2.60 mmol) was dissolved in dry CH2Cl2 (27 mL) under nitrogen and imidazole 
(0.53 g, 7.79 mmol), TBSCl (0.47 g, 3.12 mmol) and DMAP (0.032 g, 0.26 mmol) were added. 
After stirring at room temperature for 1.5 h, the reaction was quenched with the addition of 
NH4Cl(aq) (10 mL). The aqueous fraction was extracted with CH2Cl2 (3 × 10 mL) and the combined 
organic layers were dried over MgSO4 and solvent removed in vacuo. The residue was purified 
by column chromatography using 2.5% EtOAc in hexane to give corresponding ester as a 
colourless oil (0.92 g, 95%). Ester (3.13 g, 8.44 mmol) was dissolved in dry CH2Cl2 (70 mL) under 
nitrogen and the solution was cooled to −78 °C. DIBALH (1.2 g, 8.44 mmol) was added dropwise 
and stirred at this temperature for 2.5 h. Methanol (20 mL) and Rochelle’s salt (50 mL) were 
added and the aqueous phase was extracted with CH2Cl2 (3 × 30 mL). The combined organic 
layers were dried over MgSO4 and solvent removed in vacuo. The residue was purified by column 
chromatography using 2.5-5% EtOAc in petroleum ether 40-60 °C to give aldehyde 171 as a 
colourless oil (2.17 g, 97%). δH (400 MHz, CDCl3) 9.81 (1H, s, 1-H), 7.03 (2H, d, J 6, Ar), 6.77 (2H, 
d, J 6, Ar), 2.89 (2H, t, J 13, 3-H2), 2.74 (2H, t, J 13, 2-H2), 0.98 (9H, s, C(CH3)3), 0.19 (6H, s, Si(CH3)2); 
δC (100 MHz, CDCl3) 201.9 (C-1), 154.1, 133.0, 129.2, 120.2, 45.6 (C-2), 27.5 (C-3), 25.8 
(SiC(CH3)3), 18.3 (SiC(CH3)3), −4.3 (Si(CH3)2). 
3-(p-tert-Butyldimethylsilyloxyphenyl)propional     170 
 
Enone 168 (1.17 g, 7.21 mmol) was dissolved in anhydrous dichloromethane (50 mL) 
under nitrogen and imidazole (1.47 g, 31.64 mmol), TBSCl (1.30 g, 8.65 mmol) and DMAP (0.09 
g, 0.72 mmol) were added. After stirring at room temperature for 1.5 h, the reaction was 
quenched with the addition of NH4Cl(aq) (20 mL). The aqueous fraction was extracted with CH2Cl2 
(3 × 20 mL) and the combined organic layers were dried over MgSO4 and solvent removed in 
vacuo. The residue was purified by column chromatography using 2.5% EtOAc in petroleum 
ether 40-60 °C to give ketone 170 as a white crystalline solid (1.81 g, 90%). δH (400 MHz, CDCl3) 
7.47 (1H, d, J 16, 1-H), 7.44 (2H, d, J 9, Ar), 6.85 (2H, d, J 9, Ar), 6.60 (1H, d, J 16, 2-H), 2.36 (3H, 




(C-1), 130.0 , 127.7 , 125.3 (C-2), 120.7 , 27.5 (CH3) 25.7 (SiC(CH3)3), 18.3 (SiC(CH3)3), −4.3 
(Si(CH3)2). Spectroscopic data in accord with the literature.120 
(R,E)-1,7-bis(p-tert-Butyldimethylsilyloxyphenyl)-5-hydroxyhept-1-en-3-one     172 
 
(+)-Ipc2BCl (2.7 mL, 1.05 M, 2.84 mmol) was dissolved in anhydrous CH2Cl2 (35 mL) under 
nitrogen and the solution cooled to 0 °C. A solution of enone 170 (0.78 g, 2.84 mmol) in dry 
CH2Cl2 (5 mL) and Et3N (0.79 mL, 5.67 mmol) were added and the reaction mixture was stirred 
at this temperature for 3 h. After cooling to −78 °C a solution of aldehyde 171 (0.5 g, 1.90 mmol) 
was added dropwise and the mixture stirred overnight at −30 °C. The reaction was warm up to 
30 °C and stirred for 6 h. NaHCO3(aq) (50 mL) was added and the aqueous phase was extracted 
with CH2Cl2 (3 × 40 mL) and the combined organic layers dried over MgSO4 and solvent removed 
in vacuo. The residue was purified by column chromatography using 1-20% EtOAc in hexane to 
give hydroxyketone 172 as a white solid (0.34 g, 32%). δH (400 MHz, CDCl3) 7.50 (1H, d, J 16, 1-
H), 7.44 (2H, d, J 9, Ar), 7.07 (2H, d, J 9, Ar), 6.85 (2H, d, J 9, Ar), 6.76 (2H, d, J 9, Ar), 6.59 (1H, d, 
J 16, 2-H), 4.13 (1H, m, 5-H), 3.39 (1H, s, OH), 7.87 – 2.62 (4H, m, 4-H2, 7-H2), 1.91-1.82 (1H, m, 
6-HH), 1.77 – 1.70 (1H, m, 6HH), 0.99 (9H, s, C(CH3)3), 0.98 (9H, s, C(CH3)3), 0.23 (6H, s, Si(CH3)2), 
0.18 (6H, s, Si(CH3)2); δC (100 MHz, CDCl3) 201.0 (CO), 158.5 , 153.8 , 143.6 (C-1), 134.7, 130.2 , 
129.4 , 127.5 , 124.4 (C-2), 120.7, 120.0, 67.4 (C-5), 46.7 (C-4), 38.5 (C-6), 31.1 (C-7), 25.8 & 25.7 
(SiC(CH3)3), 18.3 (SiC(CH3)3), −4.3 & −4.35 (Si(CH3)2). 
(−)-(3S,5R,E)-1,7-bis(p-tert-Butyldimethylsilyloxy)phenyl)hept-1-ene-3,5-diol      173 
 
Me4NHB(OAc)3 (1.38 g, 5.23 mmol) was dissolved in a 1:1 mixture of MeCN:AcOH (2 mL) under 
nitrogen and stirred for 30 min. The solution was cooled to −30 °C and a solution of 
hydroxyketone 172 (0.35 g, 0.65 mmol) in 1:1 mixture of MeCN:THF (3 mL) was added to the 
reaction mixture and stirred overnight. Semi-saturated Rochelle’s salt solution (3 mL) was added 
and aqueous layer was extracted with CH2Cl2 (4 x 5 mL). The combined organic layers were 
washed with NaHCO3(aq) (2 × 5 ml). The organic phase was dried with MgSO4 and the solvent 
removed in vacuo. The residue was purified by column chromatography using 5-15% EtOAc in 
hexane to give diol 173 as a pale-yellow oil (0.33 g, 93%, dr 90:10). [α]𝐷




δH (400 MHz, acetone-d6) 7.31 (2H, d, J 9, Ar), 7.10 (2H, d, J 9, Ar), 6.83 (2H, d, J 9, Ar), 6.77 (2H, 
d, J 9, Ar), 6.54 (1H, d, J 16, 1-H), 6.20 (1H, dd, J 16, 6, 2-H), 4.54 (1H, m, 3-H), 3.92 (1H, m, 5-H), 
2.73 (1H, m, 7-HH), 2.61 (1H, m, 7-HH), 1.76-1.69 (4H, m, 4-H2, 6-H2), 0.99 (9H, s, C(CH3)3), 0.98 
(9H, s, C(CH3)3), 0.21 (6H, s, Si(CH3)2), 0.19 (6H, s, Si(CH3)2); δC (100 MHz, CDCl3) 155.0, 153.5, 
135.5, 132.1 (C-2), 130.9, 127.8 (C-1), 127.4, 120.0, 119.7, 69.2 (C-3), 67.2 (C-5), 44.3 (C-4), 40.0 
(C-6), 31.0 (C-7), 25.2 & 25.1 (SiC(CH3)3), 17.9 (SiC(CH3)3), 5.2 (Si(CH3)2); Found (ESI) 565.3122 
[MNa+] (C31H50O4Si2Na requires 565.3139). 
(−)-(3S,5R,E)-1,7-bis(p-Hydroxyphenyl)hept-1-ene-3,5-diol      81 
 
(−)-Diol 173 was dissolved in anhydrous THF (0.053 g, 0.097 mmol) under nitrogen and TBAF (1.4 
mL, 1M in THF, 1.36 mmol). After stirring the reaction mixture for 1 h, water (2 mL) was added 
and the aqueous phase was extracted with CH2Cl2 (5 × 5 mL). The combined organic layers were 
dried over MgSO4 and the solvent removed in vacuo. The residue was purified by column 
chromatography using 50% EtOAc in hexane to give diol 81 as a pale-yellow oil (30.5 mg, 99%). 
[α]𝐷
25 −1.0 (c. 1.0 acetone); δH (500 MHz, acetone-d6) 9.36 (1H, s, OH), 8.05 (1H, s, OH), 7.27 (2H, 
d, J 9, Ar), 7.05 (2H, d, J 9, Ar), 6.81 (2H, d, J 9, Ar), 6.75 (2H, d, J 9, Ar), 6.52 (1H, d, J 16, 1-H), 
6.16 (1H, dd, J 16, 6, 2-H), 4.55 (1H, m, 3-H), 3.93(1H, m, 5-H), 2.71 (1H, m, 7-HH), 2.60 (1H, m, 
7-HH), 1.79 – 1.66 (4H, m, 4-H2, 6-H2), δC (125 MHz, CDCl3) 156.9, 155.3, 133.3, 130.9 (C-2), 129.2, 
129.0, 128.1 (C-1), 127.5, 115.3, 115.0, 69.4 (C-3), 67.3 (C-5), 44.4 (C-4), 40.2 (C-6), 30.9 (C-7). 
Found (ESI) 319.1317 [MNa+] (C19H20O3Na requires 319.1310). 





(−)-Diol 81 (30 mg, 0.095 mmol) was dissolved in a 1:1 mixture of dry CH2Cl2:THF (0.4 mL) under 
nitrogen and the solution was cooled to 0 °C. TMSOTf (0.86 μL, 0.005 mmol) was added and the 
mixture was stirred at this temperature for 30 min. Water (3 mL) was added and the two phases 
separated. The aqueous layer was extracted with CH2Cl2 (3 × 3 mL). The combined organic layers 
were dried over MgSO4 and solvent evaporated in vacuo. The crude product was purified by 
HPLC isolating syn-dihydropyran 16 (5 mg, 17% yield), anti-dihydropyran 16 (9 mg, 32% yield) 
and (+)-blepharocalyxin D (2 mg, 7% yield). 
(3R,7R)-5,6-dehydro-4''-de-O- methylcentrolobine     16. A colourless oil. δH (500 MHz, acetone-
d6) 8.37 (1H, s, OH), 8.15 (1H, s, OH), 7.20 (2H, d, J 9, Ar), 7.03 (2H, d, J 9, Ar), 6.80 (2H, d, J 9, 
Ar), 6.74 (2H, d, J 9, Ar), 5.87 (1H, ddt, J 10, 5, 2, 5-H), 5.70 (1H, ddt, J 10, 3, 1, 6-H), 5.04 (1H, m, 
7-H), 3.65 (1H, ddt, J 10, 8, 4, 3-H), 2.71 – 2.58 (2H, m, 1-H2), 2.08 – 2.02 (2H, m, 4-H2), 1.84 – 
1.70 (2H, m, 2-H2) δC (125 MHz, acetone-d6) 156.9, 155.4, 133.1, 132.8, 130.8 (C-6), 129. , 128.4, 
124.2 (C-5), 115.1, 114.9, 77.1 (C-7), 73.0 (C-3), 38.0 (C-2), 30.8 (C-4), 30.5 (C-1). Spectroscopic 
data in accord with the literature.15 
(3R,7S)-5,6-dehydro-4''-de-O-methylcentrolobine      16. A colourless oil. δH (500 MHz, acetone-
d6) 8.43 (1H, s, OH), 8.05 (1H, s, OH), 7.23 (2H, d, J 9, Ar), 6.84 (2H, d, J 9, Ar), 6.71 (2H, d, J 9, 
Ar), 6.61 (2H, d, J 9, Ar), 5.99 (1H, m, 5-H), 5.95 (1H, ddt, J 10, 3, 1, 6-H), 5.14 (1H, m, 7-H), 3.46 
(1H, tt, J 9, 5, 3-H), 2.54 (1H, ddd, J 14, 8, 5, 1-HH), 2.38 (1H, dt, J 14, 8, 1-HH) 1.98 – 1.95 (2H, 
m, 4-H2), 1.71 (1H, dtd, J 14, 8, 5, 2-HH), 1.56 (1H, dtd, J 14 8 4, 2-HH); δC (125 MHz, acetone-d6) 
157.0, 155.2, 132.8, 132.3, 129.7, 129.3, 128.0 (C-6), 125.5 (C-5), 115.1, 114.9, 114.8, 73.5 (C-7), 





3.3 Experimental procedures chapter 2  
Tiamulin 175 
 
A solution of tiamulin (10 ml) 12.5% (Denegard®) was concentred in vacuo using toluene (25 ml) 
to azeotrope off the water to give 175 (1.25 g) as colourless oil. δH (400 MHz, CDCl3) 6.44 (1H, 
dd, J 17, 11, 19-H), 5.70 (1H, d, J 8, 14-H), 5.29 (1H, dd, J 11, 2, 20-HH), 5.19 (1H, dd, J 17, 2, 20-
HH), 3.36 (1H, d, J 6, 11-H), 3.18 (2H, dd, J 17, 16, 22-H2), 3.17 – 3.06 (2H, m, 24-H2), 3.01 (4H, q, 
J 7, 25-H4), 2.94 – 2.86 (2H, m, 23-H2), 2.37 – 2.01 (5H, m, 10-H, 2-H2, 4-H, 13-H) 1.75 (1H, dd, J 
14, 3, 8-HH), 1.69 – 1.59 (2H, m, 1-H2), 1.54 (1H, m, 6-H), 1.43 (3H, s, 15-H3), 1.39 – 1.27 (3H, m, 
7-H2, 13-H), 1.23 (6H, t, J 7, 26-H6). 1.16 (3H, s, 18-H3), 1.15 – 1.06 (1H, m, 8HH), 0.87 (3H, d, J 7, 
17-H3), 0.71 (3H, d, J 7, 16-H3); δC (100 MHz, CDCl3) 217.1 (C-3), 170.5 (C-21), 139.3 (C-19), 117.1 
(C-20), 74.6 (C-11), 69.7 (C-14), 58.2 (C-4), 50.8 (C-24), 46.1 (C-25), 45.5 (C-9), 44.8 (C-13), 44.0 
(C-12), 41.8 (C-5), 36.8 (C-6), 36.1 (C-10), 34.5 (C-22), 34.5 (C-2), 30.5 (C-8), 26.9 (C-7), 26.8 (C-
23), 26.5 (C-18), 24.9 (C-1), 17.0 (C-16), 15.0 (C-15), 11.6 (C-17), 9.1 (C-26).Spectroscopic data in 
accordance with the literature data.111 
Diol 188 
 
A solution of tiamulin 187 (3.86 g, 7.8 mmol) in EtOH:THF (1:1, 90 ml), was treated with NaBH4 
(4.84 g, 78.12 mmol). After stirring at room temperature for 1 day, a saturated solution of NH4Cl 
(30 ml) was added. The mixture was extracted with EtOAc (2 × 50 ml) and CH2Cl2 (2 × 50 ml). The 
organic mixture was washed with brine (50 ml) and dried over MgSO4, filtered and solvent 
evaporated in vacuo. The mixture reaction was purified by column chromatography using 50-
80% EtOAc in petroleum ether 40-60 °C to give diol 188 as a colourless oil (1.57 g, 41%). νmax 
(neat)/cm-1: 3457, 2936, 2876, 1714; δH (400 MHz, CDCl3) 6.50 (1H, dd, J 17, 11, 19-H), 5.60 (1H, 
d, J 9, 14-H,), 5.30 (1H, dd, J 11, 2, 20-HH), 5.17 (1H, dd, J 17, 2, 20-HH), 4.55 (1H, t, J 6, 3-H), 3.15 




(3H, m, 6-H, 10-H, 13-HH), 2.04 – 1.75 (1H, m, 8-HH), 1.85 (1H, m, 2-HH), 1.73 – 1.25 (8H, m, 2-
HH, 8-HH, 1-H2, 4-H, 7-H2, 13-HH), 1.22 (3H, s, 15-H3), 1.18 (6H, td, J 7, 3, 26-H6), 1.15 (3H, s, 18-
H3), 0.80 (3H, d, J 7, 17-H3), 0.71 (3H, d, J 7, 16-H3); δC (100 MHz, CDCl3) 168.7 (C-21), 139.7 (C-
19), 116.73 (C-20), 77.3 (C-3), 75.0 (C-11), 71.5 (C-14), 57.9 (C-24), 53.1 (C-25), 53.0 (C-23) 51.0 
(C-4), 46.0 (C-9), 45.4 (C-13), 45.0 (C-12), 41.3 (C-5), 36.6 (C-6), 35.7 (C-10), 34.7 (C-22), 34.4 (C-
8), 32.6 (C-2), 31.8 (C-1), 27.7 (C-7), 26.4 (C-23), 26.3 (C-18), 17.7 (C-15), 17.3 (C-16), 12.2 (C-17), 
8.6 (C-26); Found (ESI) 496.3450 [MH+] (C28H49NO4S requires 496.3455). 
Triol 185 
 
Diol 188 (0.053 g, 0.011 mmol) was added to a solution of methanol containing 5% potassium 
hydroxide (25 ml) and heated to reflux for 2 h. After cooling the reaction mixture was poured 
into water (25 ml) and the solution was extracted with CH2Cl2 (3 × 15 ml). The organic layers 
were washed with a saturated solution of NaHCO3 (15 ml), dried over MgSO4, filtered and solvent 
evaporated in vacuo. After purification by column chromatography using 30% EtOAc in 
petroleum ether 40-60 °C triol 185 was isolated as a white solid (11 mg, 32%). Mp. 180-182 °C; 
δH (400 MHz, CDCl3) 6.16 (1H, dd, J 18, 11, 19-H), 5.31 (1H, dd, J 18, 1, 20-HH), 5.26 (1H, dd, J 11, 
1, 20-HH), 4.53 (1H, t, J 5, 3-H), 4.32 (1H, d, J 8, 14-H), 3.24 (1H, t, J 5, 11-H), 2.29 – 2.19 (1H, m, 
6-H), 2.04 (1H, br. p, J 7, 10-H), 2.02 – 1.91 (2H, m, 8-HH,13-HH), 1.90 – 1.79 (1H, m, 2-HH), 1.73 
– 1.22 (8H, m, 1-H2, 2-HH, 4-H, 8-HH, 7-H2,13-HH), 1.14 (3H, s, 18-H3), 1.13 (3H, s, 15-H3), 0.96 
(3H, d, J 7, 16-H3), 0.86 (3H, d, J 7, 17-H3); δC (100 MHz, CDCl3) 140.0 (C-19), 115.6 (C-20), 77.5 
(C-3), 75.5 (C-11), 68.1 (C-14), 51.9 (C-4), 46.0 (C-9), 45.7 (C-13), 45.6 (C-12), 42.1 (C-5), 36.8 (C-
6), 36.1 (C-10), 34.2 (C-2), 32.4 (C-18), 32.0 (C-8), 28.5 (C-7), 27.9 (C-1), 18.6 (C-16), 16.5 (C-15), 






Tiamulin 187 (1.87 g, 3.79 mmol) was dissolved in methanol (100 ml) containing 5% potassium 
hydroxide (5 g, 89 mmol) and heated to reflux for 4.5 h. After cooling, the reaction mixture was 
poured into water (50 ml) and extracted with CH2CL2 (3 × 80 ml). The organic layers were washed 
with saturated NaHCO3 solution (50 ml) and dried over MgSO4, and solvent evaporated in vacuo 
to give diol 181 as a white solid (0.85 g, 73%). Mp. 189-191 °C [Lit. 192 °C]83; δH (400 MHz, CDCl3) 
6.15 (1H, dd, J 18, 11, 19-H), 5.37 (1H, dd, J 18, 1, 20-HH), 5.29 (1H, dd, J 11, 1, 20HH), 4.35 (1H, 
dd, J 8, 6, 14-H), 3.41 (1H, dd, J 7, 7, 11-H), 2.29 – 2.10 (3H, m, 2-H2, 10-H), 2.04 (1H, s, 4-H), 1.91 
(1H, dd, J 16, 8, 13-HH), 1.78 – 1.37 (8H, m, 6-H, 8-HH, 13-HH, 1-H2, 7-H2, CHOH), 1.36 (3H, s, 15-
H3), 1.25 (1H, d, J 6, CHOH), 1.16 – 1.08 (1H, m, 8-HH), 1.15 (3H, s, 18-H3), 0.96 (3H, d, J 7, 16-
H3), 0.92 (3H, d, J 7, 17-H3); δC (100 MHz, CDCl3) 217.6 (C-3), 139.4 (C-19), 115.9 (C-20), 75.2 (C-
11), 66.8 (C-14), 59.1 (C-4), 45.4 (C-9), 45.3 (C-12), 45.1 (C-13), 42.4 (C-5), 36.9 (C-6), 36.6 (C-10), 
34.5 (C-2), 30.5 (C-8), 28.6 (C-18), 27.2 (C-7), 25.2 (C-1), 18.3 (C-16), 13.5 (C-15), 11.3(C-17). 
Spectroscopic data in accordance with the literature data.84 
Mono- and di-protected mutilins 192 and 193 
 
To a solution diol 181 (5.44 g, 16.99 mmol) in DMF (20 ml) were added imidazole (3.47 g, 50.96 
mmol), DMAP (catalytic amount) at room temperature, then TESCl (4.28 ml, 25.48 mmol) was 
added at 0 °C under N2. After stirring at room temperature for 20 h, water (120 ml) was added. 
The mixture was extracted with EtOAc (4 × 50 ml). The combined organic layers were washed 
with a saturated solution of brine (50 ml), dried over MgSO4, filtered and solvent concentred in 
vacuo. The residue was purified by silica gel column chromatography using 30% EtOAc in 
petroleum ether 40-60 °C to give di-protected mutilin 192 (3.20 g, 34%) and mono-protected 
mutilin 193 (3.47 g, 47%) as colourless oils.  
Di-protected mutilin 193; IR νmax (neat)/cm-1: 2953, 2912, 2876, 1735; δH (400 MHz, CDCl3) 6.15 
(1H, dd, J 18, 11, 19-H), 5.26 (1H, dd, J 18, 2, 20-HH), 5.21 (1H, dd, J 11, 2, 20-HH), 4.47 (1H, d, J 
8, 14-H), 3.54 (1H, d, J 6, 11-H), 2.30 (1H, p, J 7, 10-H), 2.24 – 2.16 (2H, m, 2-H2), 2.02 (1H, s, 4-
H), 1.86 (1H, dd, J 6, 8, 13-HH), 1.75 (1H, dq, J 14, 3, 8-HH), 1.60 – 1.29 (7H, m, 6-H, 1-H2, 7-H2, 
8-HH, 13-HH), 1.34 (3H, s, 15-H3), 1.10 (3H, s, 18-H3), 1.03 – 0.87 (18H, m, SiCH2CH3), 0.87 (3H, 




(100 MHz, CDCl3) 218.2 (C-3), 141.1 (C-19), 116.0 (C-20), 77.3 (C-11), 67.5 (C-14), 59.4 (C-4), 47.3 
(C-13), 45.7 (C-9), 45.1 (C-12), 43.7 (C-5), 37.6 (C-6), 36.4 (C-10), 34.8 (C-2), 31.0 (C-8), 28.9 (C-
18), 27.3 (C-7), 25.6 (C-1), 18.4 (C-16), 14.4 (C-15), 12.0 (C-17), 7.6 (SiCH2CH3), 7.3 (SiCH2CH3), 6.2 
(SiCH2), 5.8 (SiCH2); Found (ESI) 571.3933 [MNa+] (C32H60O3Si2Na requires 571.3979).  
Mono-protected mutilin 192: νmax (neat)/cm-1: 3477, 2954, 2933, 2876, 1731; δH (400 MHz, 
CDCl3) 6.25 (1H, dd, J 17, 11, 19-H), 5.39 (1H, dd, J 11, 1, 20-HH), 5.31 (1H, dd, J 17, 1, 20-HH), 
4.54 (1H. d, J 8, 14-H), 3.34 (1H, t, J 8, 11-H), 2.28 (1H, p, J 7, 10-H), 2.23 – 2.11 (2H, m, 2-H2), 
2.07 – 1.98 (1H, m, 4-H), 1.97 (1H, dd, J 16, 8, 13-HH), 1.75 (1H, dd, J 14, 3, 8-HH), 1.67 – 1.36 
(6H, m, 6-H,1-H2,13-HH,7-H2), 1.34 (3H, s, 15-H3), 1.26 – 1.09 (1H, m, 8-HH), 1.17 (3H, s, 18-H3), 
0.94 (9H, t, J 8 SiCH2CH3), 0.89 (3H, d, J 4, 16-H3), 0.86 (3H, d, J 6, 17-H3), 0.61 (6H, q, J 8, SiCH2); 
δC (100 MHz, CDCl3) 218.0 (C-3), 139.4 (C-19), 117.9 (C-20), 75.0 (C-11), 66.6 (C-14), 59.2 (C-4), 
46.8 (C-13), 45.5 (C-9), 44.3 (C-12), 43.7 (C-5), 37.6 (C-6), 35.9 (C-10), 34.7 (C-2), 30.9 (C-8), 27.3 
(C-7), 26.5 (C-18), 25.0 (C-1), 18.4 (C-16), 14.3 (C-15), 11.6 (C-17), 7.2 (SiCH2CH3), 6.1 (SiCH2); 
Found (ESI) 457.3032 [MNa+] (C26H46O3SiNa requires 457.3114).  
11-Acetoxy-14-methylsilyl mutilin 194 
 
To a solution of mono-protected mutilin 192 (0.10 g, 0.243 mmol) in CH2Cl2 (5 ml), were added 
Ac2O (2.5 ml) and Et3N (2.5 ml). After stirring the reaction mixture at room temperature during 
3 h, 1M HCl solution (15 ml) was added and the mixture was extracted with CH2Cl2 (4 × 10 ml), 
the organic layers were dried over MgSO4 and solvent concentred in vacuo to give acetate 194 
as a colourless oil (0.06 g, 56%). νmax (neat)/cm-1: 2984, 2954, 2936, 2876, 1730; δH (400 MHz, 
CDCl3) 6.20 (1H, dd, J 18, 11, 19-H), 5.28 (1H, dd, J 18, 1, 20-HH), 5.28 (1H, dd, J 11, 1, 20-HH), 
4.85 (1H, d, J 7, 11-H), 4.44 (1H. d, J 8, 14-H), 2.44 (1H, p, J 7, 10-H), 2.35 – 2.23 (1H, m, 2-H2), 
2.11 (1H, s, 4-H), 2.05 (3H, s, COCH3), 2.00 (1H, dd, J 16, 8, 13-HH), 1.93 – 1.82 (1H, m, 1-HH), 
1.70 (1H, m, 8-HH), 1.64 – 1.21 (5H, m, 6-H, 7-H2, 13-HH, 1-HH), 1.35 (3H, s, 15-H3), 1.21 – 1.05 
(1H, m, 8-HH), 1.00 (3H, s, 18-H3), 0.94 (9H, t, J 8, SiCH2CH3), 0.87 (3H, d, J 7, 16-H3), 0.77 (3H, d, 
J 7, 17-H3), 0.62 (6H, q, J 8, SiCH2). δC (100 MHz, CDCl3) 218.1 (C-3), 170.6 (CO), 140.2 (C-19), 
116.3 (C-20), 77.0 (C-11), 67.1 (C-14), 59.4 (C-4), 47.2 (C-13), 45.4 (C-12), 43.7 (C-9), 43.1 (C-5), 




18.4 (C-16), 14.4 (C-15), 11.8 (C-17), 7.2 (SiCH2CH3), 6.2 (SiCH2); Found (ESI) 499.3206 [MNa+] 
(C28H48O4SiNa requires 499.3220). 
Mesylate 195 
 
To a solution of silyl ester 192 (0.52 g, 1.20 mmol) in CH2Cl2, were added Et3N (0.50 ml, 3.61 
mmol) and DMAP (catalytic amount). Then MsCl (0.14 ml, 1.80 mmol) was added dropwise 
slowly at 0 °C under N2. After stirring at room temperature for 18 h, were added water (10 ml) 
and 1N HCl solution (1 ml). The mixture was extracted with CH2Cl2 (4 × 5 ml). The combined 
organic layers were washed with a semi-saturated solution of NaHCO3 (20 ml) and brine (20 ml), 
dried over MgSO4, filtered and solvent evaporated. The residue was purified by silica gel column 
chromatography using 60% EtOAc in petroleum ether 40-60 °C to give mesylate 195 as a 
colourless oil (0.19 mg, 30%). νmax (neat)/cm-1: 2961, 2929, 2875, 1731; δH (400 MHz, CDCl3) 6.18 
(1H, dd, J 17, 11, 19-H), 5.32 (1H, dd, J 2,1, 20-HH), 5.28 (1H, dd, J 8, 1, 20-HH), 4.65 (1H, d, J 7, 
11-H), 4.44 (1H, d, J 8, 14-H), 3.02 (3H, s, CH3SO), 2.50 (1H, p, J 7, 10-H), 2.32 – 2.11 (1H, m, 2-
H2), 2.08 – 1.97 (1H, m, 13-HH), 1.98 (1H, s, 4-H), 1.93 – 1.81 (1H, m, 1-HH), 1.74 (1H, dd, J 14, 3, 
8-HH), 1.58 (1H, m, 6-H), 1.50 – 1.35 (4H, m, 13-HH,7-H2,1-HH), 1.34 (3H, s, 15-H3), 1.22 (3H, s, 
18-H3), 1.23 – 1.06 (1H, m, 8-HH), 1.01 (3H, d, J 7, 17-H3), 0.94 (9H, t, J 8, SiCH2CH3), 0.86 (4H, d, 
J 7, 16-H), 0.61 (6H, q, J 8, SiCH2). δC (100 MHz, CDCl3) 217.2 (C-3), 138.8 (C-19), 117.4 (C-20), 
87.1 (C-11), 66.9 (C-14), 59.3 (C-4), 47.0 (C-13), 45.6 (C-9), 43.9 (C-5), 43.7 (C-12), 38.7 (CH3SO), 
37.4 (C-6), 35.7 (C-10), 34.7 (C-2), 30.8 (C-8), 28.2 (C-18), 27.2 (C-7), 24.8 (C-1), 18.3 (C-16), 14.3 
(C-15), 12.6 (C-17), 7.2(SiCH2CH3), 6.1(SiCH2). ); Found (ESI) 529.3260 [MOH] (C27H48O5SSiOH 
requires 529.3019).  
Alcohol 196 
 
To a solution of LiAlH4 (9.30 mg, (0.24 mmol) in THF (0.25 ml) was added dropwise a solution of 




mixture was cooled, water (2 ml) and solution of 1N HCl (2 ml) were added. The mixture was 
extracted with EtOAc (4 × 4 ml). The combined organic layers were dried over MgSO4, filtered 
and solvent evaporated in vacuo to give alcohol 196 as a colourless oil (30 mg, 71%). νmax 
(neat)/cm-1: 3473, 2954, 2934, 2875; δH (400 MHz, CDCl3) 6.21 (1H, dd, J 17, 11, 19-H), 5.29 (1H, 
dd, J 3, 1, 20-HH), 5.26 (1H, dd, J 8, 1, 20-HH), 4.54 (2H, m, 3-H, 11-H), 4.41 (1H, d, J 9, 14-H), 
3.01 (3H, s, CH3SO), 2.35 (1H, p, J 7, 10-H), 2.22 – 2.10 (1H, m, 6-H), 2.10 – 1.94 (2H, m, 2-HH, 13-
HH), 1.93 – 1.77 (2H, m, 8-HH, 1-HH), 1.76 – 1.51 (2H, m, 8-HH, 2-HH), 1.50 – 1.24 (5H, m, 1-HH, 
13-HH, 7-H2, 4-H), 1.22 (3H, s, 18-H3), 1.11 (3H, s, 15-H3), 0.95 (12H, m, 17-H3, SiCH2CH3), 0.87 
(3H, d, J 7, 16-H3), 0.62 (6H, q, J 8, SiCH2); δC (100 MHz, CDCl3) 139.3 (C-19), 116.8 (C-20), 88.3 
(C-11), 77.7 (C-3), 68.3 (C-14) 52.0 (C-4), 47.7 (C-9), 45.9 (C-13), 44.6 (C-5), 43.1 (C-12), 38.8 
(CH3SO), 37.2 (C-6), 35.4 (C-10), 34.2 (C-2), 33.3 (C-8), 31.8 (C-1), 28.1 (C-18), 28.0 (C-7), 18.7 (C-
16), 17.4 (C-15), 13.3 (C-17), 7.2 (SiCH2CH3), 6.2 (SiCH2). Found (ESI) 537.3022 [MNa+] 
(C27H50O5SSiNa requires 537.3046). 
Diol   197 
 
A solution of alcohol 192 (0.90 g, 2.08 mmol) in EtOH:THF (1:1, 10 ml) was treated with NaBH4 
(0.79 g, 20.78 mmol). After stirring at room temperature for 23 h, saturated solution of NH4Cl 
(10 ml) was added carefully at 0 °C. The mixture was extracted with CH2Cl2 (3 × 10 ml). The 
combined organic extracts were washed with brine (20 ml) and dried over MgSO4, filtered and 
solvent evaporated in vacuo to give diol 197 as a colourless oil (0.88 g, 92%). νmax (neat)/cm-1: 
3465, 2953, 2875, 1728; δH (400 MHz, CDCl3) 6.26 (1H, dd, J 17, 11, 19-H), 5.35 (1H, dd, J 11, 2, 
20-HH), 5.27 (1H, dd, J 17, 1, 20-HH), 4.50 (2H, m, 3-H, 14-H), 3.17 (1H, dd, J 10, 6, 11-H), 2.19 – 
2.09 (2H, m, 10-H, 6-H), 2.02 (1H, dd, J 16, 9, 13-HH), 1.98 – 1.77 (2H, m, 2-HH, 8-HH), 1.72 (1H, 
dd, J 14, 3, 8-HH), 1.67 – 1.56 (3H, m, 2-H, 7-H2), 1.49 – 1.34 (4H, m, 4-H, 13-HH, 1-H2), 1.26 (1H, 
d, J 10, CHOH), 1.17 (3H, s, 18-H3), 1.11 (3H, s, 15-H3), 0.95 (9H, t, J 8, SiCH2CH3), 0.89 (3H, d, J 7, 
16-H3), 0.82 (3H, d, J 7, 17-H3), 0.61 (3H, q, J 8, SiCH2); δC (100 MHz, CDCl3) 140.0 (C-19), 117.3 
(C-20), 77.9 (C-3), 75.5 (C-11), 68.1 (C-14), 51.6 (C-4), 47.5 (C-13), 45.9 (C-12), 45.2 (C-9), 43.1 (C-
5), 37.5 (C-6), 35.5 (C-10), 34.2 (C-2), 33.4 (C-8), 32.0 (C-7), 28.2 (C-1), 26.6 (C-18), 18.8 (C-16), 
17.4 (C-15), 12.3 (C-17), 7.3 (SiCH2CH3), 6.2 (SiCH2); Found (ESI) 459.3108 [MNa+] (C26H48O3SiNa 






To a solution of diol 197 in THF (25 ml) was added BH3·SMe2 (13.75 ml, 27.50 mmol) dropwise 
at −78 °C under N2. After stirring at room temperature for 6 h, the reaction mixture was cooled 
at 0 °C and 2M NaOH (25 ml) and H2O2 (25 ml) were added. The resulting mixture was stirred at 
room temperature for 15 h, and then K2CO3 was added until saturation. The mixture was 
extracted with EtOAc (4 × 40 ml). The combined organic layer was washed with brine (45 ml), 
dried over MgSO4 and solvent concentred in vacuo. The residue was purified by silica gel column 
chromatography using 30% EtOAc in petroleum ether 40-60 °C to give triol 198 as a white solid 
(1.18 g, 76%). Mp. 180-182 °C; νmax (neat)/cm-1: 3172, 2951, 2927, 2907, 2874; δH (400 MHz, 
CDCl3) 4.52 (1H, t, J 6, 3-H), 4.37 (1H, d, J 9, 14-H), 3.82 (1H, td, J 11, 3, 20-HH), 3.76 – 3.66 (1H, 
m, 20-HH), 3.18 (1H, d, J 6, 11-H), 2.29 (1H, td, J 10, 5, 19-HH), 2.20 – 2.02 (2H, m, 6-H, 10-H), 
2.01 – 1.88 (3H, m, 13-HH, 7-HH, 1-HH), 1.83 (1H, td, J 13, 5, 1-HH), 1.72 (1H, dd, J 14, 3, 8-HH), 
1.67 – 1.19 (8H, m, 2-H2, 7-HH, 4-H, 19-HH, 1-HH, 13-HH), 1.10 (3H, s, 18-H3), 1.09 (3H, s, 15-H3), 
0.97 (9H, t, J 8, SiCH2CH3), 0.90 (3H d, J 7, 17-H3), 0.87 (3H, d, J 7, 16-H3), 0.64 (6H, m, SiCH2); δC 
(100 MHz, CDCl3) 77.9 (C-3), 75.4 (C-11), 68.3 (C-14), 58.8 (C-20), 51.6 (C-4), 50.7 (C-13), 46.0 (C-
9), 43.2 (C-12), 41.7 (C-5), 38.1 (C-19), 37.3 (C-6), 34.9 (C-10), 34.0 (C-2), 32.7 (C-8), 32.1 (C-7), 
28.2 (C-1), 26.7 (C-18), 18.8 (C-16), 17.5 (C-15), 11.8 (C-17), 7.3 (SiCH2CH3), 6.4 (SiCH2); Found 
(ESI) 455.1901 [M+] (C26H51O4Si requires 455.3551). 
Pivaloate ester 199 
 
To a solution of triol 198 in pyridine (20 ml) pivaloyl chloride (0.34 ml) was added dropwise at 0 
°C. After stirring at room temperature for 1.5 h, MeOH (10 drops) was added and the reaction 
mixture was diluted with EtOAc (50 ml). The resulting solution was washed with 0.5M HCl (10  
30 ml) and saturated solution of NaHCO3 (30 ml), dried over MgSO4 and solvent evaporated in 




ether 40-60 °C  to give pivaloate ester 199 as a colourless oil (0.70 mg, 71%). νmax (neat)/cm-1: 
3522, 2954, 2936, 2875, 1709; δH (400 MHz, CDCl3) 4.51 (1H, t, J 6, 3-H), 4.37 (1H, d, J 9, 14-H), 
4.32 (1H, dd, J 11, 6, 19-HH), 4.20 (1H, td, J 11, 5, 19-HH), 3.21 (1H, d, J 6, 11-H), 2.23 (1H, ddd, J 
14, 11, 6, 20-HH), 2.18 – 2.02 (2H, m, 6-H, 10-H), 1.97 – 1.78 (2H, m, 2-HH, 8-HH), 1.71 (1H, d, J 
13, 8-HH), 1.68 – 1.58 (1H, m, 2-HH), 1.55 – 1.33 (7H, m, 1-H2, 7-H2, 4-H, 13-HH, 20-HH), 1.21 
(9H, s, OCH3), 1.09 (6H, s, 15-H3, 18-H3), 0.95 (12H, q, J 8, 17-H3, SiCH2CH3), 0.87 (3H, d, J 7, 16-
H3), 0.63 (6H, qd, J 8, 2, SiCH2); δC (100 MHz, CDCl3) 178.6 (CO), 77.8 (C-3), 76.2 (C-11), 68.5 (C-
14), 62.7 (C-20), 51.6 (C-4), 48.4 (C-13), 46.0 (C-9), 43.2 (C-12), 41.2 (C-5), 38.7 (COCCH3), 37.3 
(C-6), 34.7 (C-10), 34.1 (C-2), 33.1 (C-19), 32.8 (C-8), 32.1 (C-7), 28.2 (C-1), 27.3 (3-COCCH3), 27.2 
(C-18), 18.9 (C-16), 17.5 (C-15), 11.9 (C-17), 7.3 (SiCH2CH3), 6.3 (SiCH2); Found (ESI) 561.3948 
[MNa+] (C31H58O5SiNa requires 561.3946). 
Diphenoxythiocarbonyl ester 200  
 
To a solution of 199 (0.31 g, 0.58 mmol) and PhO(CS)Cl (0.32 ml, 2.30 mmol) in THF (4 ml) was 
added dropwise NaHMDS (2.88 ml, 2.88 mmol) at −78 °C under N2. After stirring for 30 min the 
reaction mixture was diluted with EtOAc (35 ml) and washed with semi-saturated solution of 
brine (30 ml), dried over MgSO4 and solvent evaporated in vacuo. The residue was purified by 
column chromatography using 15-25% diethyl ether in petroleum ether 40-60 °C  to give 
diphenoxythiocarbonyl ester 200 as pale-yellow oil (0.42 g, 96%): νmax (neat)/cm-1: 2957, 2936, 
2875, 1725, 1489; δH (400 MHz, CDCl3) 7.41 (4H, dd, J 8, 7, Ar), 7.29 (2H, dd, J 7, 1, Ar), 7.08 (4H, 
dd, J 11, 8 Ar), 5.85 (1H, t, J 5, 3-H), 5.29 (1H, d, J 6, 11-H), 4.36 (1H, d, J 9, 14-H), 4.29 (1H, td, J 
11, 6, 19-HH), 4.17 (1H, td, J 11, 5, 19-HH), 2.42 – 2.27 (2H, m, 10-H, 20-HH), 2.23 – 1.98 (3H, m, 
2-HH, 7-HH, 13-HH), 1.93 – 1.83 (2H, m, 4-H, 7-HH), 1.76 (1H, ddd, J 12, 7, 4, 8-HH), 1.68 – 1.24 
(3H, m, 8-HH, 20-HH, 2-HH), 1.22 (9H, s, 3-COCH3), 1.10 (3H, s, 18-H3), 1.02 – 0.93 (13H, m, 15-
H3, SiCH2CH3, 17-H3), 0.88 (3H, d, J 2, 16-H3), 0.64 (6H, qd, J 8, 2, SiCH2); δC (100 MHz, CDCl3) 194.8 
(CS), 178.5 (CO), 153.3 , 129.6, 126.5, 122.0, 92.0 (C-3), 89.9 (C-11), 67.9 (C-14), 61.9 (C-20), 51.8 
(C-4), 47.9 (C-13), 46.0 (C-9), 42.8 (C-12), 41.47 (C-5), 36.5 (C-22), 36.0 (C-6), 33.8 (C-10), 33.1 (C-
19), 32.4 (C-2), 30.0 (C-8), 28.1 (C-7), 27.3 (C-1), 26.3 (COCCH3), 18.8 (C-16), 17.6 (C-15), 12.9 (C-




Pivaloyl ester 202 and phenoxythiocarbonyl ester 201 
 
To a solution of ester 200 (0.41 g, 0.55 mmol) and Bu3SnH (0.60 ml, 2.22 mmol) in benzene (6 
ml) was added Et3B (1.1 ml, 1.1 mmol) at 0 °C under N2. After stirring at 0 °C during 3 h was 
added water (10 ml). The resulting mixture was extracted with Et2O (4 × 10 ml). The combined 
organic layers were washed with saturated solution of brine (5 ml), dried over MgSO4 and 
solvent evaporated in vacuo. The residue was purified by column chromatography using 1-15% 
diethyl ether in hexane to give a 3:2 mixture of deoxygenated compounds 202 and 203 (0.11 g, 
53%) and 3-deoxy product 201 (20 mg, 8%) which was converted in 202 (10 mg, 63%) under the 
same deoxygenation conditions. To a solution of NaHCO3 (0.15 g, 1.78 mmol) and mCPBA (51 
mg, 0.30 mmol) in CH2Cl2 (1.5 ml) was added dropwise a solution of the mixture of 202 and 203 
(0.15 g, 0.30 mmol) in CH2Cl2 (1.5 ml) at 0 °C. After stirring at this temperature for 2 h, was added 
saturated solution of Na2SO3 (9 ml). The resulting mixture was stirred for 15 min and extracted 
with Et2O (3 × 10 ml). The organics layers were washed with saturated solution of NaHCO3 (20 
ml) and brine (10 ml), dried over anhydrous MgSO4 and solvent evaporated in vacuo. The residue 
was purified by silica gel column chromatography using 1% diethyl ether in hexane to give 
deoxygenated product 202 as a colourless oil (71 mg, 80%).  
Di-deoxygenated 202: νmax (neat)/cm-1: 2957, 2933, 2873, 1730, 1458; δH (400 MHz, CDCl3) 4.39 
(1H, d, J 8, 14-H), 4.26 – 4.08 (2H, m, 20-H2), 2.32 – 2.18 (1H, m, 19-HH), 1.97 (1H, dd, J 15, 8, 13-
HH), 1.91 – 1.24 (17H, m), 1.21 (9H, s, COCH3), 1.01 – 0.92 (9H, m, SiCH2CH3), 0.94 (3H, s, 18-H3), 
0.88 (3H, d, J 7, 16-H3), 0.85 – 0.82 (9H, m, 15-H3,17-H3), 0.69 – 0.52 (3H, m, SiCH2); δC (100 MHz, 
CDCl3) 178.6 (CO), 68.5 (C-14), 61.8 (C-20), 49.8 (C-13), 47.4 (C-4), 46.0 (C-9), 42.4 (C-12), 40.7 
(C-11), 38.8 (C-5), 36.6 (C-19), 35.2 (COCCH3), 35.2 (C-6), 33.8 (C-8), 31.1 (C-18), 30.4 (C-10), 29.8 
(C-7), 29.0 (C-1), 28.2 (C-3), 27.3 (3-COCCH3), 20.9 (C-15), 19.2 (C-2), 18.8 (C-16), 18.0 (C-17), 7.3 
(SiCH2CH3), 6.4 (SiCH2); Found (ESI) 529.4064 [MNa+] (C31H58O3SiNa requires 529.4053).  
Mono-deoxygenated 201: νmax (neat)/cm-1: 2957, 2934, 2875, 1727; δH (400 MHz, CDCl3) 7.44 – 
7.32 (2H, m, Ar), 7.31 – 7.19 (1H, m, Ar), 7.05 (2H, d, J 7, Ar), 5.32 (1H, d, J 7, 11-H), 4.40 (1H, d, 




20-HH), 2.28 (1H, p, J 7, 10-HH), 2.11 (1H, dd, J 16, 9, 13-HH), 2.00 – 1.22 (13H, m), 1.20 (9H, s, 
COCH3), 1.09 (3H, s, 18-H3), 0.95 (9H, t, J 8, SiCH2CH3), 0.90 (3H, d, J 4, 16-H3), 0.88 (3H, d, J 4, 17-
H3), 0.85 (3H, s, 15-H3), 0.62 (6H, dd, J 16, 8, SiCH2); δC (100 MHz, CDCl3) 194.5 (CS) , 178.4 (CO), 
153.4 , 129.6 , 126.5, 122.1, 90.1 (C-11), 68.1 (C-14), 62.1 (C-20), 47.9 (C-4), 47.5 (C-13), 45.7 (C-
9), 42.5 (C-12), 41.2 (C-5), 38.7 (COCCH3), 36.0 (C-6), 35.2 (C-10), 34.8 (C-19), 34.0 (C-8), 29.4 (C-
1), 28.2 (C-7), 27.4 (C-3), 27.3 (3-COCCH3), 26.5 (C-18), 19.2 (C-2), 18.7 (C-16), 18.2 (C-15), 13.5 
(C-17), 7.3 (SiCH2CH3), 6.4 (SiCH2); Found (ESI) 681.4 [MNa+] (C38H62O5SSiNa requires 681.3985).  
Alcohol 204 
 
To a solution of ester 202 (70 mg, 0.14 mmol) in CH2Cl2 (1.4 ml) was added DIBALH (21 µL, 0.21 
ml) at −78 °C under N2. The reaction mixture was stirred for 1 h and diluted with CH2Cl2 (2.8 ml). 
MeOH (3 drops) and saturated Rochelle salt solution (2.6 ml) were added. The mixture was 
stirred for 2 h and extracted with EtOAc (3 × 10 ml), dried over MgSO4 and solvent evaporated 
in vacuo to give alcohol 204 as a colourless oil in a quantitative yield. νmax (neat)/cm-1: 3314, 
2955, 2933, 2874, 1456; δH (400 MHz, CDCl3) 4.41 (1H, d, J 9, 14-H), 3.77 (2H, dt, J 10, 6, 20-H2), 
2.25 (2H, ddd, J 13, 9, 6, 19-H2), 1.94 (1H, dd, J 16, 9, 13-HH), 1.82 – 1.04 (15H, m), 0.97 (9H, t, J 
8, SiCH2CH3), 0.92 (3H, s, 18-H3), 0.89 (3H, d, J 7, 16-H3), 0.84 (3H, s, 15-H3), 0.80 (3H, d, J 7, 17-
H3), 0.65 (6H, q, J 9, 8, SiCH2); δC (100 MHz, CDCl3) 68.6 (C-14), 60.0 (C-20), 49.8 (C-13), 47.4 (C-
4), 46.0 (C-12), 42.4 (C-5), 41.1 (C-3), 40.9 (C-19), 35.4 (C-6), 35.3 (C-9), 33.9 (C-8), 31.3 (C-18), 
29.8 (C-10), 29.1 (C-1), 28.1 (C-7), 27.3 (C-3), 20.8 (C-17), 19.2 (C-2), 18.77 (C-16), 18.1 (C-15), 
7.4 (SiCH2CH3), 6.5 (SiCH2); Found (ESI) 445.3479 [MNa+] (C26H50O2SiNa requires 445.3478). 
3-Deoxo-11-dehydroxy-14-methylsilyl mutilin 205 
 
To a solution of alcohol 204 (15.0 mg, 35.5 µmol) in THF (0.4 ml) was added 2-NO2C6H6SeCN 
(20.1 mg, 88.7 µmol) and Bu3P (17.9 mg, 88.7 µmol). After stirring for 1.5 h at room temperature, 




stirred for 14 h at 0 °C and saturated solution of NH4Cl (2 ml) was added. The mixture was 
extracted with Et2O (4x 20 ml) and the organic layers were washed with saturated solution of 
NaHCO3 (10 ml) and brine (10 ml), were dried over MgSO4 and solvent evaporated in vacuo. The 
residue was purified by silica gel column chromatography using hexane to give silyl ester 205 as 
a colourless oil (7.1 mg, 50%). νmax (neat)/cm-1: 2956, 2921, 2874 , 1456; δH (400 MHz, CDCl3) 
6.12 (1H, dd, J 18, 11, 19-H), 5.13 – 5.09 (1H, dd, J 18, 1, 20-HH), 5.07 (1H, dd, J 11, 1, 20-HH), 
4.31 (1H, d, J 8, 14-H), 2.03 (1H, dd, J 15, 8, 13-HH), 1.91 – 1.07 (16H, m), 0.95 (9H, m, SiCH2CH3), 
0.94 (3H, s, 18-H3), 0.87 (3H, d, J 7, 16-H3), 0.84 (3H, s, 15-H3), 0.82 (d, J 7, 17-H3), 0.68  –  0.60 
(6H, m, SiCH2); δC (100 MHz, CDCl3) 147.5 (C-19), 112.2 (C-20), 69.6 (C-14), 48.3 (C-13), 47.5 (C-
4), 46.0 (C-12), 42.3 (C-5), 41.9 (C-11), 40.1 (C-9), 35.3 (C-6), 33.9 (C-8), 32.4 (C-18), 30.4 (C-10), 
29.2 (C-1), 28.1 (C-7), 27.3 (C-3), 20.9 (C-17), 19.2 (C-2), 18. 8 (C-16), 18.1 (C-15), 7.3 (SiCH2CH3), 
6.3 (SiCH2); Found (EI) 404.3468 [M] (C26H48OSi requires 404.3474). 
3-Deoxo-11-dehydroxy-mutilin   183 
 
To a solution of silyl ester 205 in MeCN was added HF-pyridine (1 drop). After the mixture 
reaction was stirred for 2 h, a saturated solution of NaHCO3 (2 drops) was added. The mixture 
was extracted with EtOAc (4 × 2 ml). The organic layers were dried over MgSO4 and solvent 
evaporated in vacuo. The residue was purified by column chromatography using 10% EtOAc in 
hexane to give alcohol 3-deoxo-11-dehydroxy-mutilin 183 as a colourless oil (3.0 mg, 43%). νmax 
(neat)/cm-1: 3486, 2956, 2924, 2863, 1456; δH (400 MHz, CDCl3) 5.84 (1H, dd, J 18, 11, 19-H), 
5.21 (1H, dd, J 18, 1, 20-HH), 5.11 (1H, dd, J 11, 1, 20-HH), 4.22 (1H, d, J 8,14-H), 2.00 (1H, dd, J 
15, 8, 13-HH), 1.83 – 1.63 (5H, m, 3-H2,4-H,10-H,6-H), 1.62 – 1.52 (1H, m, 2-HH), 1.51 – 1.06 (9H, 
m, 7-H2,8-H2,1-H2,11-HH,13-HH, 2-HH), 1.02 (1H, d, J 7, 11-HH), 0.96 (3H, d, J 7, 16-H3), 0.96 (3H, 
s, 18-H3), 0.86 (3H, s, 15-H3), 0.81 (3H, d, J 7, 17-H3); δC (100 MHz, CDCl3) 147.2 (C-19), 112.9 (C-
20), 69.0 (C-14), 47.8 (C-4), 46.3 (C-13), 45.9 (C-12), 43.2 (C-11), 41.3 (C-5), 40.6 (C-9), 35.0 (C-
6), 33.9 (C-8), 33.1 (C-18), 31.1 (C-10), 28.7 (C-1), 28.0 (C-7), 27.1 (C-3), 21.3 (C-17), 19.0 (C-2), 
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